WO2007097593A1 - Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance - Google Patents

Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance Download PDF

Info

Publication number
WO2007097593A1
WO2007097593A1 PCT/KR2007/000961 KR2007000961W WO2007097593A1 WO 2007097593 A1 WO2007097593 A1 WO 2007097593A1 KR 2007000961 W KR2007000961 W KR 2007000961W WO 2007097593 A1 WO2007097593 A1 WO 2007097593A1
Authority
WO
WIPO (PCT)
Prior art keywords
magnetic
magnetic nanocomposite
nanocomposite according
active ingredient
acid
Prior art date
Application number
PCT/KR2007/000961
Other languages
French (fr)
Inventor
Seung-Joo Ham
Jin-Suck Suh
Yong-Min Huh
Ho-Geun Yoon
Jae-Moon Yang
Original Assignee
Atgen Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atgen Co., Ltd. filed Critical Atgen Co., Ltd.
Priority to JP2008556255A priority Critical patent/JP2009531296A/en
Priority to US12/280,474 priority patent/US20090324494A1/en
Priority to EP07709086A priority patent/EP1988928A4/en
Publication of WO2007097593A1 publication Critical patent/WO2007097593A1/en
Priority to US13/590,958 priority patent/US20130045160A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/5434—Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids

Definitions

  • the present invention relates to a water soluble magnetic nanoconiposite using an amphiphilic compound. Specifically, the present invention relates to a water soluble magnetic nanocomposite which may be not only used as a contrast
  • MRI magnetic resonance imaging
  • a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enclosing a drug and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same
  • Nanotechnology is the technique of manipulating and controlling materials on an atomic or molecular scale, is suitable to invent new materials or new devices, and thus has a variety of applications such as electronics, materials, communication,
  • Nanotechnology is variously developed and is classified as the following three fields:
  • the magnetic nanoparticle is used in a broad range of applications, such as separation of biological components,
  • magnetoresistive sensors magnetoresistive sensors, micro fluidic sensors, drug/gene delivery, and a magnetic
  • the magnetic nanoparticle may be used in a diagnostic probe
  • nanoparticle is allowed to reduce a spin-spin relaxation time of a hydrogen atom in water molecules surrounding nanoparticles to show the effect of amplifying signals of magnetic resonance imaging, and thus have been broadly used in diagnosis of
  • the magnetic nanoparticle may serve as a probe material of
  • Giant magnetic resistance (GMR) sensor When the magnetic nanoparticle senses a biological molecule patterned on the surface of GMR biosensor and binds to it, it changes current signals of the GMR sensor. Using such change, a biological molecule can be selectively detected (US 6,452,763 Bl; US 6,940,277 B2; US 6,944,939 B2; US 2003/0133232 Al). Furthermore, the magnetic nanoparticle may be applied to separate a biological molecule. For example, when a cell expressing specific biomarker is
  • the magnetic nanoparticle may also be used in a biotherapy through delivering a drug or a gene.
  • the selective effect of treatment may be obtained by moving the nanoparticle loaded with a drug or a gene through a chemical bond or adsorption to the desired position by an external magnetic field and allowed to release the drug and the gene on the region of interest (US).
  • US Patent No. 6,274,121 relates to a paramagnetic nanoparticle comprising a metal such as iron oxide and discloses a nanoparticle to whose surface is bound to an inorganic substance including binding sites for coupling to a tissue-specific binding substance, a diagnostic or pharmacologically active substance.
  • US Patent No. 6,638,494 relates to a paramagnetic nanoparticle comprising a metal such as iron oxide and discloses the method of preventing aggregation and
  • carboxylic acid aliphatic dicarboxylic acid such as maleic acid, tartaric acid, or glucaric acid
  • aliphatic poly dicarboxylic acid such as citric acid, citric acid, cyclohexane, or tricarboxylic acid was used.
  • GB Patent Application No. 223,127 relates to a method for making a magnetic nanoparticle, including the step of forming a magnetic nanoparticle within a protein template, wherein described a method for encapsulating a nanoparticle into apoferritin.
  • US Patent Application Publication No. 2003/190,471 relates to a method for forming a nanoparticle of manganese zinc ferrite within dual micelles, wherein was described the nanoparticle showing an improved property through procedures of heat treating the formed magnetic nanoparticle.
  • water soluble magnetic nanoparticle covered with 16-mercaptohexadecanoic acid was described, together with detection of a virus and mRNA in an experimental rat with intracellular magnetic labeling, using a TAT peptide, a transfection agent, on the synthesized magnetic nanoparticle.
  • the resulting nanoparticle show a non-uniform size distribution.
  • the resulting nanoparticle since they are synthesized at a low temperature, the resulting nanoparticle has low crystalline property, and can be formed in a non-stoichiometric compound. Therefore, the nanoparticles prepared by the methods above have problems that show low stability of colloid in a water solution and thus aggregation on applying in vivo, and high non-selective binding, and the like.
  • the present invention intends to solve the problems above.
  • the object of the present invention is to provide a magnetic nanocomposite having so high stability in a water solution with low toxicity that may widely apply for diagnosis and treatment of organism, which is characterized in that a magnetic nanoparticle is covered with an amphiphillic compound having one or more hydrophobic domains and one or more hydrophillic domains.
  • Another object of the present invention is to provide an intelligent magnetic nanocomposite which is characterized in that a magnetic nanoparticle is covered with an amphiphillic compound having one or more hydrophobic domains and one or more hydrophillic domains, and one or more binding parts for a hydrophillic active ingredient present in said hydrophillic domain are bound to a tissue-specific binding substance.
  • binding parts for a hydrophillic active ingredient present in said hydrophillic domain are bound to a tissue-specific binding substance, and a pharmaceutically
  • active ingredient is bound to or enclosed in said hydrophobic domain.
  • Still another object of the present invention is to provide a method for separating a target substance which comprises binding a magnetic nanocomposite
  • hydrophillic domains and one or more binding parts for a hydrophillic active ingredient present in said hydrophillic domain are bound to a tissue-specific binding substance.
  • Still another object of the present invention is to provide a method for preparing the magnetic nanoparticle according to the present invention above.
  • the other object of the present invention is to provide a contrast agent, a
  • composition for diagnosis and a pharmaceutical composition comprising the
  • an amphiphillic compound is added to a surface of nanoparticle to bind
  • hydrophobic domains of an amphiphillic compound are bound to the surface of nanoparticle by a hydrogen bond, Van der
  • hydrophobic domain does not only play a role in dispersing a nanoparticle in matrix
  • a metal, a magnetic material, or a magnetic alloy as a
  • the nanoparticle may be bound to an organic surface stabilizer.
  • the bond of metal, magnetic material, or magnetic alloy to the organic surface stabilizer is achieved by coordinating the organic surface stabilizer to a precursor of metal, magnetic material, or magnetic alloy to form a complex.
  • Said organic surface stabilizer may act in stabilizing the hydrophobic domain of an amphiphillic compound.
  • the magnetic nanocomposite according to the present invention has another feature that said hydrophobic domain may have one or more binding parts for a hydrophobic active ingredient (Rl) within some part of its structure, and said hydrophilic domain may have one or more binding parts for a hydrophilic
  • the magnetic nanocomposite according to the present invention may be used in various uses such as an intelligent contrast agent for cancer diagnosis, a drug delivery system that cancer diagnosis and treatment can be simultaneously performed, and an agent for separating a protein. Its schematic diagram is depicted in Fig. 1.
  • the magnetic nanocomposite according to the present invention includes a magnetic nanocomposite comprising a core that one or more magnetic nanoparticles are distributed in the hydrophobic domain and a shell containing the hydrophilic domain ("emulsion type magnetic nanocomposite,” below) and a magnetic nanocomposite comprising a core that one magnetic nanoparticle is bound to the hydrophobic domains and a shell containing the hydrophilic domain (“suspension type magnetic nanocomposite,” below), depending on their preparation 7 000961
  • nanoparticles are physically bound to the hydrophobic domains of an amphiphilic compound.
  • the desired diameter of the emulsion type nanocomposite is 1 nm
  • suspension type nanocomposite is 1 nm to 50 nm, and more preferably 5 nm to 30
  • one or more binding parts for a hydrophilic active ingredient are bound to a
  • tissue-specific binding substance The tissue-specific binding substance.
  • binding parts for a hydrophilic active ingredient are bound to a tissue-specific binding substance, and a pharmaceutically active ingredient is bound
  • Said metal is not specifically limited, but preferably selected from the group consisting of Pt, Pd, Ag, Cu and Au.
  • said magnetic alloy is also not specifically limited, but preferably selected from the group consisting of CoCu, CoPt, FePt, CoSm, NiFe and NiFeCo.
  • the surfactant that may be used includes, but not limited to, cationic surfactant, including alkyl trimethylammonium halide; neutral surfactant, including saturated or unsaturated fatty acid such as oleic acid, lauric acid, or dodecylic acid, trialkylphosphine or trialkylphosphine oxide such as trioctylphosphine oxide (TOPO), trioctylphosphine (TOP), or tributylphosphine, alkyl amine such as dodecylamine, oleicamine, trioctylamine, or octylamine, or alkyl thiol; and anionic surfactant, including sodium alkyl phosphate.
  • cationic surfactant including alkyl trimethylammonium halide
  • neutral surfactant including saturated or unsaturated fatty acid such as oleic acid, lauric acid, or dodecylic acid, trialkylphosphine or trialkyl
  • a saturated or unsaturated fatty acid and/or alkylamine it is preferred to use a saturated or unsaturated fatty acid and/or alkylamine.
  • amphiphilic compound according to the present invention is not specifically limited, if it has one or more hydrophobic domains (Pl) and one or more
  • hydrophilic domains P2
  • hydrophobic domains P2
  • P2 and a hydrophilic domains (P2) may be linked and bounded as multi domains.
  • amphiphilic compound may have a variety of forms such as P1-P2,
  • the repeated hydrophobic domains or hydrophilic domains may be present within its structure.
  • hydrophobic domains of an amphiphilic compound according to the present invention may consist of a compound or a polymer.
  • a biocompatible saturated or unsaturated fatty acid, or a hydrophobic polymer may be
  • Said saturated fatty acid is not specifically limited, but may use one or more selected from the group consisting of butyric acid, caproic acid, caprylic acid, capric acid, lauric acid (dodecyl acid), miristic acid, palmitic acid, stearic acid, eicosanoic acid, and docosanoic acid.
  • Said unsaturated fatty acid is also not specifically limited, but may use one or more selected from the group consisting of oleic acid, linoleic acid, linolenic acid, arakydonic acid, eicosapentanoic acid, docosahexanoic
  • hydrophobic polymer that may be used in the amphiphilic
  • polyphospazene preferably one or more selected from the group consisting of polyphospazene, polylactide, polylactide-co-glycolide, polycaprolactone, poly anhydride, polymalic acid
  • polyalkylcyanoacrylate polyhydroxybutylate, polycarbonate, polyorthoester, a hydrophobic polyamino acid and a hydrophobic vinyl based polymer.
  • said hydrophobic polymer has preferably a weight average
  • the weight average molecular weight is in excess of 100,000, it is difficult to be applied.
  • present invention may consist of a compound or a polymer.
  • a biocompatible polymer may be used.
  • Said biocompatible polymer is not specifically limited, but preferably one or
  • hydrophilic vinyl based polymer a hydrophilic vinyl based polymer, and more prefeably polyethyleneglycol.
  • weight 100 to 100,000. If the weight average molecular weight is less than 100,
  • hydrophobic active ingredient (Rl) within some part of its structure, preferably in
  • hydrophilic active ingredient (R2) within some part of its structure, preferably
  • the magnetic nanocomposite according to the present invention may be used in an intelligent conatrast agent for cancer diagnosis.
  • the magnetic nanocomposite according to the present invention may be used in a drug delivery system for simultaneous diagnosis and treatment of cancer.
  • ingredient (R2) are bound to a tissue-specific binding substance.
  • Said hydrophilic active ingredient may be selected from the group consisting of a bioactive ingredient, a polymer, and an inorganic support.
  • a bioactive ingredient has the same meaning as “a tissue-specific binding substance” or "a pharmaceutically active ingredient,” which may be used interchangeably each other.
  • the binding part for a hydrophilic active ingredient (R2) may be optionally changed depending on a hydrophilic active ingredient, that is, a tissue-specific binding substance, to be bound.
  • the binding part includes, but not limited to, one or more functional groups selected from the group consisting of
  • -COOH -CHO, -NH 2 , -SH, -CONH 2 , -PO 3 H, -PO 4 H, -SO 3 H, -SO 4 H, -OH, -NR 4 + X-, -sulfonate, -nitrate, -phophonate, -succinimidyl, -maleimide, and -alkyl.
  • the tissue-specific binding substance includes, but not limited to, an antigen, an antibody, RNA, DNA, hapten, avidin, streptavidin, neutravidin, protein A, protein G, lectin, selectin, a radioisotope labeled component, or a tumor marker.
  • the nanocomposite of the present invention may be used for diagnosing and/or treating various diseases related to tumor, for example, gastric cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer and cervical cancer.
  • tumor cell expresses and/or secretes particular materials less or not at all produced by a normal cell, which generally called "tumor marker.”
  • tumor marker a material that may be specifically bound to such tumor marker to the binding parts for an active ingredient of the water soluble nanoparticle may be advantageously used in diagnosing tumor.
  • tumor markers but also materials that may be specifically bound to such tumor marker are known in this field.
  • the tumor marker may be classified as a ligand, an antigen, a receptor, and encoding nucleic acids thereof, depending on the mode of action.
  • synaptotagmin and phosphatidylserine annexin V and phosphatidylserine, integrin and receptor thereof, VEGF (Vascular Endothelial Growth Factor) and receptor thereof, angiopoietin and a Tie2 receptor, somatostatin and receptor
  • vasointestinal peptide and receptor thereof a vasointestinal peptide and receptor thereof, and the like.
  • the material that may be specifically expressed is an antigen, the material that may be specifically expressed
  • bound to the antigen can be introduced as an active ingredient of nanocomposite
  • an antigen to be used herein examples include an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein and an antigen to be used herein
  • antibody that may be specifically bound to the antigen include a carcinoembryonic antigen (colon cancer labeled antigen) and Herceptin (Genentech, USA), a
  • HER2/neu antigen breast cancer labeled antigen
  • Herceptin Herceptin
  • prostate-specific membrane antigen prostate cancer labeled antigen
  • Rituxan
  • a receptor as the tumor marker include a follic
  • follic acid in case of follic acid receptor can be introduced as an active ingredient of nanocomposite according to the present invention, and suitably, a ligand or an antibody that may be specifically bound to the receptor.
  • a ligand or an antibody that may be specifically bound to the receptor As described above, an antibody as an active ingredient is most preferably
  • the antibody has a property being selectively and stably bound to
  • -NH2 of lysine, -SH of cysteine, and -COOH of asparginic acid and glutamic acid present in Fc domain of the antibody may be usefully utilized to be bound to a functional group of binding parts for an active ingredient in a water soluble nanocomposite.
  • Such antibody is commercially available or may be prepared according to the known methods in this field.
  • a mammal for example, mouse, rat, goat, rabbit, horse or sheep
  • an appropriate amount of an antigen for example, mouse, rat, goat, rabbit, horse or sheep
  • the antibody is recovered from serum of the mammal. If desired, the recovered antibody may be purified using the known process and stored in the frozen buffer solution until use. Detail of such method is well known in this field.
  • nucleic acid includes a ligand, an antigen, a receptor or RNA and DNA encoding some of these, as described above.
  • a nucleic acid is characterized by forming base pairs between complementary sequences.
  • the nucleic acid having particular base sequences may be detected, using the nucleic acid having complementary base sequences to said base sequences.
  • acid encoding an enzyme, a ligand, an antigen, a receptor above may be used as an active ingredient of nanocomposite according to the present invention.
  • the nucleic acid has a functional group such as -NH2, -SH, -COOH on the 5'- and 3'- ends, and thus may be usefully used to be bound to the functional group of binding parts for an active ingredient.
  • nucleic acid can be synthesized by the standard method known in this field, for example, using an automatic DNA synthesizer (for example, those
  • phosphorothioate oligonucleotide may be synthesized by the method described in
  • oligonucleotide may be synthesized using the controlled glass polymer support
  • nanocomposite according to the present invention has one or more binding parts for
  • hydrophobic active ingredient may be bound or enclosed
  • the hydrophobic active ingredient is preferably selected from the group
  • tissue-specific binding substance is simultaneously bound, to the binding parts for
  • the magnetic nanocomposite may be used in a hydrophilic active ingredient (R2)
  • hydrophobic domain (Pl) may be optionally changed depending on the kind of hydrophobic active ingredient to be bound.
  • representative examples
  • the hydrophobic active ingredient is not specifically limited, if it is a pharmaceutically active ingredient, but preferably one or more selected from the
  • an anticancer agent an antibiotic, a hormone, a hormone antagonist, interleukin, interferon, a growth factor, a tumor necrosis factor, endotoxin, lymphotoxin, eurokinase, streptokinase, a tissue plasminogen activator, a protease inhibitor, alkylphosphocholine, a radioisotope labeled component, a surfactant, a cardiovascular system drug, a gastrointestinal system drug and a nervous system drug.
  • an antibiotic a hormone, a hormone antagonist, interleukin, interferon, a growth factor, a tumor necrosis factor, endotoxin, lymphotoxin, eurokinase, streptokinase, a tissue plasminogen activator, a protease inhibitor, alkylphosphocholine, a radioisotope labeled component, a surfactant, a cardiovascular system drug, a gastrointestinal system drug and a nervous system drug.
  • the hydrophobic active ingredient present in the hydrophobic domain may be enclosed by a physical inclusion, a chemical inclusion, or a combination thereof.
  • the inclusion of a drug is achieved through a physical bond of an anticancer agent with a hydrophobic active ingredient of an amphiphilic polymer, for preparing magnetic nanocomposite by an emulsion method and a suspension method.
  • an anticancer agent which can be bound to binding parts for a hydrophobic active ingredient of an amphiphilic polymer constituting a magnetic nanocomposite, it may be bound to binding parts for a hydrophobic active ingredient of the amphiphilic polymer by an appropriate cross-linking agent and thus the inclusion of a drug in the magnetic nanocomposite
  • the anticancer agent which may be used in the method of treatment according the present invention includes, but not limited to, Epirubicin, Docetaxel, Gemcitabine, Paclitaxel, Cisplatin, Carboplatin, Taxol, Procarbazine, Cyclophosphamide, Dactinomycin, Daunorubicin, Etoposide, Tamoxifen, Doxorubicin, Mitomycin, Bleomycin, Plicomycin, Transplatinum, Vinblastin and Methotrexate.
  • an amphiphilic compound consists of a hydrophobic domain- a hydrophilic domain, or a hydrophilic domain- a hydrophobic domain- a hydrophilic domain.
  • the amphiphilic compound may consist of binding parts for a hydrophobic active ingredient- a hydrophobic domain- a
  • hydrophilic domain-a binding part for a hydrophilic active ingredient or binding parts for a hydrophilic active ingredient- a hydrophilic domain- a hydrophobic domain(- a binding part for a hydrophobic active ingredient)- a hydrophilic domain- a binding part for a hydrophilic active ingredient.
  • a functional group such as -NH2- in the hyrophilic domains and hyrophobic domains, such as binding parts for a hydrophobic active ingredient- a hydrophobic domain -NH2- a hydrophilic domain- a binding part for a hydrophilic active ingredient.
  • -NH2- group present in the hydrophilic domains and hydrophobic domains may have more stable structure, if an amphiphilic compoud is added to a
  • examples of an amphiphilic compound in the magnetic nanocomposite according to the present invention include
  • nanocomposite which comprises the steps of:
  • hydrophilic domain to the surfaces of nanoparticles to bind the amphiphilic
  • present invention further comprises optionally
  • nanoparticles are reacted with a surface stabilizer, and preferably includes the
  • the precursors of nanoparticle are poured into the solvent including an organic surface stabilizer, which is subsequently coordinated to the surfaces of nanoparticles.
  • a metal As a nanoparticle in the step a), a metal, a magnetic material, or a magnetic
  • the organic surface stabilizer may be selected from the
  • organic metal compounds including a metal
  • carbonyl based compound such as iron pentacarbonyl (Fe(CO)s), ferrocene, or
  • Manganese carbonyl Mn2(CO)io
  • metal acetylacetonate based compound such as
  • Fe(acac)3 iron acetylacetonate
  • a metal ion containing metal salt that the metal is bound to a known anion such as Cl", or NO3" may be also used as a precursor of nanoparticle.
  • Fe(NO3)3 iron nitrate
  • a mixture of at least two metal precursors mentioned above may be used in synthesizing an alloy nanoparicle
  • the solvent that may be used in the step a) has high boiling point attaching to the thermolysis temperature of complex that the organic surface
  • the stabilizer is coordinated to the surface of nanoparticle.
  • the solvent selected from the group consisting of an ether compound, a heterocyclic compound, an aromatic compound, a sulfoxide compound, an amide compound, an alcohol, a hydrocarbon and water may be used.
  • the usable solvent is an ether compound such as octyl ether, butyl ether, hexyl ether, or decyl ether; a heterocyclic compound such as pyridine, or
  • tetrahydrofuran an aromatic compound such as toluene, xylene, mesitylen, or benzene; a sulfoxide compound such as dimethylsulfoxide (DMSO); an amide compound such as dimethylformamide (DMF); an alcohol such as octyl alcohol, or decanol; a hydrocarbon such as pentane, hexane, heptane, octane, decane, dodecane, tetradecane, or hexadecane; or water.
  • DMSO dimethylsulfoxide
  • amide compound such as dimethylformamide (DMF)
  • alcohol such as octyl alcohol, or decanol
  • a hydrocarbon such as pentane, hexane, heptane, octane, decane, dodecane, tetradecane, or hexadecane; or water.
  • the complex that the organic surface stabilizer is coordinated to the surface of nanoparticle is thermolyzed to grow nanoparticle.
  • a metal nanoparticle with uniform size and shape may be formed.
  • the thermolysis temperature may be also suitably regulated depending on the kinds of metal precursor and surface stabilizer.
  • the reaction is suitably subjected in a range of about 50 to 500 ° C .
  • the step b) may be separated and purified by the known means.
  • the step B) comprises adding the amphiphilic compound having
  • hydrophobic domains and a hydrophilic domains to the surface of nanoparticle to
  • the method of adding the amphiphilic compound to the surface of magnetic nanoparticle is classified into an emulsion type and a suspension type as described
  • the adding step B) preferably comprises the steps of:
  • nanocomposite according to the present invention may be prepared.
  • the suspension type magnetic nanocomposite according to the present invention may be prepared.
  • the amphiphilic compound may be prepared by the
  • it may be prepared by polymerizing
  • polylactide-co-glycolide a biodegaradable polymer, constituting the hydrophobic
  • the biding part for a hydrophilic active ingredient may be any suitable biding part for a hydrophilic active ingredient.
  • amphiphilic polymer may be also substituted with a carboxyl group by polymerizing
  • the biodegradable amphiphilic polymer may be prepared by ring-opening polymerization using lactide as a monomer. Polymerization of lactide
  • octoate may be used as a catalyst.
  • the polymerization may be carried out in a temperature of 100 to 180 °C under nitrogen atmosphere.
  • the molecular weight of compolymer may be regulated.
  • the step C), for binding the material to which the binding part for a hydrophilic active ingredient present in the hydrophilic domain and a tumor marker may be specifically bound comprises the steps of:
  • the cross linking agent to be used is not specifically limited, but preferably includes one or more selected from the group consisting of
  • 1,4-Diisothiocyanatobenzene 1,4-Phenylene diisocyanate, 1,6-Diisocyanatohexane, 4-(4-Maleimidophenyl)butyric acid N-hydroxysuccinimide ester, Phosgene solution,
  • Ethylenediamine Bis(4-nitrophenyl) carbonate, Succinyl chloride, N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide Hydrochloride,
  • -COOH -CHO, -NH 2 , -SH, -CONH 2 , -PO 3 H, -PO 4 H, -SO 3 H, -SO 4 H, -OH, -NR 4 + X", -sulfonate, -nitrate, -phophonate, -succinimidyl, -maleimide, or -alkyl.
  • ingredient may be changed depending on the kind of active ingredient, that is, a tissue-specific binding component, and its chemical formula.
  • the step D) for binding or enclosing the pharmaceutically active ingredient in the hydrophobic domain can be classified into a step of physically enclosing the pharmaceutically active ingredient in the hydrophobic domain and a step of chemically binding the pharmaceutically active ingredient to the hydrophobic domain.
  • the chemically binding step comprises the steps of: i) providing some of the hydrophobic domain with the binding part for a hydrophobic active ingredient, using a cross linking agent; and j) binding the binding part for a hydrophobic active ingredient and the pharmaceutically active ingredient.
  • the cross linking agent in the step g) above may be employed, without limitation.
  • the cross linking agent is reacted with some of the hydrophobic domain to provide the binding part for a hydrophobic active ingredient such as -COOH, -CHO, -NH2, -SH, -CONH2,
  • the step of physical inclusion may be carried out by dissolving the pharmaceutically active ingredient along with nanoparticles and enclosing the ingredient in them in the step B) for binding the amphiphilic compound and nanoparticles. More specifically, when the pharmaceutically active ingredient is enclosed in the emulsion type nanocomposite, the pharmaceutically active ingredient may be physically enclosed in the hydrophobic domain by dissolving the
  • the pharmaceutically active ingredient may be any pharmaceutically active ingredient.
  • the solvent in the step e) for preparing suspension by dispersing nanoparticles in the solution dissolving the amphiphilic compound.
  • hydrophilic or hydrophobic active ingredient in the steps h) and i) may be changed depending on the kind of each active ingredient, and its chemical formula. Specific example is set forth in Table 4 below.
  • the present invention further relates to a contrast agent comprising a magnetic nanocomposite using an amphiphilic comound and a pharmaceutically acceptable carrier; a composition for diagnosing disease comprising a conjugate of a tissue-specific binding ingredient and the magnetic nanocomposite, and a pharmaceutically acceptable carrier; a pharmaceutical composition for simultaneous diagnosis and treatment comprising a conjugate of a tissue-specific binding ingredient and a pharmaceutically active ingredient and the magnetic nanocomposite, and a pharmaceutically acceptable carrier.
  • composition according to the present invention may be any composition according to the present invention.
  • the composition according to the present invention may be any composition according to the present invention.
  • a form of water soluble solution for the parenteral administration Preferably, Hank s solution, Ringer s solution or a buffer solution such as a
  • injection may be added a substrate that may increase the viscosity of suspension
  • Another preferable aspect of the present composition may be in a form of
  • a suitable dispersing agent or wetting agent for example,
  • the usable vehicle and solvent includes mannitol, water, Ringer's solution and an
  • any of less irritable organic compound used as a solvent or a suspending medium.
  • any of less irritable organic compound used as a solvent or a suspending medium.
  • any of less irritable organic compound used as a solvent or a suspending medium.
  • the present invention also relates to a method for using a contrast
  • composition which comprises the steps of:
  • the present invention also relates to a method for diagnosing disease which
  • the present invention also relates to a method for simultaneously diagnosing
  • specimen refers to a tissue or a cell separated from the
  • the contrast composition may be administrated by routes
  • administration for example, the intravenous, intraperitoneal, intramuscular,
  • Magnetic Resonance Imaging Apparatus refers to an apparatus for imaging
  • the emitting energy is obtained by putting an organism in a powerful magnetic field, irradiating a radio wave with particular frequency on the organism, and stopping the radio wave after an atomic
  • the magnetic field or the radio wave is not
  • a clear three-dimensional tomographic imaging may
  • imaging apparatus is preferably T2 spin-spin relaxation magnetic resonance
  • the present invention relates to a method for separating a target substance
  • nanoparticle is covered with an amphiphilic
  • a target substance refers to a biological molecule
  • a cell specifically, includes, but not limited to, a cell, a protein, an antigen, a peptide, DNA, RNA, or a virus.
  • the magnetic nanocomposite formed according to the present invention may be any magnetic nanocomposite formed according to the present invention.
  • nanoprobe for separation, diagnosis, treatment, etc. of a biological molecule, and a drug or gene delivery system, and the like.
  • a representative example of biological diagnosis using magnetic nanocomposite includes molecular magnetic resonance imaging diagnosis or
  • the magnetic relaxation sensor The magnetic nanocomposite shows much better T2
  • nanocomposite may be used in a sensor for detecting biological moulecules. That is,
  • the magnetic nanocomposite according to the present invention can constitute a diagnosing material for Giant magnetic resistance (GMR) sensor.
  • Giant magnetic resistance (GMR) sensor Giant magnetic resistance
  • the magnetic nanocomposite may show more excellent magnetic characteristic
  • the magnetic nanocomposite may be also used in separation and detection
  • the magnetic nanocomposite according to the present invention, covered with the amphiphilic compound having hydrophobic domains and a hydrophilic domains may be used in a contrast agent for high sensitive MRI, an intelligent contrast agent for diagnosing cancer by binding to the binding parts materials that may specifically be bound to tumor markers, a drug delivery system for diagnosis and treatment of cancer by polymerizing or enclosing a drug in the hydrophobic domains, and a formulation for separating cells and proteins using magnetism by binding an antibody or a protein specific to surface antigens of functional cells, stem cells or cancer cells thereto.
  • Fig. 1 is a schematic diagram which depicts applications of the magnetic nanocomposite according to the present invention.
  • Fig. 2 is a schematic diagram which depicts the method for preparing a magnetic nanocomposite using an amphiphilic polymer, according to one embodiment of the present invention.
  • Fig. 3 is a concept diagram of the emulsion type or suspension type magnetic nanocomposite according to one embodiment of the present invention.
  • Fig. 4 is transmission electron microphotographs of the magnetic nanoparticle using a saturated fatty acid, according to one embodiment of the present invention and a graph which depicts its magnteic property.
  • Fig. 5 is transmission electron microphotographs of the magnetic nanoparticle using a unsaturated fatty acid, according to another embodiment of the present invention and a graph which depicts its magnetic property.
  • Fig. 6 is a schematic diagram which depicts the method for preparing a
  • Fig. 8 is a graph which depicts the Proton Nuclear Magnetic Resonance
  • Fig. 9 is a schematic diagram which depicts the polymerizing process of the
  • amphiphilic polymer whose binding part for a hydrophilic active ingredient is
  • Fig. 10 is a graph which depicts the 1 H-NMR result of the biodegradable
  • amphiphilic compound whose binding part is substituted with a carboxyl group
  • Fig. 11 is a graph which depicts the IR spectrometry result of the
  • biodegradable amphiphilic compound whose binding part is substituted with a
  • Fig. 12 is a schematic diagram which depicts the polymerizing process of
  • biodegradable amphiphilic polymer whose binding part for a hydrophilic active
  • Fig. 13 is a graph which depicts the IR spectrometry (FT-IR) result of the
  • Fig. 15 is the synthesizing process of biodegradable amphiphilic polymer
  • Fig. 16 is electron microphotographs of the emulsion type magnetic
  • nanoparticles using the nanoparticles and a biodegradable amphiphilic polymer
  • Fig. 17 is electron microphotographs of the suspension type magnetic
  • nanoparticles using the nanoparticles and a biodegradable amphiphilic polymer
  • Fig. 18 is electron microphotographs of the emulsion type magnetic
  • nanoparticles using the nanoparticles and a fatty acid amphiphilic polymer
  • Fig. 19 is a graph which depicts the result of hysteresis loop in the emulsion
  • Fig. 20 is electron microphotographs showng the state that the magnetic
  • nanoparticles according to the present invention are enclosed by
  • Fig. 21 is a graph which depicts the ratio by weight in the state that the
  • Fig. 22 is hysteresis loops of magnetic nanoparticles and magnetic nanocomposite, according to the present invention.
  • Fig. 23 is an electron microphoto graph of the magnetic nanocomposite prepared by the suspension method according to the present invention and a graph which depicts their size distribution by a dynamic laser light scattering method.
  • Fig. 24 is a thermogravimetric analysis graph of the magnetic nanoparticles prepared by the suspension method according to the present invention.
  • Fig. 25 is a transmission electron microphotograph of the water soluble magnetic nanocomposite according to one embodiment of the present invention and a graph which depicts the result of dynamic laser light scattering method.
  • Fig. 26 is a graph which depicts the IR spectrometry result of the water soluble magnetic nanocomposite according to one embodiment of the present
  • Fig. 27 is an electron microphotograph of the magnetic nanocomposite prepared by the suspension method according to the present invention and their size distribution view by a light scattering method.
  • Fig. 28 is a thermogravimetric analysis graph of the magnetic nanoparticles prepared by the suspension method according to the present invention.
  • Fig. 29 is an electron microphotograph of the nanocomposite prepared by the
  • Fig. 30 is a result of the ratio by weight obtained through thermogravimetric analysis in the state that MnFe2 ⁇ 4 prepared according to the present invention is enclosed by polylactide-co-glycolide-polyethyleneglycol, and its hysteresis loops.
  • Fig. 32 shows solubility of organic nanoparticles in an organic solvent and solubility of water soluble magnetic nanocomposite, using a biodegradable amphiphilic compound, in a water solution, according to one embodiment of the present invention.
  • Fig. 33 shows solubility of organic nanoparticles in an organic solvent, solubility of water soluble magnetic nanocomposite, using a fatty acid amphiphilic
  • Fig. 34 is graphs which depict salt concentrations of a water soluble magnetic nanocomposite using a fatty acid amphiphilic comound according to one embodiment of the present invention and the stability test results of them with pH.
  • Fig. 35 is a photograph showng the particle stability of the water soluble magnetic nanocomposite with pH, according to one embodiment of the present invention and a graph of size change with pH.
  • Fig. 36 is a photograph showng the particle stability of the water soluble
  • Fig. 37 is a graph which depicts the change of MRI signals (T2) with
  • concentrations of the water soluble magnetic nanocomposite using a biodegradable amphiphilic compound according to one embodiment of the present invention.
  • Fig. 38 is a graph which depicts the change of MRI signals (T2) with
  • amphiphilic compound according to another embodiment of the present invention.
  • Fig. 39 is photographs that MRI is identified with concentrations of solutions
  • the present invention are dispersed and a graph of R2 value change.
  • Fig. 40 is a solution MRI photograph of the water soluble magnetic nanocomposite according to one embodiment of the present invention.
  • Fig. 41 is a graph which depicts T2 value of MRI of the water soluble
  • Fig. 42 is photographs that MRI is identified with concentrations of solutions
  • Fig. 43 is photographs that MRI is identified with concentrations of solutions in which magnetic nanoparticles prepared by the suspension method according to the present invention are dispersed, and a graph of T2 value change with
  • Fig. 44 is a graph which depicts fluorescence intensity by Fluorescence Activated Cell Sorter (FACS) of the cell reacted with the intelligent contrast agent for MRI according to one embodiment of the present invention.
  • FACS Fluorescence Activated Cell Sorter
  • Fig. 45 is MRI photographs of the positive cells reacted with the intelligent contrast agent for MRI according to one embodiment of the present invention.
  • Fig. 47 is a view identifying affinity of Herceptin-magnetic nanocomposite, in
  • Fig. 48 is a view identifying by flow cytometry to estimate the degree of binding Herceptin-magnetic nanocomposite and cells, according to the present invention.
  • Fig. 49 is a photograph obtained by MRI, after the emulsion type Herceptin-magnetic nanocomposite prepared according to another embodiment of the present invention is reacted with a target cell line (MDA-MB-231, NIH3T6.7 cell
  • Fig. 50 is a photograph obtained by MRI, after the suspension type
  • the present invention is reacted with a target cell line (MDA-MB-231, NIH3T6.7 cell line), and a comparative graph of T2 value.
  • a target cell line MDA-MB-231, NIH3T6.7 cell line
  • Fig. 52 is a graph of drug release behavior in the emulsion type magnetic
  • Fig. 53 is a graph of drug release behavior in the suspension type magnetic
  • nanocomposite according to another embodiment of the present invention.
  • Fig. 55 is a photograph identifying an appearance that the target cells
  • Figs. 59, 60 and 62 are MRIs of animal models scanned using the water
  • Figs. 61 and 63 are graphs of R2 value change with injection time period of
  • Dodecanoic acid (0.6 mol) and dodecylamine(0.6 mol) in a benzylether solvent and iron triacetylacetonate (Aldrich) were thermolyzed at 290 ° C for 30 minutes to
  • Oleic acid (0.6 mol) and olecylamine(0.6 mol) in a benzylether solvent and iron triacetylacetonate (Aldrich) were thermolyzed at 290 °C for 30 minutes to
  • monomethoxypolyethyleneglycol-dodecanoic acid was depicted in Fig. 6. 5 g of monomethoxypolyethyleneglycol (MPEG) with an average molecular weight of 5,000
  • DA dodecanoic acid
  • carboxylic acid (-COOH) in dodecanoic acid was identified at 1695 cm- 1 and a peak of an ester bond, being binding part of dodecanoic acid and polyethylene glycol, was identified at 1734 cm 1 by IR Spectroscopy. As shown in Fig. 8, using 1 H-NMR, a
  • hydrophilic active ingredient for a hydrophilic active ingredient is substituted with a carboxyl group through an active ingredient of hydrphilic polymer
  • binding part for a hydrophilic active ingredient was substituted with a carboxyl group through an active ingredient of hydrphilic polymer was depicted in Fig. 12.
  • Pluronic based nonionic commercially available surfactant has a form of polyethyleneoxide-polypropyleneoxide-polyethyleneoxide (PEO-PPO-PEO, hydrophilic-hydrophobid-hydrophilic).
  • the terminal hydroxyl group (-OH) of this surfactant was substituted with a carboxyl group to which a ligand such as an antibody may be bound.
  • a biodegradable amphiphilic polymer that a binding part for a hydrophilic active ingredient was substituted with a succinimidyl group was synthesized through the process shown in Fig. 15a.
  • 0.05 mol of polylactide-co-glycolide, 0.4 mol of N-hydroxysuccinimide (NHS) and l ⁇ -dicyclohexylcarbodiimide were dissolved in methylene chloride, and then reacted at room temperature for 24 h under nitrogen atmosphere.
  • the reactant was filtered through a filter and dropped on cold diethylether to be precipitated. This precipitate was washed several times with diethylether, and then stored in vacuum. 0.01 mol of the polymer activated by the
  • the reactant was washed and stored by the method as mentioned above.
  • an amphiphilic polymer was subjected through the process as shown in Fig. 15b.
  • amphiphilic polymer and the anticancer agent, triethylamine was added to
  • DOX doxorubicin
  • a gel filtration column (Sephacryl S-300) to prepare the emulsion type magnetic nanocomposite with removed impurities.
  • the prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 16a and 16b, respectively.
  • Magnetic nanoparticles prepared in Preparation Example 1 above were dispersed in a chloroform solution dissolving 50 mg of the amphiphilic biodegradable polymer (monomethoxypolyethyleneglycol-polylactide-co-glycolide) prepared in Preparation Example 3 above.
  • the dispersion was heated to 40 ° C,
  • PBS phosphate buffered saline
  • FIG. 3b The schematic diagram of a suspension type magnetic nanocomposite using the biodegradable amphiphilic polymer, monomethoxypolyethyleneglycol-polylactide-co-glycolide, was depicted in Fig. 3b.
  • the prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 17a and 17b, respectively.
  • a fatty acid amphiphilic polymer, monomethoxypolyethyleneglycol-dodecanoic acid, prepared in Preparation Example 4 above was dissolved in 20 ml of deionized water as an aqueous phase.
  • 20 mg of magnetic nanoparticles prepared in Preparation Example 1 were dissolved in 5 ml of chloroform as an oil phase.
  • the aqueous phase was mixed with the oil phase, and then the mixture was saturated for 10 minutes by ultrasound of 300 W.
  • the resulting emulsion was stirred for 6 h to vaporize the oil phase, and subjected to centrifugation and a gel filtration column (Sephacryl S-300) to prepare the magnetic nanocomposite for high sensitive MRI with removed impurities.
  • Fig. 3c The schematic diagram of the emulsion type magnetic nanocomposite using the fatty acid amphiphilic polymer, monomethoxypolyethyleneglycol-dodecanoic acid, was depicted in Fig. 3c.
  • the prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results
  • Fig. 18a and 18b were depicted in Fig. 18a and 18b, respectively.
  • the magnetic property was identified as superparamagnetism by vibration sample magnetometer, and the result was depicted in Fig. 19.
  • a solid line represents a hysteresis loop of magnetic nanop article s
  • a dotted line represents a hysteresis loop of the emulsion type magnetic nanocomposite using a fatty acid amphiphilic compound.
  • an amphiphilic polymer monomethoxypolyethyleneglycol-dodecanoic
  • Example 5 A. above was dissolved in 20 ml of deionized water as an aqueous phase.
  • emulsion type magnetic nanocomposite that said anticancer agent was enclosed and the binding part for a hydrophilic active ingredient was substituted with a carboxyl group, was depicted in Fig. 3d.
  • the prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and
  • FIG. 20 represents a photograph of the emulsion type magnetic nanocomposite in which magnetite (Fe3U4) is enclosed, (b) represents a photograph of the emulsion type magnetic nanocomposite in which
  • Magnetic nanoparticles prepared in Preparation Example 1 above were dispersed in a chloroform solution dissolving 50 mg of the amphiphilic biodegradable polymer prepared in Preparation Example 5, B. above.
  • the dispersion was heated to 40 °C, with stirring, to vaporize the solvent, and re-dispersed in 0.5 ml of a phosphate buffered saline (PBS) solution.
  • PBS phosphate buffered saline
  • the solution was heated /stirred at 30 0 C for 6 h to complete the suspension. After removing micelles without magnetic particles through centrifugation, the suspension was re-dispersed in 0.5 ml of a PBS solution.
  • the schematic diagram of the suspension type magnetic nanocomposite that the binding part for a hydrophilic active ingredient was substituted with a carboxyl group was depicted in Fig. 3e.
  • the prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 23a and 23b, respectively.
  • the weight ratio of the enclosed magnetic nanoparticles was analyzed by a thermogravimetric analysis method, and the result was depicted in Fig. 24.
  • the mixture was stirred for 30 minutes in the absence of the ultrasound, and saturated for further 10 minutes with applying ultrasound of 600 W.
  • the resulting emulsion was stirred for 24 h to vaporize the oil phase and prepare the magnetic nanocomposite for high sensitive MRI.
  • Fig. 3f The prepared particles were identified by a
  • Magnetic nanocomposite prepared in Example 6 herceptin as an antibody for
  • amphiphilic biodegradable polymer prepared in Preparation Example 7 was
  • part for a hydrophilic active ingredient is substituted with a carboxyl group
  • the suspension After removing micelles without magnetic nanoparticles through centrifugation, the suspension was re-dispersed in 0.5 ml of a PBS solution.
  • the suspension was re-dispersed in 0.5 ml of a
  • anticancer agent is enclosed by the physical method and the chemical method
  • the suspension was re-dispersed in 0.5 ml of a PBS solution.
  • the prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 27a and 27b, respectively.
  • the weight ratio of the enclosed magnetic nanoparticles was analyzed by a thermogravimetric analysis method, and the result was depicted in Fig. 28.
  • the reaction of the herceptin-magnetic nanocomposite was subjected at room temperature for 4 h, by dispersing 3 mg of the water soluble magnetic nanocomposite prepared in Example 8 above in a PBS solution of pH 7.4 and adding
  • herceptin-magnetic nanocomposite 0.1 mg of herceptin thereto. After completing the reaction, the unreacted herceptin and water soluble magnetic nanocomposite was removed via Separcryl S-300 column to prepare the herceptin-magnetic nanocomposite.
  • the reaction was subjected at room temperature for 4 h, after dispersing the water soluble magnetic nanocomposite in a PBS solution of pH 7.4 and adding 0.5 mg of herceptin thereto.
  • the unreacted herceptin and water soluble magnetic nanocomposite was removed via Separcryl S-300 column to prepare the herceptin-magnetic nanocomposite.
  • immunoglobulin (IgG) which does not react with a target cell was bound to magnetic nanocomposite by the method above to prepare IgG-magnetic nanocomposite.
  • the reaction was subjected at room temperature for 4 h, after dispersing the water soluble magnetic nanocomposite in a PBS solution of pH 7.4 and adding 0.5 mg of herceptin thereto. After completing the reaction, the unreacted herceptin and water soluble magnetic nanocomposite was removed via Separcryl S-300 column to prepare the herceptin-magnetic nanocomposite.
  • immunoglobulin which does not react with a target cell was bound to magnetic nanocomposite by the method above to prepare IgG-magnetic nanocomposite.
  • chloroform was used as an oil phase, in which 100 mg of the amphilic biodegradable polymer prepared in Preparation Example 3 above was dissolved and 20 mg of magnetic nanoparticles prepared in Preparation Example 1 was dispersed.
  • 2 mg of Nile red was added to the oil phase.
  • 20 ml of deionized water was used as an aqueous phase.
  • the mixture was emulsified for 10 minutes by ultrasound. This emulsion was stirred for 12 h to vaporize the oil phase, and subjected several times to centrifugation and Sephacryl S-300 column to obtain the high pure water soluble magnetic nanocomposite.
  • the prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 29.
  • the weight ratio of the enclosed magnetic nanoparticles was analyzed by a thermogravimetric analysis
  • hydrophilic polymer was substituted with a carboxyl group, prepared in Example 11,
  • nanocomposite was removed via Separcryl S-300 column to prepare the
  • herceptin-magnetic nanocomposite It was identified in Fig. 31 to sensitively
  • Fig. 34 Stability of the nanocomposite prepared in Example 3 was examined according to concentrations of a salt (NaCl) and pH, and the results were depicted in Fig. 34. It could be identified from Fig. 34a, a graph representing the size change of nanocomposite according to a concentration of 0.0 ⁇ 1.0 M, that the size of nanocomposite according to concentration was not nearly changed. It could be also identified from Fig. 34b, a graph representing the size change of nanocomposite according to pH 5 ⁇ pH 10, that the size of nanocomposite according to pH was not nearly changed.
  • Fig. 34a a graph representing the size change of nanocomposite according to a concentration of 0.0 ⁇ 1.0 M, that the size of nanocomposite according to concentration was not nearly changed.
  • Fig. 34b a graph representing the size change of nanocomposite according to pH 5 ⁇ pH 10, that the size of nanocomposite according to pH was not nearly changed.
  • Example 3 To identify the contrasting effect for MRI of water soluble magnetic nanocomposite, the water soluble magnetic nanocomposite prepared in Example 3 above was titrated and injected into micro-tubes. 1.5 T system (Intera; Philips
  • the binding part for a hydrophilic active ingredient is substituted with a carboxyl
  • Example 4 prepared in Example 4 above was titrated and injected into micro-tubes. 1.5 T system (Intera; Philips Medical Systems, Best, The Netherlands) was used for the
  • FFE Fast Field Echo
  • nanocomposite was, the more the signals of MRI were amplified.
  • Example 6 shows the sufficient contrasting effect for MRI, the water soluble magnetic nanocomposite was titrated in a concentration of 1.0, 2.0, 5.0, 10.0, 20.0, 40.0 and 80.0 ⁇ m/mi and injected into micro-tubes.
  • 1.5 T system (Intera; Philips Medical Systems, Best, The Netherlands) was used for the contrasting effect of MRI, employing micro-47 coil.
  • T2 maps were performed to quantitatively evaluate the contrasting effect for MRI. Specific parameters were as follows: resolution 156 156 ⁇ m, slice thickness 0.6 mm,
  • binding part for a hydrophilic active ingredient is substituted with a succinimidyl group as a contrast agent
  • Netherlands was used for the contrasting effect of MRI, employing micro-47 coil.
  • Coronal images were obtained with Fast Field Echo (FFE) pulse sequence.
  • FFE Fast Field Echo
  • TR 400 ms, number of image excitation 1, time of image acquisition 6 minutes.
  • binding part for a hydrophilic active ingredient is substituted with a
  • Netherlands was used for the contrasting effect of MRI, employing micro-47 coil.
  • Coronal images were obtained with Fast Field Echo (FFE) pulse sequence.
  • FFE Fast Field Echo
  • T2 maps were performed to quantitatively evaluate the MRI contrasting effect for antigen specificity.
  • Herceptin-magnetic nanocomposite and nanocomposite as a control group were treated to cell lines each expressing HER2/new receptor (MDA-MB-231 cell line, NIH3T6.7 cell line), and reacted with
  • FACS FACS was employed. Each cell line was measured in 10,000 events.
  • Herceptin-magnetic nanocomposite and nanocomposite as a control group were treated to cell lines each expressing HER2/new receptor (MDA-MB-231 cell line, NIH3T6.7 cell line), and reacted with
  • HER2/neu receptor degree of expressing HER2/neu receptor is increased.
  • each cell was transformed into PCR tubes and then precipitated by centrifugation.
  • Fig. 49 met with the results of fluorescence expression as shown in Fig. 47. It was identified that the signals of MRI appeared gradually from gray to black, as the degree of expressing HER2/neu receptor was increasing. In case of the cell line with a low expressing degree, it could be identified that the signal turns a little dark color relative to the case employing nanocomposite as a control group, and that it turns gradually black as the degree of expressing the receptor is increased.
  • herceptin-magnetic nanocomposite was selectively bound to the cell line expressing HER2/neu receptor, whereby the signals of MRI appeared gradually black. It could be consequently identified that herceptin-magnetic nanocomposite of the present invention may be used in diagnosing in vitro breast cancer.
  • each cell was transformed into PCR tubes and then precipitated by centrifugation.
  • 1.5 T system (Intera; Philips Medical Systems, Best, The Netherlands) was used for the contrasting effect of MRI according to antigen specificity of each cell line, employing micro-47 coil.
  • Coronal images were obtained with Fast Field Echo (FFE) pulse sequence, and depicted in Fig. 50. Specific parameters were as follows: resolution 156 156 ⁇ m, slice thickness 0.6 mm,
  • TE 20 ms
  • TR 400 ms
  • number of image excitation 1 time of image acquisition 6 minutes.
  • Fig. 50 met with the results of fluorescence expression as shown in Fig. 48. It was identified that the signals of MRI appeared gradually from gray to black, as the degree of expressing HER2/neu receptor was increasing.
  • herceptin-magnetic nanocomposite was selectively bound to the cell line expressing HER2/neu receptor, whereby the signals of MRI appeared gradually black. It could be consequently identified that herceptin-magnetic nanocomposite of the present invention may be used in diagnosing in vitro breast cancer.
  • herceptin-magnetic nanocomposite The drug release experiment of water soluble magnetic nanocomposite enclosing anticancer agent prepared in Example 10, C. above was performed by making a titration curve using UV and extracting samples in certain time interval to measure their concentrations, and the results were depicted in Fig. 53.
  • Fig. 53b In case of enclosing a drug only by the physical method (Fig. 53b), the amount of initial release was large.
  • Fig. 53c the speed of release was slow, but a linear release behavior was shown.
  • the release mode was linear, and the drug release behavior approaching to 100% for relatively short time was shown (Fig. 53a).
  • FACS Flow cytometer, FACScan, Becton Dickinson, San Diego, CA
  • MCF-7 cell line « NIH3T6.7 cell line was measured in 10,000 events. Fluorescence intensity distribution in a range of mean value to median value was employed as fluorescence indexes.
  • Herceptin-magnetic nanocomposite and a nanocomposite as a control group were treated to cell lines each expressing HER2/new receptor. Then, fluorescence expression was identified using FACS, and the results were depicted in Fig. 54. As shown in Fig. 54, it could be identified that the intensity of fluorescence expression is increased as the degree of expressing
  • herceptin-magnetic nanocomposite prepared Example 12 above 1 mg/ml of herceptin-magnetic nanocomposite was incubated in 4*10 4 NIH3T6.7 for 30 minutes. The unreacted
  • Magnetic nanocomposite was separated and inserted in macro-tube.
  • An external magnetic field (Nd-B-Be magnet, 0.35T) was applied on the outside wall of tube. After applying the magnetic field, it was identified using microscope that the nanocomposite was sensitively moved into the direction of magnet within several seconds. The result was depicted in Fig. 55.
  • cytotoxicity analysis was proceeded on NIH3T6.7 cell with concentrations of nanocomposite, and the results were depicted in Fig. 34.
  • the cytotoxicity was identified by examining the concentration of nanocomposite in a range of 10 4 ⁇ 10° mg/ml and proceeding incubation time of cells for 0 ⁇ 72 h. As shown in Fig. 56, the cytotoxicity of the magnetic nanocomposite could not be identified at even higher concentrations.
  • binding part for a hydrophilic active ingredient was substituted with a carboxyl group using a commercially available surfactant
  • NIH3T6.7 cell and MDA-MB-231 cell The cytotoxicity was identified by representing as a ratio the degree of inhibiting cell growth by DOX alone, herceptin alone, DOX and herceptin, herceptin-magnetic nanop articles, IgG-magnetic nanocomposite, and herceptin-magnetic nanocomposite. 4*10 3 Cells were injected into 96-well, and the test materials were inserted in the cell containing well, based on the equivalent of herceptin and DOX. After 4 h, the residue was washed and the cells were grown for further 72 h. The cytotoxicity obtained from MTT agent was depicted in Fig. 58.
  • NIH3T6.7 cells were into the mouse to express cancer cells.
  • the nanocomposite (80 ⁇ g Fe + Mn) prepared in Example 3 were injected therein, when the size of cancer cells was 30 mm.
  • MRIs before and after injection were depicted in Fig. 59. That is, there are MRIs before injection (a), just after injection (b), one hour after injection (c), two hours after injection (d), and five hours after injection (e), of the nanocomposite.
  • Fig. 59 it could be identified that images of liver and cancer cells were apparently changed and the contrasting effect was kept after 1 h, 2 h and 5 h.
  • the difference of T2 values after even 5 h is highly kept relative to the value before injection (Fig. 59f).
  • NIH3T6.7 cells positve against antibody were into the mouse to express cancer cells.
  • the contrast agent prepared in Example 6 was injected therein, when the size of cancer cells was 10 mm.
  • MRIs before and after injection were depicted in Fig. 60.
  • Fig. 14 there are MRIs before injection (a), just after injection (b), and two hours after injection (c), of the contrast agent.
  • Fig. 60 it could be identified that images of liver and cancer cells were apparently changed.
  • Fig. 61 As depicted in Fig. 61, it could be identified that the T2 values after injection were highly changed.
  • the magnetic nanocomposite according to the present invention, covered with the aniphiphilic compound having hydrophobic domains and a hydrophilic domains may be used in a contrast agent for high sensitive MRI, an intelligent contrast agent for diagnosing cancer by binding to the binding parts materials that may specifically be bound to tumor markers, a drug delivery system for diagnosis and treatment of cancer by polymerizing or enclosing a drug in the hydrophobic domains, and a formulation for separating cells and proteins using magnetism by binding an antibody or a protein specific to surface antigens of functional cells, stem

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific binder ingredient, a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enveloping drugs and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same.

Description

[DESCRIPTION] [Invention Title]
MAGNETIC NANO-COMPOSITE FOR CONTRASTAGENT, INTELLIGENT CONTRASTAGENT, DRUG DELIVERYAGENT FOR SIMULTANEOUS
DIAGNOSIS AND TREATMENT, AND SEPARATIONAGENT FOR TARGET
SUBSTANCE [Technical Field]
The present invention relates to a water soluble magnetic nanoconiposite using an amphiphilic compound. Specifically, the present invention relates to a water soluble magnetic nanocomposite which may be not only used as a contrast
agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific binder ingredient, a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enclosing a drug and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same
[Background Art]
Nanotechnology is the technique of manipulating and controlling materials on an atomic or molecular scale, is suitable to invent new materials or new devices, and thus has a variety of applications such as electronics, materials, communication,
mechanics, medicine, agriculture, energy, and environment Nanotechnology is variously developed and is classified as the following three fields:
First, it relates to the technique of synthesizing new materials with an ultramicroscopic size as nano -materials.
Second, it relates to the technique of manufacturing devices, such as nano
devices, displaying a certain function by combining or arranging materials with a
nano scale.
Third, it relates to the technique of applying the nanotechnology, called nanobiotechnology, to biotechnology.
Especially, among the field of nanobiotechnology, the magnetic nanoparticle is used in a broad range of applications, such as separation of biological components,
a diagnostic probe for magnetic resonance imaging, biosensors including giant
magnetoresistive sensors, micro fluidic sensors, drug/gene delivery, and a magnetic
hyperthermia. In particular, the magnetic nanoparticle may be used in a diagnostic probe
(contrast agent) of molecular magnetic resonance imaging. The magnetic
nanoparticle is allowed to reduce a spin-spin relaxation time of a hydrogen atom in water molecules surrounding nanoparticles to show the effect of amplifying signals of magnetic resonance imaging, and thus have been broadly used in diagnosis of
resonance imaging.
In addition, the magnetic nanoparticle may serve as a probe material of
Giant magnetic resistance (GMR) sensor. When the magnetic nanoparticle senses a biological molecule patterned on the surface of GMR biosensor and binds to it, it changes current signals of the GMR sensor. Using such change, a biological molecule can be selectively detected (US 6,452,763 Bl; US 6,940,277 B2; US 6,944,939 B2; US 2003/0133232 Al). Furthermore, the magnetic nanoparticle may be applied to separate a biological molecule. For example, when a cell expressing specific biomarker is
mixed with other cells, only the desired cell may be separated along direction of the magnetic field by selectively binding the nanoparticle to a specific biomarker and then applying an external magnetic field (Whitehead et al. US patent 4,554,088,US 5,665,582, US 5,508,164, US 2005/0215687 Al). Furthermore, it may be applied to separate various biological molecules, including a protein, an antigen, a peptide, DNA, RNA, and a virus as well as a cell. Also, the magnetic nanoparticle may be applied to micro fluidic censors to separate and detect biological molecules. It is possible to detect and separate a biological molecule in a micro unit system by forming very small channels on a chip and a flowing magnetic nanoparticle therein.
Meanwhile, the magnetic nanoparticle may also be used in a biotherapy through delivering a drug or a gene. The selective effect of treatment may be obtained by moving the nanoparticle loaded with a drug or a gene through a chemical bond or adsorption to the desired position by an external magnetic field and allowed to release the drug and the gene on the region of interest (US
6,855,749).
As another example of application for biotherapy using the magnetic nanoparticle, it includes hyperthermia using magnetic spin energy (US 6,530,944
B2, US 5,411,730). Along an external alternating current with radio frequency on the magnetic nanoparticle, heat is released through a spin flipping procedure. If the temperature around nanoparticle is more than 40 °C, a cell is killed due to high heat and thus a disease cell may be selectively killed.
To apply the magnetic nanoparticle for the uses described above, it should have an excellent magnetic property, be stably carried and dispersed in vivo, that is, in a water soluble environment, and be capable to easily combine with a bioactive material. A variety of techniques have been developed until now to meet such
conditions.
US Patent No. 6,274,121 relates to a paramagnetic nanoparticle comprising a metal such as iron oxide and discloses a nanoparticle to whose surface is bound to an inorganic substance including binding sites for coupling to a tissue-specific binding substance, a diagnostic or pharmacologically active substance. US Patent No. 6,638,494 relates to a paramagnetic nanoparticle comprising a metal such as iron oxide and discloses the method of preventing aggregation and
sedimentation of a nanoparticle in a gravitational field or in a magnetic field by binding a particular carboxylic acid to its surface. As said carboxylic acid, aliphatic dicarboxylic acid such as maleic acid, tartaric acid, or glucaric acid, or aliphatic poly dicarboxylic acid such as citric acid, citric acid, cyclohexane, or tricarboxylic acid was used.
US Patent Application Publication No. 2004/58457 relates to a functionalized nanoparticle coated with a monolayer. A bifunctional peptide is attached to said monolayer, to which various biopolymers including DNA and RNA may be bound.
GB Patent Application No. 223,127 relates to a method for making a magnetic nanoparticle, including the step of forming a magnetic nanoparticle within a protein template, wherein described a method for encapsulating a nanoparticle into apoferritin.
US Patent Application Publication No. 2003/190,471 relates to a method for forming a nanoparticle of manganese zinc ferrite within dual micelles, wherein was described the nanoparticle showing an improved property through procedures of heat treating the formed magnetic nanoparticle.
In US Patent Application Publication No. 2005/130,167, the synthesis of a
water soluble magnetic nanoparticle covered with 16-mercaptohexadecanoic acid was described, together with detection of a virus and mRNA in an experimental rat with intracellular magnetic labeling, using a TAT peptide, a transfection agent, on the synthesized magnetic nanoparticle.
KR Patent Application No. 10-1998-0705262 discloses a particle comprising a superparamagnetic iron oxide core provided with a starch coating and optionally a
polyalkyleneoxide coating and MRI contrast media containing the same.
However, water soluble nanoparticles prepared by the methods above have
the following disadvantages:
In US Patent Nos. 6,274,121, 6,638,494, and 2004/58457; US Patent Application Publication No. 2003/190,471, and 2005/130,167, GB Patent Application No. 223,127, and KR Patent Application No. 10-1998-0705262, since the disclosed nanoparticle is mainly synthesized in a water solution, the size of nanoparticle is
not easily controlled and the resulting nanoparticle show a non-uniform size distribution. In addition, since they are synthesized at a low temperature, the resulting nanoparticle has low crystalline property, and can be formed in a non-stoichiometric compound. Therefore, the nanoparticles prepared by the methods above have problems that show low stability of colloid in a water solution and thus aggregation on applying in vivo, and high non-selective binding, and the like.
[Disclosure]
[Technical Problem]
The present invention intends to solve the problems above. The object of the present invention is to provide a magnetic nanocomposite having so high stability in a water solution with low toxicity that may widely apply for diagnosis and treatment of organism, which is characterized in that a magnetic nanoparticle is covered with an amphiphillic compound having one or more hydrophobic domains and one or more hydrophillic domains.
Another object of the present invention is to provide an intelligent magnetic nanocomposite which is characterized in that a magnetic nanoparticle is covered with an amphiphillic compound having one or more hydrophobic domains and one or more hydrophillic domains, and one or more binding parts for a hydrophillic active ingredient present in said hydrophillic domain are bound to a tissue-specific binding substance.
Still another object of the present invention is to provide a magnetic nanocomposite for simultaneous diagnosis and treatment which is characterized in
that a magnetic nanoparticle is covered with an amphiphillic compound having one
or more hydrophobic domains and one or more hydrophillic domains, one or more
binding parts for a hydrophillic active ingredient present in said hydrophillic domain are bound to a tissue-specific binding substance, and a pharmaceutically
active ingredient is bound to or enclosed in said hydrophobic domain.
Still another object of the present invention is to provide a method for separating a target substance which comprises binding a magnetic nanocomposite
to a target substance and applying a magnetic field on the combination of the
magnetic nanocomposite and the target substance, wherein said nanocomposite is
characterized in that a magnetic nanoparticle is covered with an amphiphillic
compound having one or more hydrophobic domains and one or more hydrophillic
domains, and one or more binding parts for a hydrophillic active ingredient present in said hydrophillic domain are bound to a tissue-specific binding substance.
Still another object of the present invention is to provide a method for preparing the magnetic nanoparticle according to the present invention above.
The other object of the present invention is to provide a contrast agent, a
composition for diagnosis and a pharmaceutical composition, comprising the
magnetic nanocomposite according to the present invention above and a pharmaceutically acceptable carrier, and a method for using the same.
[Technical Solution]
The magnetic nanocomposite according to the present invention is described
in more detail below.
The magnetic nanocomposite according to the present invention has one
feature that an amphiphillic compound is added to a surface of nanoparticle to bind
the hydrophobic domains of amphiphillic compounds to the surface of nanoparticle,
and to distribute the hydrophillic domains of an amphiphillic compound over the
outermost part of nanoparticle. The hydrophobic domains of an amphiphillic compound are bound to the surface of nanoparticle by a hydrogen bond, Van der
Waals force, and a physical bond such as a polar attraction. Therefore, said
hydrophobic domain does not only play a role in dispersing a nanoparticle in matrix
of the hydrophobic domain or binding to the surface of nanoparticle, but also, if
necessary, may physically enclose a drug in the matrix of hydrophobic domain or
chemically bind a drug to one end of the hydrophobic domain. Meanwhile, the
hydrophillic domain of an amphiphilic compound may be distributed in the outermost part of nanocomposite to stabilize a water insoluble nanoparticle in a water soluble medium and maximize bioavailibility.
In addition, the magnetic nanocomposite according to the present invention
has another feature that a metal, a magnetic material, or a magnetic alloy as a
nanoparticle may be bound to an organic surface stabilizer. The bond of metal, magnetic material, or magnetic alloy to the organic surface stabilizer is achieved by coordinating the organic surface stabilizer to a precursor of metal, magnetic material, or magnetic alloy to form a complex. Said organic surface stabilizer may act in stabilizing the hydrophobic domain of an amphiphillic compound. Furthermore, the magnetic nanocomposite according to the present invention has another feature that said hydrophobic domain may have one or more binding parts for a hydrophobic active ingredient (Rl) within some part of its structure, and said hydrophilic domain may have one or more binding parts for a hydrophilic
active ingredient (R2) within some part of its structure. When various active ingredients are bound to the binding parts for a hydrophilic active ingredient and the binding parts for a hydrophobic active ingredient, the magnetic nanocomposite according to the present invention may be used in various uses such as an intelligent contrast agent for cancer diagnosis, a drug delivery system that cancer diagnosis and treatment can be simultaneously performed, and an agent for separating a protein. Its schematic diagram is depicted in Fig. 1.
As shown in Fig. 2, the magnetic nanocomposite according to the present invention as above includes a magnetic nanocomposite comprising a core that one or more magnetic nanoparticles are distributed in the hydrophobic domain and a shell containing the hydrophilic domain ("emulsion type magnetic nanocomposite," below) and a magnetic nanocomposite comprising a core that one magnetic nanoparticle is bound to the hydrophobic domains and a shell containing the hydrophilic domain ("suspension type magnetic nanocomposite," below), depending on their preparation 7 000961
methods.
It is preferred that all the magnetic nanoparticles of the emulsion type
magnetic nanocomposite and suspension type magnetic nanocomposite is
coordinated to a metal, a magnetic material, or a magnetic alloy, and that magnetic
nanoparticles are physically bound to the hydrophobic domains of an amphiphilic compound.
In addition, the desired diameter of the emulsion type nanocomposite is 1 nm
to 500 nm, and more preferably 25 nm to 100 nm. The desired diameter of the
suspension type nanocomposite is 1 nm to 50 nm, and more preferably 5 nm to 30
nm.
It is also preferred the magnetic nanocomposite according to the present
invention that a magnetic nanoparticle is covered with an amphiphilic compound
having one or more hydrophobic domains and one or more hydrophilic domains, and
one or more binding parts for a hydrophilic active ingredient are bound to a
tissue-specific binding substance.
It is also preferred the magnetic nanocomposite according to the present
invention that a magnetic nanoparticle is covered with an amphiphilic compound
having one or more hydrophobic domains and one or more hydrophilic domains, one
or more binding parts for a hydrophilic active ingredient are bound to a tissue-specific binding substance, and a pharmaceutically active ingredient is bound
or enclosed in the hydrophobic domains.
"Magnetic nanoparticle" in the magnetic nanocomposite according to the present invention may be used without limitation, as long as it has magnetism and have a diameter of 1 nm to 1000 nm, and preferably 2 nm to 100 nm, but it is
preferably a metal material, a magnetic material, or a magnetic alloy.
Said metal is not specifically limited, but preferably selected from the group consisting of Pt, Pd, Ag, Cu and Au.
Said magnetic material is also not specifically limited, but preferably selected from the group consisting of Co, Mn, Fe, Ni, Gd, Mo, MM^O4, and MxOy (each M or M' independently represents Co, Fe, Ni, Mn, Zn, Gd, or Cr, 0 < x =3, 0 < y =5).
In addition, said magnetic alloy is also not specifically limited, but preferably selected from the group consisting of CoCu, CoPt, FePt, CoSm, NiFe and NiFeCo.
It is also preferred that a metal, a magnetic material, or a magnetic alloy is bound to an organic surface stabilizer. The organic surface stabilizer is referred to an organic functional molecule being capable to stabilize the state or size of nanoparticle, and includes a surfactant as a representative example. The surfactant that may be used includes, but not limited to, cationic surfactant, including alkyl trimethylammonium halide; neutral surfactant, including saturated or unsaturated fatty acid such as oleic acid, lauric acid, or dodecylic acid, trialkylphosphine or trialkylphosphine oxide such as trioctylphosphine oxide (TOPO), trioctylphosphine (TOP), or tributylphosphine, alkyl amine such as dodecylamine, oleicamine, trioctylamine, or octylamine, or alkyl thiol; and anionic surfactant, including sodium alkyl phosphate.
Especially, considering stabilization and uniform size distribution of nanoparticles, it is preferred to use a saturated or unsaturated fatty acid and/or alkylamine.
The amphiphilic compound according to the present invention is not specifically limited, if it has one or more hydrophobic domains (Pl) and one or more
hydrophilic domains (P2). In the amphiphilic compound, the hydrophobic domains
(Pl) and a hydrophilic domains (P2) may be linked and bounded as multi domains.
That is, the amphiphilic compound may have a variety of forms such as P1-P2,
P1-P2-P1, P2-P1-P2, Pl-(P2-Pl)n-P2, Pl-(P2-Pl)n-Pl, P2-(P1-P2)n-Pl, or
P2-(P1-P2)n-P2. Of course, the repeated hydrophobic domains or hydrophilic domains may be present within its structure.
The hydrophobic domains of an amphiphilic compound according to the present invention may consist of a compound or a polymer. For example, a biocompatible saturated or unsaturated fatty acid, or a hydrophobic polymer may be
used. Said saturated fatty acid is not specifically limited, but may use one or more selected from the group consisting of butyric acid, caproic acid, caprylic acid, capric acid, lauric acid (dodecyl acid), miristic acid, palmitic acid, stearic acid, eicosanoic acid, and docosanoic acid. Said unsaturated fatty acid is also not specifically limited, but may use one or more selected from the group consisting of oleic acid, linoleic acid, linolenic acid, arakydonic acid, eicosapentanoic acid, docosahexanoic
acid, and erucic acid.
Saturated or unsaturated fatty acids that may be used in the amphiphilic compound according to the present invention are set forth in Tables 1 and 2 below: [Table 1]
Figure imgf000015_0001
[Table 2]
Figure imgf000015_0002
Figure imgf000016_0001
Meanwhile, the hydrophobic polymer that may be used in the amphiphilic
compound according to the present invention is not specifically limited, but
preferably one or more selected from the group consisting of polyphospazene, polylactide, polylactide-co-glycolide, polycaprolactone, poly anhydride, polymalic acid
or derivatives thereof, polyalkylcyanoacrylate, polyhydroxybutylate, polycarbonate, polyorthoester, a hydrophobic polyamino acid and a hydrophobic vinyl based polymer. In addition, said hydrophobic polymer has preferably a weight average
molecular weight of 100 to 100,000. If the weight average molecular weight is less
than 100, toxicity of the polymer is occurred. If the weight average molecular weight is in excess of 100,000, it is difficult to be applied.
The hydrophilic domains of an amphiphilic compound according to the
present invention may consist of a compound or a polymer. For example, a biocompatible polymer may be used.
Said biocompatible polymer is not specifically limited, but preferably one or
more selected from the group consisting of polyalkyleneglycol (PAG), polyetherimide(PEI), polyvinylpyrrolidone (PVP), a hydrophilic polyamino acid and
a hydrophilic vinyl based polymer, and more prefeably polyethyleneglycol. In
addition, said hydrophilic polymer has preferably a weight average molecular
weight of 100 to 100,000. If the weight average molecular weight is less than 100,
toxicity of the polymer is occurred. If the weight average molecular weight is in
excess of 100,000, it is difficult to be applied.
Especially, said polyalkyleneglycol is preferably polyethyleneglycol (PEG) or monomethoxypolyethyleneglycol (mPEG), and more preferably polyethyleneglycol
substituted with carboxyl or amine.
In addition, said hydrophobic domain (Pl) has one or more binding parts for a
hydrophobic active ingredient (Rl) within some part of its structure, preferably in
the end of structure. Said hydrophilic domain (P2) has one or more binding parts
for a hydrophilic active ingredient (R2) within some part of its structure, preferably
in the end of structure.
When a material that may specifically be bound to, for example, a tumor marker is bound to the binding parts for a hydrophilic ingredient (R2), the magnetic nanocomposite according to the present invention may be used in an intelligent conatrast agent for cancer diagnosis.
When a drug is polymerized or enclosed in the binding parts for a hydrophobic active ingredient (Rl) or the hydrophobic domains (Pl), and the material that may specifically be bound to a tumor marker is simultaneously bound to the binding parts for a hydrophilic ingredient (R2), the magnetic nanocomposite according to the present invention may be used in a drug delivery system for simultaneous diagnosis and treatment of cancer.
Meanwhile, when an antibody or a protein specific to a surface antigen of functional cell, stem cell or cancer cell is bound to the binding parts for a hydrophilic active ingredient (R2), the magnetic nanocomposite according to the present invention may be used for separating a cell and a protein using magnetism. In addition, said hydrophilic domain (P2) of the magnetic nanocomposite according to the present invention is characterized in that the domain has the binding parts for a hydrophilic active ingredient (R2) within its structure, preferably in the end of structure, and the binding parts for a hydrophilic active
ingredient (R2) are bound to a tissue-specific binding substance.
Said hydrophilic active ingredient may be selected from the group consisting of a bioactive ingredient, a polymer, and an inorganic support. In the specification of the present invention, "a bioactive ingredient" has the same meaning as "a tissue-specific binding substance" or "a pharmaceutically active ingredient," which may be used interchangeably each other. The binding part for a hydrophilic active ingredient (R2) may be optionally changed depending on a hydrophilic active ingredient, that is, a tissue-specific binding substance, to be bound. Preferably, the binding part includes, but not limited to, one or more functional groups selected from the group consisting of
-COOH, -CHO, -NH2, -SH, -CONH2, -PO3H, -PO4H, -SO3H, -SO4H, -OH, -NR4 +X-, -sulfonate, -nitrate, -phophonate, -succinimidyl, -maleimide, and -alkyl.
The tissue-specific binding substance includes, but not limited to, an antigen, an antibody, RNA, DNA, hapten, avidin, streptavidin, neutravidin, protein A, protein G, lectin, selectin, a radioisotope labeled component, or a tumor marker. The nanocomposite of the present invention may be used for diagnosing and/or treating various diseases related to tumor, for example, gastric cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer and cervical cancer. Such tumor cell expresses and/or secretes particular materials less or not at all produced by a normal cell, which generally called "tumor marker." The nanocomposite prepared by binding a material that may be specifically bound to such tumor marker to the binding parts for an active ingredient of the water soluble nanoparticle may be advantageously used in diagnosing tumor. Not only various
tumor markers but also materials that may be specifically bound to such tumor marker are known in this field.
In addition, the tumor marker may be classified as a ligand, an antigen, a receptor, and encoding nucleic acids thereof, depending on the mode of action.
[Table 3]
Figure imgf000020_0001
When the tumor marker is a ligand, the material that may be specifically bound to said ligand can be introduced as an active ingredient of the nanocomposite
according to the present invention, and suitably, a receptor or an antibody that may be specifically bound to the ligand. Examples of a ligand to be used herein and a receptor that may be specifically bound to the ligands include, but not limited to, C2
of synaptotagmin and phosphatidylserine, annexin V and phosphatidylserine, integrin and receptor thereof, VEGF (Vascular Endothelial Growth Factor) and receptor thereof, angiopoietin and a Tie2 receptor, somatostatin and receptor
thereof, a vasointestinal peptide and receptor thereof, and the like.
When the tumor marker is an antigen, the material that may be specifically
bound to the antigen can be introduced as an active ingredient of nanocomposite
according to the present invention, and suitably, an antibody that may be
specifically bound to the antigen. Examples of an antigen to be used herein and an
antibody that may be specifically bound to the antigen include a carcinoembryonic antigen (colon cancer labeled antigen) and Herceptin (Genentech, USA), a
HER2/neu antigen (breast cancer labeled antigen) and Herceptin, a
prostate-specific membrane antigen (prostate cancer labeled antigen) and Rituxan
(IDCE/Genentech, USA), and the like.
Representative examples of "a receptor" as the tumor marker include a follic
acid receptor expressed in ovarian cancer. The material that may be specifically
bound to the receptor (follic acid in case of follic acid receptor) can be introduced as an active ingredient of nanocomposite according to the present invention, and suitably, a ligand or an antibody that may be specifically bound to the receptor. As described above, an antibody as an active ingredient is most preferably
herein, because the antibody has a property being selectively and stably bound to
the particular subject only and -NH2 of lysine, -SH of cysteine, and -COOH of asparginic acid and glutamic acid present in Fc domain of the antibody may be usefully utilized to be bound to a functional group of binding parts for an active ingredient in a water soluble nanocomposite.
Such antibody is commercially available or may be prepared according to the known methods in this field. Generally, a mammal (for example, mouse, rat, goat, rabbit, horse or sheep) is immunized more than one time with an appropriate amount of an antigen. After a certain time period, when the titer reaches to the appropriate level, the antibody is recovered from serum of the mammal. If desired, the recovered antibody may be purified using the known process and stored in the frozen buffer solution until use. Detail of such method is well known in this field.
Meanwhile, said "nucleic acid" includes a ligand, an antigen, a receptor or RNA and DNA encoding some of these, as described above. As known in this field, a nucleic acid is characterized by forming base pairs between complementary sequences. Thus, the nucleic acid having particular base sequences may be detected, using the nucleic acid having complementary base sequences to said base sequences. The nucleic acid having complementary base sequences to the nucleic
acid encoding an enzyme, a ligand, an antigen, a receptor above may be used as an active ingredient of nanocomposite according to the present invention.
In addition, the nucleic acid has a functional group such as -NH2, -SH, -COOH on the 5'- and 3'- ends, and thus may be usefully used to be bound to the functional group of binding parts for an active ingredient.
Such nucleic acid can be synthesized by the standard method known in this field, for example, using an automatic DNA synthesizer (for example, those
available from Biosearch, Applied Biosystems, and the like). For example,
phosphorothioate oligonucleotide may be synthesized by the method described in
Stein et al. Nucl. Acids Res. 1988, vol.16, p.3209. Methylphosphonate
oligonucleotide may be synthesized using the controlled glass polymer support
(Sarin et al. Proc. Natl. Acad. Sci. U.S.A. 1988, vol.85, p.7448).
Meanwhile, it is preferred that the hydrophobic domain (Pl) of the magnetic
nanocomposite according to the present invention has one or more binding parts for
a hydrophobic active ingredient (Rl) within some part of its structure, preferably, in
the end of structure. The hydrophobic active ingredient may be bound or enclosed
in said binding parts for a hydrophobic active ingredient (Rl) or said hydrophobic
domains (Pl).
The hydrophobic active ingredient is preferably selected from the group
consisting of a bioactive ingredient, a polymer, and an inorganic support. For example, when a drug as a hydrophobic active ingredient is bound or enclosed, and
a tissue-specific binding substance is simultaneously bound, to the binding parts for
a hydrophilic active ingredient (R2), the magnetic nanocomposite may be used in a
drug delivery system for simultaneous diagnosis and treatment of cancer.
The binding parts for a hydrophobic active ingredient (Rl) in said
hydrophobic domain (Pl) may be optionally changed depending on the kind of hydrophobic active ingredient to be bound. Preferably, representative examples
include, but not limited to, one or more functional groups selected from the group consisting of -COOH, -CHO, -NH2, -SH, -CONH2, -PO3H, -PO4H, -SO3H, -SO4H, -OH, -succinimidyl, -maleimide, and -alkyl.
The hydrophobic active ingredient is not specifically limited, if it is a pharmaceutically active ingredient, but preferably one or more selected from the
group consisting of an anticancer agent, an antibiotic, a hormone, a hormone antagonist, interleukin, interferon, a growth factor, a tumor necrosis factor, endotoxin, lymphotoxin, eurokinase, streptokinase, a tissue plasminogen activator, a protease inhibitor, alkylphosphocholine, a radioisotope labeled component, a surfactant, a cardiovascular system drug, a gastrointestinal system drug and a nervous system drug.
Meanwhile, the hydrophobic active ingredient present in the hydrophobic domain, particularly, an anticancer agent may be enclosed by a physical inclusion, a chemical inclusion, or a combination thereof. The inclusion of a drug is achieved through a physical bond of an anticancer agent with a hydrophobic active ingredient of an amphiphilic polymer, for preparing magnetic nanocomposite by an emulsion method and a suspension method. In case of an anticancer agent which can be bound to binding parts for a hydrophobic active ingredient of an amphiphilic polymer constituting a magnetic nanocomposite, it may be bound to binding parts for a hydrophobic active ingredient of the amphiphilic polymer by an appropriate cross-linking agent and thus the inclusion of a drug in the magnetic nanocomposite
can be achieved.
The anticancer agent which may be used in the method of treatment according the present invention includes, but not limited to, Epirubicin, Docetaxel, Gemcitabine, Paclitaxel, Cisplatin, Carboplatin, Taxol, Procarbazine, Cyclophosphamide, Dactinomycin, Daunorubicin, Etoposide, Tamoxifen, Doxorubicin, Mitomycin, Bleomycin, Plicomycin, Transplatinum, Vinblastin and Methotrexate.
In the magnetic nanocomposite according to the present invention, it is
preferred that an amphiphilic compound consists of a hydrophobic domain- a hydrophilic domain, or a hydrophilic domain- a hydrophobic domain- a hydrophilic domain. When each binding part for an active ingredient is included in hydrophilic domains and hydrophobic domains, the amphiphilic compound may consist of binding parts for a hydrophobic active ingredient- a hydrophobic domain- a
hydrophilic domain-a binding part for a hydrophilic active ingredient, or binding parts for a hydrophilic active ingredient- a hydrophilic domain- a hydrophobic domain(- a binding part for a hydrophobic active ingredient)- a hydrophilic domain- a binding part for a hydrophilic active ingredient. Especially, it is preferred to have a functional group such as -NH2- in the hyrophilic domains and hyrophobic domains, such as binding parts for a hydrophobic active ingredient- a hydrophobic domain -NH2- a hydrophilic domain- a binding part for a hydrophilic active ingredient. -NH2- group present in the hydrophilic domains and hydrophobic domains may have more stable structure, if an amphiphilic compoud is added to a
surface of magnetic nanoparticle.
Most preferably, examples of an amphiphilic compound in the magnetic nanocomposite according to the present invention include
carboxylpolyethyleneglycol-polylactide-co-glycolide copolymer or poly(ethylene oxide) -poly (propylene oxide)-poly(etylene oxide) copolymer substituted with carboxy groups on both ends.
The present invention also relates to a method for preparing a magnetic
nanocomposite which comprises the steps of:
A) synthersizing nanoparticles in a solvent; and
B) adding an amphiphilic compound having a hydrophobic domain and a
hydrophilic domain to the surfaces of nanoparticles to bind the amphiphilic
compound and nanoparticles.
The method for preparing the magnetic nanocomposite according to the
present invention further comprises optionally
C) binding the binding part present in said hydrophilic domain and the
material that may be specifically bound to a tumor marker; and
D) binding or enclosing a pharmaceutically active ingredient in the
hydrophobic domain.
The method for preparing the magnetic nanocomposite according to the present invention is described in more detail below.
The step A) of synthesizing nanoparticles in a solvent is one that precursors
of nanoparticles are reacted with a surface stabilizer, and preferably includes the
steps of a) reacting an organic surface stabilizer with the precursors of nanoparticles in presence of a solvent; and
b) thermolyzing the resulting reactant.
In the step a), the precursors of nanoparticle are poured into the solvent including an organic surface stabilizer, which is subsequently coordinated to the surfaces of nanoparticles.
As a nanoparticle in the step a), a metal, a magnetic material, or a magnetic
alloy is preferably used. The organic surface stabilizer may be selected from the
group consisting of alkyl trimethylammonium halide, saturated or unsaturated
fatty acid, trialkylphosphine oxide, alkyl amine, alkyl thiol, sodium alkyl sulfate,
and sodium alkyl phosphate. The specific example of a metal, a magnetic material, a magnetic alloy and an organic surface stabilizer is described above.
As a precursor of nanoparticle in the step a), a metal compound that the metal is bound to -CO, -NO, -C5H5, alkoxides or other known ligands may be used.
Specifically, various organic metal compounds may be used, including a metal
carbonyl based compound such as iron pentacarbonyl (Fe(CO)s), ferrocene, or
manganese carbonyl (Mn2(CO)io); or a metal acetylacetonate based compound such
as iron acetylacetonate (Fe(acac)3). A metal ion containing metal salt that the metal is bound to a known anion such as Cl", or NO3" may be also used as a precursor of nanoparticle. Specifically, trichloroiron (FeCIa), dichloroiron (FeCl2),
or iron nitrate (Fe(NO3)3) may be used. Furthermore, a mixture of at least two metal precursors mentioned above may be used in synthesizing an alloy nanoparicle
and a combined nanoparticle. Preferably, the solvent that may be used in the step a) has high boiling point attaching to the thermolysis temperature of complex that the organic surface
stabilizer is coordinated to the surface of nanoparticle. For example, the solvent selected from the group consisting of an ether compound, a heterocyclic compound, an aromatic compound, a sulfoxide compound, an amide compound, an alcohol, a hydrocarbon and water may be used.
Specifically, the usable solvent is an ether compound such as octyl ether, butyl ether, hexyl ether, or decyl ether; a heterocyclic compound such as pyridine, or
tetrahydrofuran (THF); an aromatic compound such as toluene, xylene, mesitylen, or benzene; a sulfoxide compound such as dimethylsulfoxide (DMSO); an amide compound such as dimethylformamide (DMF); an alcohol such as octyl alcohol, or decanol; a hydrocarbon such as pentane, hexane, heptane, octane, decane, dodecane, tetradecane, or hexadecane; or water.
The reaction conditions in the step a) are not specifically limited, and may be suitably regulated depending on the kinds of metal precursor and surface stabilizer. The reaction may be occurred at room temperature or below. Usually, it is preferred to heat and keep the step in the range of about 30 to 200 °C .
In the step b), the complex that the organic surface stabilizer is coordinated to the surface of nanoparticle is thermolyzed to grow nanoparticle. According to the reaction conditions, a metal nanoparticle with uniform size and shape may be formed. The thermolysis temperature may be also suitably regulated depending on the kinds of metal precursor and surface stabilizer. Preferably, the reaction is suitably subjected in a range of about 50 to 500 °C . The nanoparticle prepared in
the step b) may be separated and purified by the known means.
In the method for preparing a magnetic nanocomposite according to the
present invention, the step B) comprises adding the amphiphilic compound having
hydrophobic domains and a hydrophilic domains to the surface of nanoparticle to
bond the amphiphilic compound and the nanoparticle.
The method of adding the amphiphilic compound to the surface of magnetic nanoparticle is classified into an emulsion type and a suspension type as described
above, whose schematic diagram is set forth in Fig. 2.
More specifically, the adding step B) preferably comprises the steps of:
a) dissolving a nanoparticle in an organic solvent to prepare an oil phase;
b) dissolving an amphiphilic compound in an aqueous solvent to prepare an
aqueous phase;
c) mixing the oil phase with the aqueous phase to form an emulsion; and d) separating the oil phase from the emulsion. The emulsion type magnetic
nanocomposite according to the present invention may be prepared.
In addition, the adding step B) preferably comprises the steps of:
e) dispersing a nanoparticle in a solution dissolving an amphiphilic
compound to prepare a suspension; and f) separating the solvent from the suspension. The suspension type magnetic nanocomposite according to the present invention may be prepared.
In the adding step B), the hydrophobic domain is preferably a saturated or unsaturated fatty acid or a hydrophobic polymer, and the hydrophilic domain is preferably a biodegradable polymer. Specific example is described above.
In the adding step B), the amphiphilic compound may be prepared by the
known methods in this field. For example, it may be prepared by polymerizing
diamine polyethylene glycol (NH2-PEG-NH2) constituting the hydrophilic group and
polylactide-co-glycolide, a biodegaradable polymer, constituting the hydrophobic
group.
In addition, the biding part for a hydrophilic active ingredient may be
substituted with a succinimidyl group, using N,N'-disuccinimidyl carbonate in the
binding part for a hydrophilic active ingredient substituted with an amine group of
the amphiphilic polymer. The biding part for a hydrophilic active ingredient of the
amphiphilic polymer may be also substituted with a carboxyl group by polymerizing
carboxyl/amine polyethylene glycol (NH2-PEG-COOH) constituting the hydrophilic
group and polylactide-co-glycolide, a biodegaradable polymer, constituting the
hydrophobic group. The biodegradable amphiphilic polymer may be prepared by ring-opening polymerization using lactide as a monomer. Polymerization of lactide
is initiated by an amine group of carboxyl/amine polyethylene glycol. Stannous
octoate may be used as a catalyst. The polymerization may be carried out in a temperature of 100 to 180 °C under nitrogen atmosphere. By regulating a
molecular weight and an amount of carboxyl/amine polyethylene glycol, an initial
macroinitiator, the molecular weight of compolymer may be regulated.
Preferably, the step C), for binding the material to which the binding part for a hydrophilic active ingredient present in the hydrophilic domain and a tumor marker may be specifically bound, comprises the steps of:
g) providing some of the hydrophilic domain with the binding part for a hydrophilic active ingredient, using a cross linking agent; and h) binding the binding part for a hydrophilic active ingredient and the material that may specifically bind to a tumor marker.
In the step g), the cross linking agent to be used is not specifically limited, but preferably includes one or more selected from the group consisting of
1,4-Diisothiocyanatobenzene, 1,4-Phenylene diisocyanate, 1,6-Diisocyanatohexane, 4-(4-Maleimidophenyl)butyric acid N-hydroxysuccinimide ester, Phosgene solution,
4-(Maleinimido)phenyl isocyanate, 1,6-Hexanediamine, p-Nitrophenyl chloroformate, N-Hydroxysuccinimide, 1, S-Dicyclohexylcarbodiimide, l,l'-Carbonyldiimidazole, 3-Maleimidobenzoic acid N-hydroxysuccinimide ester,
Ethylenediamine, Bis(4-nitrophenyl) carbonate, Succinyl chloride, N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide Hydrochloride,
N,N'-Disuccinimidyl carbonate, N-Succinimidyl 3-(2-pyridyldithio)propionate, and sucinic anhydride. The cross linking agent is reacted with some of the hydrophilic domain to provide the binding part for a hydrophilic active ingredient such as
-COOH, -CHO, -NH2, -SH, -CONH2, -PO3H, -PO4H, -SO3H, -SO4H, -OH, -NR4 +X", -sulfonate, -nitrate, -phophonate, -succinimidyl, -maleimide, or -alkyl.
In the step h), the functional group of binding part for a hydrophilic active
ingredient may be changed depending on the kind of active ingredient, that is, a tissue-specific binding component, and its chemical formula.
In the method for preparing a nanocomposite according to the present invention, the step D) for binding or enclosing the pharmaceutically active ingredient in the hydrophobic domain can be classified into a step of physically enclosing the pharmaceutically active ingredient in the hydrophobic domain and a step of chemically binding the pharmaceutically active ingredient to the hydrophobic domain.
Preferably, the chemically binding step comprises the steps of: i) providing some of the hydrophobic domain with the binding part for a hydrophobic active ingredient, using a cross linking agent; and j) binding the binding part for a hydrophobic active ingredient and the pharmaceutically active ingredient.
As the cross linking agent that may be used in the step i), the cross linking agent in the step g) above may be employed, without limitation. The cross linking agent is reacted with some of the hydrophobic domain to provide the binding part for a hydrophobic active ingredient such as -COOH, -CHO, -NH2, -SH, -CONH2,
-PO3H, -PO4H, -SO3H, -SO4H, -OH, -succinimidyl, -maleimide, or -alkyl above.
The step of physical inclusion may be carried out by dissolving the pharmaceutically active ingredient along with nanoparticles and enclosing the ingredient in them in the step B) for binding the amphiphilic compound and nanoparticles. More specifically, when the pharmaceutically active ingredient is enclosed in the emulsion type nanocomposite, the pharmaceutically active ingredient may be physically enclosed in the hydrophobic domain by dissolving the
pharmaceutically active ingredient in an organic solvent along with nanop articles,
mixing with the aqueous phase to form an emulsion, and separating the oil phase, in the step a) that the nanoparticles above are dissolved in an organic solvent to
prepare the oil phase. When the pharmaceutically active ingredient is enclosed in
the suspension type nanocomposite, the pharmaceutically active ingredient may be
physically enclosed in the hydrophobic domain by dispersing the pharmaceutically
active ingredient along with nanoparticles to prepare suspension and separating
the solvent, in the step e) for preparing suspension by dispersing nanoparticles in the solution dissolving the amphiphilic compound.
The bond of binding part for a hydrophilic or hydrophobic active ingredient
and a hydrophilic or hydrophobic active ingredient in the steps h) and i) may be changed depending on the kind of each active ingredient, and its chemical formula. Specific example is set forth in Table 4 below.
[Table 4]
Figure imgf000033_0001
Figure imgf000034_0001
The resulting water soluble nanocomposite in the steps A), B), C) and D) above can be separated using the known methods in this field. Generally, the water soluble nanocomposite is produced in a precipitate. Thus, it is preferred to separate it using centrifugation or filtration.
The present invention further relates to a contrast agent comprising a magnetic nanocomposite using an amphiphilic comound and a pharmaceutically acceptable carrier; a composition for diagnosing disease comprising a conjugate of a tissue-specific binding ingredient and the magnetic nanocomposite, and a pharmaceutically acceptable carrier; a pharmaceutical composition for simultaneous diagnosis and treatment comprising a conjugate of a tissue-specific binding ingredient and a pharmaceutically active ingredient and the magnetic nanocomposite, and a pharmaceutically acceptable carrier.
The carrier used in the composition according to the present invention
includes carriers and vehicles usually used in the pharmaceutical field. Specifically, it includes, but not limited to, ion exchange, alumina, aluminium stearate, lechitin, serum protein (for example, human serum albumin), buffer materials (for example, various phosphate, glycine, sorbic acid, potassium sorbate, partial glyceride mixture of vegetable saturated fatty acids), water, a salt or an elecrolyte (for example, protamyne sulfate, disodium hydrogenphosphate, potasium hydrogenphosphate, sodium chloride, and a zinc salt), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose based substrate, polyethylene glycol, sodium carboxylmethylcellulose, polyacrlyate, wax, polyethylene glycol or lanoline. The composition of the present invention may further comprises a lubricant, a wetting agent, an emulsifier, a suspending agent, or a preservative, in addition to the components above.
In one aspect, the composition according to the present invention may be
prepared in a form of water soluble solution for the parenteral administration. Preferably, Hank s solution, Ringer s solution or a buffer solution such as a
physically buffered saline may be used. To the water soluble suspension for
injection may be added a substrate that may increase the viscosity of suspension,
such as sodium carboxymethylcellulose, sorbitol or dextran.
Another preferable aspect of the present composition may be in a form of
sterile injection formulation in an aqueous or oil suspension. Such suspension may
be formulated using a suitable dispersing agent or wetting agent (for example,
Tween 80), according to the known technique in this field. The sterile injection
formulation may be a sterile injection solution or suspension (for example, a
solution in 1,3-butandiol) in a non-toxic, parenterally acceptable diluent or solvent.
The usable vehicle and solvent includes mannitol, water, Ringer's solution and an
isotonic sodium chloride solution. In addition, sterile nonvolatile oil is usually
used as a solvent or a suspending medium. For this purpose any of less irritable
nonvolatile oil including synthetic mono or diglyceride may be used.
The present invention also relates to a method for using a contrast
composition which comprises the steps of:
administrating the contrast composition according to the present invention to
an organism or a specimen; and sensing signals emitted by the magnetic nanocomposite from the organism or the specimen to obtain images.
The present invention also relates to a method for diagnosing disease which
comprises the steps of:
administrating a composition for diagnosis according to the present invention
to an organism or a specimen; and
sensing signals emitted by the magnetic nanocomposite from the organism or
the specimen to obtain images.
The present invention also relates to a method for simultaneously diagnosing
and treating disease which comprises the steps of:
administrating the pharmaceutical composition according to the present
invention to an organism or a specimen; and
sensing signals emitted by the magnetic nanocomposite from the organism or
the specimen to obtain images.
The term "specimen" used above refers to a tissue or a cell separated from the
subject to be diagnosed. In the step for injecting the contrast composition to an
organism or a specimen, the contrast composition may be administrated by routes
usually used in the pharmaceutical field, and preferably the parenteral
administration, for example, the intravenous, intraperitoneal, intramuscular,
subcutaneous or topical route.
In the method for using it, the signals emitted by magnetic nanocomposite
may be sensed by various apparatuses using the magnetic field, and more
preferably, Magnetic Resonance Imaging (MRI) Apparatus. Magnetic Resonance Imaging Apparatus refers to an apparatus for imaging
signals transformed from the emitting energy of an atomic nucleus such as
hydrogen through computer processing, wherein the emitting energy is obtained by putting an organism in a powerful magnetic field, irradiating a radio wave with particular frequency on the organism, and stopping the radio wave after an atomic
nucleus, such as hydrogen, present in a tissue of the oragnism absorbs energy and
ends up in the upper energy state. The magnetic field or the radio wave is not
interfered with bones. Thus, a clear three-dimensional tomographic imaging may
be obtained at longitudinal, transverse, an optional angle about tumor of bone
surroundings, brain or bone marrow. In particular, the magnetic resonance
imaging apparatus is preferably T2 spin-spin relaxation magnetic resonance
imaging apparatus.
The present invention relates to a method for separating a target substance
by binding magnetic nanocomposite to the target substance and applying a
magnetic field to conjugates of the magnetic nanocomposite and the target
substance, characterized in that nanoparticle is covered with an amphiphilic
compound having one or more of hyddrophobic domains and one or more hydrophilic
domains, and one or more binding parts for a hydrophilic active ingredient are
bound to a tissue -specific binding ingredient. In the method for separating according to the present invention, the
preferable example of a target substance refers to a biological molecule, more
specifically, includes, but not limited to, a cell, a protein, an antigen, a peptide, DNA, RNA, or a virus.
The magnetic nanocomposite formed according to the present invention may
be used in a nanoprobe for separation, diagnosis, treatment, etc. of a biological molecule, and a drug or gene delivery system, and the like.
A representative example of biological diagnosis using magnetic nanocomposite includes molecular magnetic resonance imaging diagnosis or
magnetic relaxation sensor. The magnetic nanocomposite shows much better T2
contrasting effect, as its size is increased. Using such property, the magnetic
nanocomposite may be used in a sensor for detecting biological moulecules. That is,
particular biological molecules lead to aggregation of the magnetic nanocomposite,
whereby the T2 magnetic resonance imaging effect is increased. The biological
molecule is detected using this difference.
In addition, the magnetic nanocomposite according to the present invention can constitute a diagnosing material for Giant magnetic resistance (GMR) sensor.
The magnetic nanocomposite may show more excellent magnetic characteristic,
better stability of colloid in a water solution and lower non-selective binding than
that of conventional beads with micrometer (106 m) size (US 6,452,763 Bl; US
6,940,277 B2; US 6,944,939 B2; US 2003/0133232 Al), and thus have the possibility
to improve the detecting limit of conventional GMR sensor.
The magnetic nanocomposite may be also used in separation and detection
using magnetic micro fluid sensors, delivery of drugs or genes, and magnetic
hyperthermia. Meanwhile, the magnetic nanocomposite according to the present invention may be used in dual- or multi-diagnostic probe, combining with other diagnostic probes. For example, when a water soluble magnetic nanocomposite is combined with a diagnostic probe of Tl magnetic resonance imaging, simultaneous diagnosis for T2 magnetic resonance imaging and Tl magnetic resonance imaging can be performed. When the nanocomposite is combined with an optical diagnostic probe, magnetic resonance imaging and optical imaging can be simultaneously performed. When the nanocomposite is combined with CT diagnostic probe, magnetic resonance imaging and CT diagnosis can be simultaneously performed. In addition, when the nanocomposite is combined with radioisotopes, magnetic resonance imaging, PET, SPECT can be simultaneously performed.
The diagnostic probe of Tl magnetic resonance imaging comprises a Gd compound, a Mn compound, and the like; the optical diagnostic probe comprises an organic fluorescent dye, a quantom dot, or a dye labeled inorganic support (for example, Siθ2, AI2O3); the CT diagnostic probe comprises a I (iodine) compound, a gold nanoparticle; and the radioisotope comprises In, Tc, F and the like. [Advantageous Effects]
The magnetic nanocomposite according to the present invention, covered with the amphiphilic compound having hydrophobic domains and a hydrophilic domains may be used in a contrast agent for high sensitive MRI, an intelligent contrast agent for diagnosing cancer by binding to the binding parts materials that may specifically be bound to tumor markers, a drug delivery system for diagnosis and treatment of cancer by polymerizing or enclosing a drug in the hydrophobic domains, and a formulation for separating cells and proteins using magnetism by binding an antibody or a protein specific to surface antigens of functional cells, stem cells or cancer cells thereto. [Description of Drawings ]
Fig. 1 is a schematic diagram which depicts applications of the magnetic nanocomposite according to the present invention.
Fig. 2 is a schematic diagram which depicts the method for preparing a magnetic nanocomposite using an amphiphilic polymer, according to one embodiment of the present invention.
Fig. 3 is a concept diagram of the emulsion type or suspension type magnetic nanocomposite according to one embodiment of the present invention.
Fig. 4 is transmission electron microphotographs of the magnetic nanoparticle using a saturated fatty acid, according to one embodiment of the present invention and a graph which depicts its magnteic property.
Fig. 5 is transmission electron microphotographs of the magnetic nanoparticle using a unsaturated fatty acid, according to another embodiment of the present invention and a graph which depicts its magnetic property.
Fig. 6 is a schematic diagram which depicts the method for preparing a
magnetic nanocomposite using a fatty acid amphiphilic polymer, according to one embodiment of the present invention.
Fig. 7 is a graph which depicts the infrared spectrometry (FT-IR) results of the magnetic nanoparticles and magnetic nanocomposite according to one
embodiment of the present invention.
Fig. 8 is a graph which depicts the Proton Nuclear Magnetic Resonance
(1H-NMR) result of the fatty acid amphiphilic compound according to one
embodiment of the present invention.
Fig. 9 is a schematic diagram which depicts the polymerizing process of the
amphiphilic polymer whose binding part for a hydrophilic active ingredient is
substituted with a carboxyl group by binding the active ingredient of a polymer,
according to one embodiment of the present invention.
Fig. 10 is a graph which depicts the 1H-NMR result of the biodegradable
amphiphilic compound whose binding part is substituted with a carboxyl group,
according to the present invention.
Fig. 11 is a graph which depicts the IR spectrometry result of the
biodegradable amphiphilic compound whose binding part is substituted with a
carboxyl group, according to the present invention.
Fig. 12 is a schematic diagram which depicts the polymerizing process of
biodegradable amphiphilic polymer whose binding part for a hydrophilic active
ingredient is substituted with a carboxyl group via active ingredient of a polymer,
according to the present invention.
Fig. 13 is a graph which depicts the IR spectrometry (FT-IR) result of the
biodegradable amphiphilic compound according to one embodiment of the present
invention. Fig. 14 is a graph which depicts the 1H-NMR result of the amphiphilic
polymer according to another preparation example of the present invention.
Fig. 15 is the synthesizing process of biodegradable amphiphilic polymer
substituted with a binding part for a hydrophilic active ingredient.
Fig. 16 is electron microphotographs of the emulsion type magnetic
nanoparticles using the nanoparticles and a biodegradable amphiphilic polymer,
according to one embodiment of the present invention and a graph which depicts
their size distribution.
Fig. 17 is electron microphotographs of the suspension type magnetic
nanoparticles using the nanoparticles and a biodegradable amphiphilic polymer,
according to one embodiment of the present invention and a graph which depicts
their size distribution.
Fig. 18 is electron microphotographs of the emulsion type magnetic
nanoparticles using the nanoparticles and a fatty acid amphiphilic polymer,
according to one embodiment of the present invention and a graph which depicts
their size distribution.
Fig. 19 is a graph which depicts the result of hysteresis loop in the emulsion
type magnetic nanocomposite using a fatty acid amphiphilic compound, according to
one embodiment of the present invention.
Fig. 20 is electron microphotographs showng the state that the magnetic
nanoparticles according to the present invention are enclosed by
carboxylpolyethyleneglycol-polylactide-co-glycolide and a graph which depicts their size distribution.
Fig. 21 is a graph which depicts the ratio by weight in the state that the
magnetic nanoparticles according to the present invention are enclosed by carboxylpolyethyleneglycol-polylactide-co-glycolide. Fig. 22 is hysteresis loops of magnetic nanoparticles and magnetic nanocomposite, according to the present invention.
Fig. 23 is an electron microphoto graph of the magnetic nanocomposite prepared by the suspension method according to the present invention and a graph which depicts their size distribution by a dynamic laser light scattering method. Fig. 24 is a thermogravimetric analysis graph of the magnetic nanoparticles prepared by the suspension method according to the present invention.
Fig. 25 is a transmission electron microphotograph of the water soluble magnetic nanocomposite according to one embodiment of the present invention and a graph which depicts the result of dynamic laser light scattering method. Fig. 26 is a graph which depicts the IR spectrometry result of the water soluble magnetic nanocomposite according to one embodiment of the present
invention.
Fig. 27 is an electron microphotograph of the magnetic nanocomposite prepared by the suspension method according to the present invention and their size distribution view by a light scattering method.
Fig. 28 is a thermogravimetric analysis graph of the magnetic nanoparticles prepared by the suspension method according to the present invention. Fig. 29 is an electron microphotograph of the nanocomposite prepared by the
emulsion method of the present invention, in which MnFβ2θ4 is enclosed by
polylactide-co-glycolide-polyethyleneglycol, and a size distribution view by a light scattering method. Fig. 30 is a result of the ratio by weight obtained through thermogravimetric analysis in the state that MnFe2θ4 prepared according to the present invention is enclosed by polylactide-co-glycolide-polyethyleneglycol, and its hysteresis loops.
Fig. 31 is photographs showng the arrangement of the magnetic nanocomposite by an external magnetic field, in which a fluorescent dye is enclosed, according to the present invention.
Fig. 32 shows solubility of organic nanoparticles in an organic solvent and solubility of water soluble magnetic nanocomposite, using a biodegradable amphiphilic compound, in a water solution, according to one embodiment of the present invention. Fig. 33 shows solubility of organic nanoparticles in an organic solvent, solubility of water soluble magnetic nanocomposite, using a fatty acid amphiphilic
compound, in a water solution, and a response appearance in an external magnetic field, according to one embodiment of the present invention.
Fig. 34 is graphs which depict salt concentrations of a water soluble magnetic nanocomposite using a fatty acid amphiphilic comound according to one embodiment of the present invention and the stability test results of them with pH. Fig. 35 is a photograph showng the particle stability of the water soluble magnetic nanocomposite with pH, according to one embodiment of the present invention and a graph of size change with pH.
Fig. 36 is a photograph showng the particle stability of the water soluble
magnetic nanocomposite with salt concentrations, according to one embodiment of
the present invention and a graph of size change with salt concentration.
Fig. 37 is a graph which depicts the change of MRI signals (T2) with
concentrations of the water soluble magnetic nanocomposite using a biodegradable amphiphilic compound, according to one embodiment of the present invention.
Fig. 38 is a graph which depicts the change of MRI signals (T2) with
concentrations of the water soluble magnetic nanocomposite using a fatty acid
amphiphilic compound, according to another embodiment of the present invention.
Fig. 39 is photographs that MRI is identified with concentrations of solutions
in which magnetic nanoparticles prepared by the suspension method according to
the present invention are dispersed and a graph of R2 value change.
Fig. 40 is a solution MRI photograph of the water soluble magnetic nanocomposite according to one embodiment of the present invention.
Fig. 41 is a graph which depicts T2 value of MRI of the water soluble
magnetic nanocomposite with Fe concentrations, according to one embodiment of
the present invention. Fig. 42 is photographs that MRI is identified with concentrations of solutions
dispersing magnetic nanoparticles whose hydrophilic end group is substituted with
a succinimidyl group, according to the present invention, and a graph of T2 value change with concentrations.
Fig. 43 is photographs that MRI is identified with concentrations of solutions in which magnetic nanoparticles prepared by the suspension method according to the present invention are dispersed, and a graph of T2 value change with
concentrations.
Fig. 44 is a graph which depicts fluorescence intensity by Fluorescence Activated Cell Sorter (FACS) of the cell reacted with the intelligent contrast agent for MRI according to one embodiment of the present invention.
Fig. 45 is MRI photographs of the positive cells reacted with the intelligent contrast agent for MRI according to one embodiment of the present invention.
Fig. 46 is a result of analyzing cell specificity of Herceptin-magnetic nanocomposite according to the present invention.
Fig. 47 is a view identifying affinity of Herceptin-magnetic nanocomposite, in
which MnFβ2U4 is enclosed, according to the present invention, to a cancer cell by flow cytometry.
Fig. 48 is a view identifying by flow cytometry to estimate the degree of binding Herceptin-magnetic nanocomposite and cells, according to the present invention.
Fig. 49 is a photograph obtained by MRI, after the emulsion type Herceptin-magnetic nanocomposite prepared according to another embodiment of the present invention is reacted with a target cell line (MDA-MB-231, NIH3T6.7 cell
line), and a comparative graph of T2 value. Fig. 50 is a photograph obtained by MRI, after the suspension type
Herceptin-magnetic nanocomposite prepared according to another embodiment of
the present invention is reacted with a target cell line (MDA-MB-231, NIH3T6.7 cell line), and a comparative graph of T2 value.
Fig. 51 is a graph of drug release behavior in the emulsion type magnetic
nanocomposite according to one embodiment of the present invention.
Fig. 52 is a graph of drug release behavior in the emulsion type magnetic
nanocomposite according to another embodiment of the present invention.
Fig. 53 is a graph of drug release behavior in the suspension type magnetic
nanocomposite according to another embodiment of the present invention.
Fig. 54 is a view identifying affinity of the magnetic nanocomposite, in which
MnFe2U4 is enclosed, according to the present invention, to a target cell by flow
cytometry.
Fig. 55 is a photograph identifying an appearance that the target cells
attached with magnetic nanocomposite, in which MnFβ2θ4 is enclosed, according to
the present invention, are moved toward one side surface of a wall by an external
magnetic field.
Figs. 56 to 58 are graphs which depict the cytotoxic test results of the water soluble magnetic nanocomposite according to one embodiment of the present
invention.
Figs. 59, 60 and 62 are MRIs of animal models scanned using the water
soluble magnetic nanocomposite according to one embodiment of the present invention.
Figs. 61 and 63 are graphs of R2 value change with injection time period of
the intelligent contrast agent for MRI according to one embodiment of the present invention. [Best Mode]
The present invention is described by examples in more detail below.
However, the examples below are intended to illustrate the present invention, do
not limit the present invention in any manner.
<Preparation Example 1>
Preparation of high sensitive magnetic nanoparticles using a saturated fatty
acid
Dodecanoic acid (0.6 mol) and dodecylamine(0.6 mol) in a benzylether solvent and iron triacetylacetonate (Aldrich) were thermolyzed at 290 °C for 30 minutes to
synthesize 6 nm magnetite (Fβ3θ4). The benzylether solution including dodecanoic
acid (0.2 mol), dodecylamine (0.1 mol), said 6 nm iron oxide nanoparticles (10
mg/ml) and iron triacetylacetonate was heated at 290 °C for 30 minutes to prepare
12 nm iron oxide nanoparticles. To the reaction above was added managnese II
acetylacetonate to prepare manganese ferrite (MnFβ2θ4). Transmission electron microphotographs of the prepared magnetite and manganese ferrite were depicted in Figs. 4a and 4b, respectively. The magnetic property of magnetite and manganese ferrite was measured using VSM. The measurements were
represented by a dotted line and a solid line, respectively and depicted in Fig. 4c. <Preparation Example 2>
Preparation of high sensitive magnetic nanoparticles using an unsaturated fatty acid
Oleic acid (0.6 mol) and olecylamine(0.6 mol) in a benzylether solvent and iron triacetylacetonate (Aldrich) were thermolyzed at 290 °C for 30 minutes to
synthesize 6 nm magnetite (FeSO4). The benzylether solution including oleic acid
(0.2 mol), oleylaniine (0.1 mol), said 6 nm iron oxide nanoparticles (10 mg/ml) and iron triacetylacetonate was heated at 290 °C for 30 minutes to prepare 12 nm iron
oxide nanoparticles. To the reaction above was added managnese II acetylacetonate to prepare manganese ferrite (MnFβ2θ4). Transmission electron microphotographs of the prepared magnetite and manganese ferrite were depicted in Figs. 5a and 5b, respectively. The magnetic property of magnetite and manganese ferrite was measured using VSM. The measurements were represented by a dotted line and a solid line, respectively and depicted in Fig. 5c. <Preparation Example 3>
Polymerization of a biodegradable amphiphilic polymer, monomethoxy-polyethyleneglycol-polylactide - co - glycolide
Moisture was removed from 2 g of monomethoxypolye thy Ie ne glycol (MPEG, molecular weight 5000) under reduced pressure. 2.0 mg of stannous octoate as a catalyst was added to absolute toluene, followed by reducing pressure at 100 °C for
20 to 30 minutes. 1.15 g of D,L-lactide and 0.93 g of glycolide were added to the reaction and polymerized at 140 "C for 12 h. To 5 ml of chloroform, the resulting block copolymer was added to be dissolved. An excess of diethylether was
portionwise dropped on the solution to obtain a precipitate, which was subsequently filtered, washed with diethylether and dried at 50 °C under reduced pressure to
obtain a block copolymer of monomethoxypolyethyleneglycol-polylactide-co-glycolide (Yield 72.5 %, including a loss amount).
A variety of double block copolymers were prepared using components described in Table 5 below, by the same method above. Output and yield of the resulting double block copolymers are as follows: [Table 5]
Figure imgf000051_0001
The resulting block copolymers were identified by 1H-NMR, with
representing a peak of polyethyleneglycol adjacent to 3.6 ppm and peak of
polylactide-co-glycolide adjacent to 4.9 and 1.6 ppm. Relative molecular weights
and molecular weight distributions of the resulting block copolymers by gel
permeation chromatography (GPC) are set forth in Table 6 below.
[Table 6]
Figure imgf000052_0001
<Preparation Example 4>
Polymerization of a fatty acid amphiphilic compound, monomethoxypolyethylene-glycol - dodecanoic acid
The process of polymerizing a fatty acid amphiphilic compound,
monomethoxypolyethyleneglycol-dodecanoic acid was depicted in Fig. 6. 5 g of monomethoxypolyethyleneglycol (MPEG) with an average molecular weight of 5,000
and 0.6 g of dodecanoic acid (DA) were dissolved in methylene chloride, and then
0.91 g of l^-dicyclohexylcarbodiimide and 0.37 g of 4-dimethylaminopyridine were
added thereto to proceed the reaction.. After 24 h, the obtained by-product was
filtered off and an excess of cold diethylether was added. The resulting precipitate
was filtered, washed with diethylether, and dried under reduced pressure to
prepare an amphiphilic polymer of monomethoxypolyethyleneglycol-dodecanoic acid (MPEG-DA) (Yield 92.5 %). The structure of polymer was identified by FT-IR and 1H-NMR, and the results were depicted in Figs. 7 and 8, respectively. In Fig. 7, the
spectrums of water soluble magnetic nanocomposite are represented, using (a)
monomethoxypolyethyleneglycol, (b) dodecanoic acid, (c)
monomethoxy-polyethyleneglycol-dodecanoic acid and (d)
monomethoxypolyethyleneglycol-dodecanoic acid. As shown in Fig. 7, a peak of
carboxylic acid (-COOH) in dodecanoic acid was identified at 1695 cm-1 and a peak of an ester bond, being binding part of dodecanoic acid and polyethylene glycol, was identified at 1734 cm 1 by IR Spectroscopy. As shown in Fig. 8, using 1H-NMR, a
peak of -CH2CH2O- in monomethoxypolyethylene glycol was identified at 3.62 ppm,
and a peak of dodecanoic acid was identified at 1.27 ppm.
<Preparation Example 5> Synthesis of a biodegradable amphophilic polymer that a binding part for a hydrophilic active ingredient is substituted with a carboxyl group
A. Synthesis of a biodegradable amphiphilic polymer that a binding part for a hydrophilic active ingredient is substituted with a carboxyl group, by combining an active ingredient of polymer
The process of synthesizing biodegradable amphiphilic polymer that a binding part for a hydrophilic active ingredient was substituted with a carboxyl group, by combining an active ingredient of polymer was depicted in Fig. 9. 0.05 mol
of polylactide-co-glycolide, 0.2 mol of N-hydroxysuccinimide (NHS) and l.S-dicyclohexylcarbodiimide (DCC) were dissolved in methylene chloride, and then reacted at room temperature for 24 h under nitrogen atmosphere. The reactant was filtered through a filter and dropped on cold diethylether to be precipitated. This precipitate was washed several times with diethylether, and then stored in
vacuum. 0.01 mol of the polymer activated by the above method was taken and dissolved in 8 ml of methylene chloride. 0.01 mol of polyethylene glycol, both ends whose terminal functional groups were substituted with an amine group and a carboxyl group, was taken and dissolved in 2 ml of methylene chloride, and was reacted, with the solution dropped portionwise. The reaction was subjected at room temperature for 12 h under nitrogen atmosphere. The reactant was washed and stored by the method as mentioned above. The structure of the synthesized polymer was analyzed by 1H-NMR and FT-IR, and the results were depicted in Figs. 10 and 11.
B. Polymerization of a biodegradable amphophilic polymer that a binding part
for a hydrophilic active ingredient is substituted with a carboxyl group through an active ingredient of hydrphilic polymer
The process of polymerizing a biodegradable amphophilic polymer that a
binding part for a hydrophilic active ingredient was substituted with a carboxyl group through an active ingredient of hydrphilic polymer was depicted in Fig. 12.
Moisture in 0.2 g of polyethylene glycol (molecular weight of 3400), both ends whose
terminal functional groups were substituted with an amine group and a carboxyl
group, was removed under reduced pressure. 20 mg of stannous octoate as a catalyst was added to absolute toluene, followed by reducing pressure at 100 °C for
20 to 30 minutes. 0.119 g of D,L-lactide was added to the reactant and polymerized at 140 °C for 12 h. To 5 ml of chloroform, the resulting block
copolymer was added to be dissolved. An excess of diethylether was portionwise
dropped on the solution to obtain a precipitate, which was subsequently filtered, washed with diethylether and dried at 500C under reduced pressure overnight to
obtain a block copolymer of monomethoxypolyethyleneglycol-polylactide-co-glycolide
(Yield 87.2 %).
<Preparation Example 6>
Synthesis of amphiphilic polyer that a binding part for a hydrophilic active
ingredient of a commercially available surfactant is substituted with a carboxyl
group A Pluronic based nonionic commercially available surfactant has a form of polyethyleneoxide-polypropyleneoxide-polyethyleneoxide (PEO-PPO-PEO, hydrophilic-hydrophobid-hydrophilic). The terminal hydroxyl group (-OH) of this surfactant was substituted with a carboxyl group to which a ligand such as an antibody may be bound. 30 g of Pluronic F-127, 476.5 mg of succinic anhydride as a carboxyl group substituent, 290.9 mg of 4-dimethylaminopyridine as a catalyst, and 331.9 μi of triethylamine were dissolved in 500 ml of 1,4-dioxane as a solvent, and reacted for 24 h at room temperature. After completing the reaction, the solvent was removed by lyophilization, followed by adding carbon tetrachloride and
filtering through a filter to remove the unreacted succinic anhydride. In order to remove the remaining impurities, the filtered reactant was dropped on cold
diethylether to be precipitated. This precipitate was washed several times with diethylether and stored. Pluronic F-127 that a binding part for a hydrophilic active ingredient was substituted with a carboxyl group was identified by analyzing IR spectroscopy and 1H-ISTMR. The results were depicted in Figs. 13 and 14, respectively. In Fig. 13, (a) represents a peak of Pluronic F-127 that a binding part for a hydrophilic active ingredient was substituted with a carboxyl group, (b)
represents a peak of Pluronic F-127 and (c) represents a peak of succinic anhydride. Also, in Fig. 14, (a) is the 1H-NMR result of Pluronic F-127 before substituting a binding part for a hydrophilic active ingredient with a carboxyl group, according to another Preparation Example of the present invention, (b) is the 1H-NMR result of Pluronic F-127 substituted with a carboxyl group. <Preparation Example 7>
Synthesis of biodegradable amphiphilic polymer that a binding part for a hydrophilic active ingredient is substituted with a succinimidyl group
A biodegradable amphiphilic polymer that a binding part for a hydrophilic active ingredient was substituted with a succinimidyl group was synthesized through the process shown in Fig. 15a. 0.05 mol of polylactide-co-glycolide, 0.4 mol of N-hydroxysuccinimide (NHS) and l^-dicyclohexylcarbodiimide were dissolved in methylene chloride, and then reacted at room temperature for 24 h under nitrogen atmosphere. The reactant was filtered through a filter and dropped on cold diethylether to be precipitated. This precipitate was washed several times with diethylether, and then stored in vacuum. 0.01 mol of the polymer activated by the
above method was taken and dissolved in 8 ml of methylene chloride. 0.05 mol of polyethylene glycol (molecular weight 3,400), both ends whose terminal functional groups were substituted with amine groups, was taken and dissolved in 2 ml of methylene chloride, and was reacted, with the solution dropped portionwise. The reaction was subjected at room temperature for 12 h under nitrogen atmosphere.
The reactant was washed and stored by the method as mentioned above.
N,N'-Disuccinimidyl carbonate was used in transforming the hydrophilic terminal functional group substituted with a amine group of the biodegradable amphiphilic
polymer into a succinimidyl group to which an amine group of an antibody may be bound. 0.01 mol of N,N'-Disuccinimidyl carbonate was taken and dissolved in 4 ml of methylene chloride, 0.05 mol of amphiphilic polymer that a hydrophilic part was substituted with an amine group was dissolved in 1 ml of methylene chloride, and was reacted, with the solution dropped portionwise. The reaction was subjected for
4 h under nitrogen atmosphere. Through gel filtration process (Sephadex G-25), N,N'-Disuccinimidyl carbonate not bound to polymer was removed.
<Preparation Example 8>
Preparation of an amphiphilic polymer for enclosing a drug in a magnetic
nanocomposite
The binding of an anticancer agent to a hydrophobic active binding domain of
an amphiphilic polymer was subjected through the process as shown in Fig. 15b. The biodegradable amphiphilic polymer that a binding part for a hydrophilic active
ingredient was substituted with a carboxyl group, as prepared in Preparation
Example 5, B., and p-Nitrophenyl chloroformate were dissolved in absolute
methylene chloride. To the solution at 0°C, pyridine was added and reacted at
room temperature for 3 h under nitrogen atmosphere. For binding the activated
amphiphilic polymer and the anticancer agent, triethylamine was added to
dimethylformaldehyde in which doxorubicin (DOX) was dissolved, and reacted at room temperature for 3 h under nitrogen atmosphere. The unreacted DOX and other materials were removed by several times of separations.
<Example 1>
Preparation of an emulsion type magnetic nanocomposite using a
biodegradable amphiphilic polymer
100 mg of Amphiphilic biodegradable polymer, monomethoxypolyethyleneglycol-polylactide-co-glycolide, prepared in Preparation Example 3 above was dissolved in 20 ml of deionized water as an aqueous phase. 20 mg of magnetic nanoparticles prepared in Preparation Example 1 were dissolved in 5 ml of chloroform as an oil phase. The aqueous phase was mixed with the oil phase, and then the mixture was saturated for 10 minutes by ultrasound of 300 W. The resulting emulsion was stirred for 12 h to vaporize the oil phase, and subjected
to centrifugation and a gel filtration column (Sephacryl S-300) to prepare the emulsion type magnetic nanocomposite with removed impurities. The schematic diagram of the emulsion type magnetic nanocomposite using the biodegradable amphiphilic polymer, monomethoxypolyethyleneglycol-polylactide-co-glycolide, was depicted in Fig. 3a. The prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 16a and 16b, respectively.
<Example 2> Preperation of a suspension type magnetic nanocomposite using a biodegradable amphiphilic polymer
3 mg of Magnetic nanoparticles prepared in Preparation Example 1 above were dispersed in a chloroform solution dissolving 50 mg of the amphiphilic biodegradable polymer (monomethoxypolyethyleneglycol-polylactide-co-glycolide) prepared in Preparation Example 3 above. The dispersion was heated to 40 °C,
with stirring, to vaporize the solvent, and re-dispersed in 0.5 ml of a phosphate buffered saline (PBS) solution. The solution was heated /stirred at 30 °C for 6 h to complete the suspension. After removing micelles without magnetic particles through centrifugation, the suspension was re-dispersed in 0.5 ml of a PBS solution.
The schematic diagram of a suspension type magnetic nanocomposite using the biodegradable amphiphilic polymer, monomethoxypolyethyleneglycol-polylactide-co-glycolide, was depicted in Fig. 3b. The prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 17a and 17b, respectively.
<Example 3> Preparation of an emulsion type magnetic nanocomposite using a fatty acid amphiphilic compound
600 mg of a fatty acid amphiphilic polymer, monomethoxypolyethyleneglycol-dodecanoic acid, prepared in Preparation Example 4 above was dissolved in 20 ml of deionized water as an aqueous phase. 20 mg of magnetic nanoparticles prepared in Preparation Example 1 were dissolved in 5 ml of chloroform as an oil phase. The aqueous phase was mixed with the oil phase, and then the mixture was saturated for 10 minutes by ultrasound of 300 W. The resulting emulsion was stirred for 6 h to vaporize the oil phase, and subjected to centrifugation and a gel filtration column (Sephacryl S-300) to prepare the magnetic nanocomposite for high sensitive MRI with removed impurities. The schematic diagram of the emulsion type magnetic nanocomposite using the fatty acid amphiphilic polymer, monomethoxypolyethyleneglycol-dodecanoic acid, was depicted in Fig. 3c. The prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results
were depicted in Fig. 18a and 18b, respectively. The magnetic property was identified as superparamagnetism by vibration sample magnetometer, and the result was depicted in Fig. 19. A solid line represents a hysteresis loop of magnetic nanop article s, and a dotted line represents a hysteresis loop of the emulsion type magnetic nanocomposite using a fatty acid amphiphilic compound. In addition, the presence of an amphiphilic polymer, monomethoxypolyethyleneglycol-dodecanoic
acid and magnetic nanoparticles was identified by IR spectroscopy, and the result was depicted in Fig. 7d. <Example 4>
Preparation of an emulsion type magnetic nanocomposite that the binding part for a hydrophilic active ingredient is substituted with a carboxyl group, using a biodegradable amphiphilic polymer 100 mg of Amphiphilic biodegradable polymer prepared in Preparation
Example 5, A. above was dissolved in 20 ml of deionized water as an aqueous phase.
20 mg of magnetite and manganese ferrite prepared in Preparation Example 1 as magnetic nanoparticles were dissolved in 5 ml of chloroform as an oil phase, together with 2 mg of doxorubicin. The aqueous phase was mixed with the oil phase, and then the mixture was saturated for 10 minutes by ultrasound of 300 W. The resulting emulsion was stirred for 12 h to vaporize the oil phase, and subjected to centrifugation and a gel filtration column (Sephacryl S-300) to prepare the magnetic nanocomposite with removed impurities. The schematic diagram of the
emulsion type magnetic nanocomposite that said anticancer agent was enclosed and the binding part for a hydrophilic active ingredient was substituted with a carboxyl group, was depicted in Fig. 3d. The prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and
the results were depicted in Fig. 20. In Fig. 20, (a) represents a photograph of the emulsion type magnetic nanocomposite in which magnetite (Fe3U4) is enclosed, (b) represents a photograph of the emulsion type magnetic nanocomposite in which
manganese ferrite (MnFe3θ4) is enclosed, and (c) represents a view of size distribution of the magnetic nanocomposite. In addition, the weight ratio of the enclosed magnetic nanoparticles was analyzed by a thermogravimetric analysis method, and the result was depicted in Fig. 21. The magnetic property was identified by VSM, and the result was depicted in Fig. 22. <Example 5> Preparation of the suspension type magnetic nanocomposite that the binding part for a hydrophilic active ingredient is substituted with a carboxyl group using a
biodegradable amphiphilic polymer
3 mg of Magnetic nanoparticles prepared in Preparation Example 1 above were dispersed in a chloroform solution dissolving 50 mg of the amphiphilic biodegradable polymer prepared in Preparation Example 5, B. above. The dispersion was heated to 40 °C, with stirring, to vaporize the solvent, and re-dispersed in 0.5 ml of a phosphate buffered saline (PBS) solution. The solution was heated /stirred at 30 0C for 6 h to complete the suspension. After removing micelles without magnetic particles through centrifugation, the suspension was re-dispersed in 0.5 ml of a PBS solution. The schematic diagram of the suspension type magnetic nanocomposite that the binding part for a hydrophilic active ingredient was substituted with a carboxyl group was depicted in Fig. 3e. The prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 23a and 23b, respectively. The weight ratio of the enclosed magnetic nanoparticles was analyzed by a thermogravimetric analysis method, and the result was depicted in Fig. 24.
<Example 6>
Preparation of the emulsion type magnetic nanocomposite that the binding part for a hydrophilic active ingredient is substituted with a carboxyl group using a commercially available surfactant I g of the amphiphilic polymer prepared in Preparation Example 6 above was dissolved in 40 ml of deionized water as an aqueous phase. 30 mg of magnetic nanoparticles prepared in Preparation Example 1 above were dissolved in 5 ml of hexane as an oil phase. The aqueous phase was mixed with the oil phase, and then the mixture was stirred for 10 minutes with applying ultrasound of 190 W. Then,
the mixture was stirred for 30 minutes in the absence of the ultrasound, and saturated for further 10 minutes with applying ultrasound of 600 W. The resulting emulsion was stirred for 24 h to vaporize the oil phase and prepare the magnetic nanocomposite for high sensitive MRI. The schematic diagram of the emulsion
type magnetic nanocomposite that the binding part for a hydrophilic active ingredient was substituted with a carboxyl group using a commercially available
surfactant was depicted in Fig. 3f. The prepared particles were identified by a
transmission electron microscope and a dynamic laser light scattering method, and
the results were depicted in Fig. 25. The presence of the amphiphilic polymer
Pluronic F- 127 and magnetic nanoparticles in the prepared nanocomposite was
identified by IR spectroscopy, and the result was depicted in Fig. 26.
<Example 7> Preparation of novel tumor specific intelligent contrast agent for MRI
Using magnetic nanocomposite prepared in Example 6 above, a tumor
specific intelligent contrast agent for MRI was prepared by the following process.
Magnetic nanocomposite prepared in Example 6, herceptin as an antibody for
treatment [a mole ratio of nanocompoistes to herceptin 100:1], and NHS
(N-hydroxysuccinimide) and EDC
(N-(3-Dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride) as a cross-linking
agent (a mole ratio of NHS to EDC 1:2) were mixed with 2 ml of a PBS buffer, and the mixture was reacted for about 6 h. After completing the reaction, impurities
were removed using gel filtration column.
<Example 8>
Preparation of the emulsion type magnetic nanocomposite that the binding
part for a hydrophilic active ingredient is substituted with a succinimidyl group To prepare an emulsion type water soluble magnetic nanocomposite that an
anticancer agent was enclosed and the binding part for a hydrophilic active ingredient was substituted with a succinimidyl group (Fig. 3g), chloroform was used as an oil phase, in which 2 mg of doxorubicin (DOX) was dissolved and 20 mg of
magnetic nanoparticles prepared in Preparation Example 1 were dispersed. 20 ml
of deionized water was used as an aqueous phase, in which 100 mg of the
amphiphilic biodegradable polymer prepared in Preparation Example 7 was
dissolved. After both phases were mixed to be saturated, the mixture was
emulsified for 10 minutes by ultrasound. This emulsion was stirred for 12 h to vaporize the oil phase, and subjected several times to centrifugation and Sephacryl
S-300 column to obtain the high pure water soluble magnetic nanocomposite.
<Example 9>
Preparation of the suspension type magnetic nanocomposite that the binding
part for a hydrophilic active ingredient is substituted with a carboxyl group
A. Preparation of the suspension type magnetic nanocomposite in which an anticancer agent is only physically enclosed
To prepare the suspension type water soluble magnetic nanocomposite that
an anticancer agent was only physically enclosed and the binding part for a hydrophilic active ingredient was substituted with a carboxyl group (Fig. 3h), 3 mg
of magnetic nanoparticles prepared in Preparation Example 1 and 2 mg of DOX
were dispersed in chloroform in which 50 mg of the amphiphilic biodegradable
polymer prepared in Preparation Example 5, B. was dissolved. The dispersion was heated to 40 °C, with stirring, to vaporize the solvent, and re-dispersed in 0.5ml of a
PBS solution. The solution was heated /stirred at 30 °C for 6 h to complete the
suspension. After removing micelles without magnetic nanoparticles through centrifugation, the suspension was re-dispersed in 0.5 ml of a PBS solution.
B. Preparation of the suspension type magnetic nanocomposite that an anticancer agent is only chemically enclosed
To prepare the suspension type water soluble magnetic nanocomposite that
an anticancer agent was only chemically enclosed and the binding part for a
hydrophilic active ingredient was substituted with a carboxyl group (Fig. 3h), 3 mg
of magnetic nanoparticles prepared in Preparation Example 1 was dispersed in chloroform in which 50 mg of the amphiphilic biodegradable polymer binding the
anticancer agent prepared in Preparation Example 8 was dissolved. The dispersion was heated to 40 "C , with stirring, to vaporize the solvent, and
re-dispersed in 0.5ml of a PBS solution. The solution was heated /stirred at 30 °C
for 6 h to complete the suspension. After removing micelles without magnetic
nanoparticles through centrifugation, the suspension was re-dispersed in 0.5 ml of a
PBS solution.
C. Preparation of the suspension type magnetic nanocomposite that an
anticancer agent is enclosed by the physical method and the chemical method
To prepare the suspension type water soluble magnetic nanocomposite that
an anticancer agent was enclosed by the physical method and the chemical method
and the binding part for a hydrophilic active ingredient was substituted with a carboxyl group (Fig. 3h), 3 mg of magnetic nanoparticles prepared in Preparation Example 1 and 2 mg of DOX were dispersed in chloroform in which 25 mg of the amphiphilic biodegradable polymer prepared in Preparation Example 5, B. and 25 mg of the amphiphilic biodegradable polymer binding the anticancer agent prepared in Preparation Example 8 were dissolved. The dispersion was heated to 40 °C, with stirring, to vaporize the solvent, and re-dispersed in 0.5 ml of a PBS solution. The solution was heated /stirred at 30 °C for 6 h to complete the suspension. After
removing micelles without magnetic nanoparticles through centrifugation, the suspension was re-dispersed in 0.5 ml of a PBS solution. The prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 27a and 27b, respectively. The weight ratio of the enclosed magnetic nanoparticles was analyzed by a thermogravimetric analysis method, and the result was depicted in Fig. 28.
<Example 10> Preparation of herceptin-mgenetic nanocomposite for simultaneous diagnosis
and treatment of cancer
A. Preparation of herceptin-mgenetic nanocomposite using succinimidyl
group -magnetic nanocomposite
The reaction of the herceptin-magnetic nanocomposite was subjected at room temperature for 4 h, by dispersing 3 mg of the water soluble magnetic nanocomposite prepared in Example 8 above in a PBS solution of pH 7.4 and adding
0.1 mg of herceptin thereto. After completing the reaction, the unreacted herceptin and water soluble magnetic nanocomposite was removed via Separcryl S-300 column to prepare the herceptin-magnetic nanocomposite.
B. Prepartion of herceptin-magnetic nanocomposite using the carboxyl group-magnetic nanocomposite
The magnetic nanocomposite that the terminal functional group of hydrophilic polymer was substituted with a carboxyl group, prepared in Example 4 above, were dispersed in 0.5 ml of a PBS solution. The reaction was subjected at room temperature for 4 h, after dispersing the water soluble magnetic nanocomposite in a PBS solution of pH 7.4 and adding 0.5 mg of herceptin thereto. After completing the reaction, the unreacted herceptin and water soluble magnetic nanocomposite was removed via Separcryl S-300 column to prepare the herceptin-magnetic nanocomposite. To identify cell selectivity of the magnetic nanocomposite bound to an antibody, immunoglobulin (IgG) which does not react with a target cell was bound to magnetic nanocomposite by the method above to prepare IgG-magnetic nanocomposite.
C. Preparation of herceptin-magnetic nanocomposite using the carboxyl
group-magnetic nanocomposite
The magnetic nanocomposite that the terminal functional group of hydrophilic polymer was substituted with a carboxyl group, prepared in Example 9, C. above, were dispersed in 0.5 ml of a PBS solution. The reaction was subjected at room temperature for 4 h, after dispersing the water soluble magnetic nanocomposite in a PBS solution of pH 7.4 and adding 0.5 mg of herceptin thereto. After completing the reaction, the unreacted herceptin and water soluble magnetic nanocomposite was removed via Separcryl S-300 column to prepare the herceptin-magnetic nanocomposite. To identify cell selectivity of the magnetic nanocomposite bound to an antibody, immunoglobulin (IgG) which does not react with a target cell was bound to magnetic nanocomposite by the method above to prepare IgG-magnetic nanocomposite. <Example 11>
Preparation of the emulsion type magnetic nanocomposite that the binding part for a hydrophilic active ingredient is substituted with a carboxyl group To prepare an emulsion type water soluble magnetic nanocomposite that the binding part for a hydrophilic active ingredient was substituted with a caboxyl
group, chloroform was used as an oil phase, in which 100 mg of the amphilic biodegradable polymer prepared in Preparation Example 3 above was dissolved and 20 mg of magnetic nanoparticles prepared in Preparation Example 1 was dispersed. To give fluorescence to the magnetic nanocomposite, 2 mg of Nile red was added to the oil phase. 20 ml of deionized water was used as an aqueous phase. After both phases were mixed to be saturated, the mixture was emulsified for 10 minutes by ultrasound. This emulsion was stirred for 12 h to vaporize the oil phase, and subjected several times to centrifugation and Sephacryl S-300 column to obtain the high pure water soluble magnetic nanocomposite. The prepared particles were identified by a transmission electron microscope and a dynamic laser light scattering method, and the results were depicted in Fig. 29. The weight ratio of the enclosed magnetic nanoparticles was analyzed by a thermogravimetric analysis
method and the magnetic property was measured by VSM, and the results were
depicted in Fig. 30.
<Example 12>
Preperation of herceptin-magnetic nanocomposite for separating cells by
magnetic field
The magnetic nanocomposite that the terminal functional group of
hydrophilic polymer was substituted with a carboxyl group, prepared in Example 11,
C. above, were dispersed in 0.5 ml of a PBS solution. The reaction was subjected at
room temperature for 4 h, after dispersing the water soluble magnetic
nanocomposite in a PBS solution of pH 7.4 and adding 0.5 mg of herceptin thereto.
After completing the reaction, the unreacted herceptin and water soluble magnetic
nanocomposite was removed via Separcryl S-300 column to prepare the
herceptin-magnetic nanocomposite. It was identified in Fig. 31 to sensitively
arrange the magnetic nanocomposite bound to the antibody in an external magnetic
field (Nb-B-Fe magnet, 0.35 T). To identify cell selectivity of the magnetic
nanocomposite bound to an antibody, immunoglobulin (IgG) which does not react
with a target cell was bound to magnetic nanocomposite by the method above to
prepare IgG-magnetic nanocomposite.
<Experimental Example 1>
Expreiment of stability in the emulsion type magnetic nanocomposite using
biodegradable aniphiphilic polymer The organic magnetic nanoparitcles in prepared in Preparation Example 1 was dissolved in hexane, and water was added thereto. In addition, the emulsion type magnetic nanocomposite using' the biodegradable amphiphilic polymer prepared in Example 1 was dissolved in water, and hexane was added thereto. Analyazing the change of solubility, the results were depicted in Fig. 32. As shown in Fig. 32, it could be identified that the organic nanopariticle (Fig. 32a) having a
fatty acid surface stabilizer to its surface was transformed into a water soluble nanocomposite (Fig. 32b). Upon viewing by naked eye, precipitation or aggregation was not caused. Thus, it could be known that the water soluble iron oxide nanoparticle is well dispersed in an aqueous solution.
<Experimental Example 2>
Expreiment of stability in the suspension type magnetic nanocomposite using a fatty acid amphiphilic polymer
The organic magnetic nanoparitcles in prepared in Preparation Example 1 were dissolved in hexane, and water was added thereto. In addition, the emulsion type magnetic nanocomposite using the biodegradable amphiphilic polymer prepared in Example 3 was dissolved in water, and hexane was added thereto.
Analyazing the change of solubility, the results were depicted in Fig. 33. As shown in Fig. 33, it could be identified that the organic nanopariticle (Fig. 33a, left) having a fatty acid surface stabilizer to its surface was transformed into a water soluble nanocomposite (Fig. 33a, right). When an external magnetic field (Nd-B-Fe magnet,
0.35 T) was applied thereto, the sensitive response could be idnetified (Fig. 33b). In addition, upon viewing by naked eye, precipitation or aggregation was not caused. Thus, it could be known that the water soluble iron oxide nanoparticle is well dispersed in an aqueous solution.
Stability of the nanocomposite prepared in Example 3 was examined according to concentrations of a salt (NaCl) and pH, and the results were depicted in Fig. 34. It could be identified from Fig. 34a, a graph representing the size change of nanocomposite according to a concentration of 0.0 ~ 1.0 M, that the size of nanocomposite according to concentration was not nearly changed. It could be also identified from Fig. 34b, a graph representing the size change of nanocomposite according to pH 5 ~ pH 10, that the size of nanocomposite according to pH was not nearly changed.
<Experimental Example 3>
Experiment of stability in the emulsion type magnetic nanocomposite that the binding part for a hydrophilic active ingredient is substituted with a carboxyl group, using a commercially available surfactant
The results of examining dispersion stability of nanocomposite prepared in Example 6 according to pH were depicted in Fig. 35. As shown in Fig. 35, the particle aggregation of nanocomposite could not be identified in a range of pH 4 ~ 13, and the size change of particles could be hardly identified. In addition, stability was examined according to concentrations of salt (NaCl), and the results were depicted in Fig. 36. As shown in Fig. 36, the particle aggregation of nanocomposite could not be identified in a concentration of from 0.005 M to 1.0 M, and the size change of particles could be hardly identified. <Experimental Example 4>
Identification of possibility of the emulsion type magnetic nanocomposite using the biodegradable amphiphilic polymer as a contrast agent To identify the contrasting effect for MRI of the water soluble magnetic nanocomposite, the water soluble magnetic nanocomposite prepared in Example 1 above was titrated in 0.1, 0.05, 0.025 and 0.125 βg/βi and injected into PCR tubes. 1.5 T system (Intera; Philips Medical Systems, Best, The Netherlands) was used for
the contrasting effect of MRI, employing micro-47 coil. Coronal images were obtained with Fast Field Echo (FFE) pulse sequence. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm, TE = 20 ms, TR =400 ms,
number of image excitation 1, time of image acquisition 6 minutes.
As shown in Fig. 37, it could be identified that the higher the concentration of water soluble magnetic nanocomposite was, the more the signals of MRI were amplified.
<Experimental Example 5>
Identification of possibility of the emulsion type magnetic nanocomposite using the fatty acid amphiphilic polymer as a contrast agent
To identify the contrasting effect for MRI of water soluble magnetic nanocomposite, the water soluble magnetic nanocomposite prepared in Example 3 above was titrated and injected into micro-tubes. 1.5 T system (Intera; Philips
Medical Systems, Best, The Netherlands) was used for the contrasting effect of MRI, employing micro-47 coil. Coronal images were obtained with Fast Field Echo
(FFE) pulse sequence. Specific parameters were as follows: resolution 156 156 μm,
slice thickness 0.6 mm, TE = 20 ms, TR =400 ms, number of image excitation 1,
time of image acquisition 6 minutes. As shown in Fig. 38, it could be identified
that the higher the concentration of water soluble magnetic nanocomposite was, the
more the signals of MRI were amplified.
<Experimental Example 6>
Identification of possibility of the emulsion type magnetic nanocomposite that
the binding part for a hydrophilic active ingredient is substituted with a carboxyl
group as a contrast agent
To identify the contrasting effect for MRI of the emulsion type water soluble
magnetic nanocomposite that the binding part for a hydrophilic active ingredient was substituted with a carboxyl group, the water soluble magnetic nanocomposite
prepared in Example 4 above was titrated and injected into micro-tubes. 1.5 T system (Intera; Philips Medical Systems, Best, The Netherlands) was used for the
contrasting effect of MRI, employing micro-47 coil. Coronal images were obtained
with Fast Field Echo (FFE) pulse sequence. Specific parameters were as follows:
resolution 156 156 μm, slice thickness 0.6 mm, TE = 20 ms, TR =400 ms, number of
image excitation 1, time of image acquisition 6 minutes. As shown in Fig. 39, it
could be identified that the higher the concentration of water soluble magnetic
nanocomposite was, the more the signals of MRI were amplified.
Experimental Example 7> Identification of possibility of the emulsion type magnetic nanocomposite that the binding part for a hydrophilic active ingredient is substituted with a carboxyl group, using a commercially available surfactant, as a contrast agent
To identify whether the emulsion type magnetic nanocomposite that the binding part for a hydrophilic active ingredient was substituted with a carboxyl
group using a commercially available surfactant, prepared in Example 6 shows the sufficient contrasting effect for MRI, the water soluble magnetic nanocomposite was titrated in a concentration of 1.0, 2.0, 5.0, 10.0, 20.0, 40.0 and 80.0 μm/mi and injected into micro-tubes. 1.5 T system (Intera; Philips Medical Systems, Best, The Netherlands) was used for the contrasting effect of MRI, employing micro-47 coil.
Coronal images were obtained with Fast Field Echo (FFE) pulse sequence. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm, TE = 20
ms, TR =400 ms, number of image excitation 1, time of image acquisition 6 minutes.
T2 maps were performed to quantitatively evaluate the contrasting effect for MRI. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm,
TR = 4000 ms, TE = 20, 40, 60, 80, 100, 120, 140, 160 ms, number of image excitation 2, time of image acquisition 4 minutes. As shown in Figs. 40 and 41, it could be identified that the higher the concentration of water soluble magnetic nanocomposite was, the more the signals of MRI were amplified. It is indicated that the water soluble magnetic nanocomposite may be used as a nano-contrast
agent.
<Experimental Example 8> Identification of possiblity of the magnetic nanocomposite as a contrast agent A. Identification of possibility of the emulsion type magnetic nanocomposite
that the binding part for a hydrophilic active ingredient is substituted with a succinimidyl group as a contrast agent
To identify the contrasting effect for MRI of the emulsion type water soluble
magnetic nanocomposite that the binding part for a hydrophilic active ingredient
was substituted with a succinimidyl group, the water soluble magnetic
nanocomposite prepared in Example 8 above was titrated and injected into micro-tubes. 1.5 T system (Intera; Philips Medical Systems, Best, The
Netherlands) was used for the contrasting effect of MRI, employing micro-47 coil.
Coronal images were obtained with Fast Field Echo (FFE) pulse sequence. Specific
parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm, TE = 20
ms, TR =400 ms, number of image excitation 1, time of image acquisition 6 minutes.
T2 maps were performed to quantitatively evaluate the MRI contrasting effect for antigen specificity. Specific parameters were as follows: resolution 156 156 μm,
slice thickness 0.6 mm, TR = 4000 ms, TE = 20, 40, 60, 80, 100, 120, 140, 160 ms,
number of image excitation 2, time of image acquisition 4 minutes. As shown in
Fig. 42, it could be identified that the higher the concentration of water soluble
magnetic nanocomposite was, the more the signals of MRI were amplified.
B. Identification of possibility of the suspension type magnetic nanocomposite
that the binding part for a hydrophilic active ingredient is substituted with a
carboxyl group as a contrast agent To identify the contrasting effect for MRI of the suspension type water soluble magnetic nanocomposite that the binding part for a hydrophilic active ingredient was substituted with a carobxyl group, the water soluble magnetic nanocomposite prepared in Example 9, C. above was titrated and injected into micro-tubes. 1.5 T system (Intera; Philips Medical Systems, Best, The
Netherlands) was used for the contrasting effect of MRI, employing micro-47 coil.
Coronal images were obtained with Fast Field Echo (FFE) pulse sequence. Specific parameters were as follows: resolution 156 156 βm, slice thickness 0.6 mm, TE = 20 ms, TR =400 ms, number of image excitation 1, time of image acquisition 6 minutes. T2 maps were performed to quantitatively evaluate the MRI contrasting effect for antigen specificity. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm, TR = 4000 ms, TE = 20, 40, 60, 80, 100, 120, 140, 160 ms, number of image excitation 2, time of image acquisition 4 minutes. As shown in
Fig. 43, it could be identified that the higher the concentration of water soluble magnetic nanocomposite was, the more the signals of MRI were amplified.
<Experimental Example 9>
Identification of the binding degree of novel tumor specific intelligent contrast agent for MRI to cells and their contrasting effect
For novel intelligent contrast agent for MRI with removed impurities prepared in Example 7, the possibility as an intelligent contrast agent was identified through identifying the binding degree of NIH3T6.7 cell positive and
MDAMB231 cell negative against an antigen-antibody specific binding to an antibody for treatment, herceptin. Secondary antibody adhered by a fluorescent staining agent (FITC, Fluorescin isothiocyanate) was adhered to the cells, followed by analyzing through FACS, and the result was depicted in Fig. 55. In Fig. 44, (a) represents the fluorescence intensity of the cell unreacted with the intelligent contrast agent for MRI according to the present invention by FACS, (b) represents that of the antibody negative cell (MDAMB231) reacted with the intelligent contrast agent for MRI by FACS, and (c) represents that of the antibody positive cell (NIH3T6.7) reacted with the intelligent contrast agent for MRI by FACS. As shown in Fig. 12, it could be known that the positive NIH3T6.7 cell has higher fluorescence intensity over the negative MDAMB231 cell. It is said from this fact that the prepared contrast agent may be used as the intelligent contrast agent for specifically binding to particular tumor. In addition, the contrasting effect of the NIH3T6.7 cell positive against antibody was identified by MRI, and the result was
depicted in Fig. 45. Experimental Example 10>
Identification of cancer cell selectivity in the tumor specific magnetic
nanocomposite via a flow cytometry
A. Identification of cancer cell selectivity in the herceptin-magnetic nanocomposite using the succinimidyl group -magnetic nanocomposite via a flow
cytometry
To analyze the binding specificity and efficiency of herceptin-magnetic
nanocomposite prepared in Example 10, A. above against a breast cancer labeled antigen, FACS was employed. Each cell line was measured in 10,000 events. Fluorescence intensity distribution in a range of mean value to median value was employed as fluorescence indexes, and the results were depicted in Fig. 46. Herceptin-magnetic nanocomposite and nanocomposite as a control group were treated to cell lines each expressing HER2/new receptor (MDA-MB-231 cell line « NIH3T6.7 cell line), and reacted with the secondary antibody polymerized with FITC as described above. It could be identified that the intensity of fluorescence expression is increased as the degree of expressing HER2/neu receptor is increased. In case of MDA-MB-231 cell line with a low expression of HER2/neu receptor, it
could be shown that the intensity of fluorescence expression is slightly increased relative to the case employing nanocomposite as a control group, and that the intensity of fluorescence expression is gradually increased as the degree of expressing the receptor is increased.
B. Identification of cancer cell selectivity in the herceptin-magnetic nanocomposite using the emulsion type carboxyl group -magnetic nanocomposite via
a flow cytometry
To analyze the binding specificity and efficiency of herceptin-magnetic nanocomposite prepared in Example 10, B. above against a breast cancer labeled antigen, FACS was employed. Each cell line was measured in 10,000 events. Fluorescence intensity distribution in a range of mean value to median value was employed as fluorescence indexes. Herceptin-magnetic nanocomposite and nanocomposite as a control group were treated to cell lines each expressing HER2/new receptor (MDA-MB-231 cell line, NIH3T6.7 cell line), and reacted with
the secondary antibody polymerized with FITC as described above. Fluorescence
expression was identified using FACS, and the results were depicted in Fig. 47. It
could be identified that the intensity of fluorescence expression is increased as the degree of expressing HER2/neu receptor is increased.
C. Identification of cancer cell selectivity in the herceptin-magnetic
nanocomposite using the suspension type carboxyl group -magnetic nanocomposite via a flow cytometry
To analyze the binding specificity and efficiency of the herceptin-magnetic
nanocomposite prepared in Example 10, C. above against a breast cancer labeled
antigen, FACS was employed. Each cell line was measured in 10,000 events.
Fluorescence intensity distribution in a range of mean value to median value was
employed as fluorescence indexes. Herceptin-magnetic nanocomposite and nanocomposite as a control group were treated to cell lines each expressing HER2/new receptor (MDA-MB-231 cell line, NIH3T6.7 cell line), and reacted with
the secondary antibody polymerized with FITC as described above. Fluorescence
expression was identified using FACS, and the results were depicted in Fig. 48. It
could be identified that the intensity of fluorescence expression is increased as the
degree of expressing HER2/neu receptor is increased.
<Experimental Example 11>
Identification of cell selectivity in the tumor specific magnetic nanocomposite
via MRI A. Identification of cancer cell selectivity in the emulsion type carboxyl group-magnetic nanocomposite using herceptin-magnetic nanocomposite via MRI
To analyze antigen specificity of herceptin-magnetic nanocomposite prepared in Example 10, B. above via MRI, each cell was transformed into PCR tubes and then precipitated by centrifugation. 1.5 T system (Intera; Philips Medical Systems, Best, The Netherlands) was used for the contrasting effect of MRI according to antigen specificity of each cell line, employing micro-47 coil. Coronal images were obtained with Fast Field Echo (FFE) pulse sequence, and depicted in Fig. 49. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm, TE = 20 ms, TR =400 ms, number of image excitation 1, time of image acquisition 6 minutes. T2 maps were performed to quantitatively evaluate the MRI contrasting
effect for antigen specificity. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm, TR = 4000 ms, TE = 20, 40, 60, 80, 100, 120, 140, 160 ms, number of image excitation 2, time of image acquisition 4 minutes. The results in Fig. 49 met with the results of fluorescence expression as shown in Fig. 47. It was identified that the signals of MRI appeared gradually from gray to black, as the degree of expressing HER2/neu receptor was increasing. In case of the cell line with a low expressing degree, it could be identified that the signal turns a little dark color relative to the case employing nanocomposite as a control group, and that it turns gradually black as the degree of expressing the receptor is increased. That is, herceptin-magnetic nanocomposite was selectively bound to the cell line expressing HER2/neu receptor, whereby the signals of MRI appeared gradually black. It could be consequently identified that herceptin-magnetic nanocomposite of the present invention may be used in diagnosing in vitro breast cancer.
B. Identification of cancer cell selectivity in the suspension type carboxyl group-magnetic nanocomposite using herceptin-magnetic nanocomposite via MRI
To analyze antigen specificity of herceptin-magnetic nanocomposite prepared in Example 10, C. above via MRI, each cell was transformed into PCR tubes and then precipitated by centrifugation. 1.5 T system (Intera; Philips Medical Systems, Best, The Netherlands) was used for the contrasting effect of MRI according to antigen specificity of each cell line, employing micro-47 coil. Coronal images were obtained with Fast Field Echo (FFE) pulse sequence, and depicted in Fig. 50. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm,
TE = 20 ms, TR =400 ms, number of image excitation 1, time of image acquisition 6 minutes. T2 maps were performed to quantitatively evaluate the MRI contrasting effect for antigen specificity. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm, TR = 4000 ms, TE = 20, 40, 60, 80, 100, 120, 140, 160 ms, number of image excitation 2, time of image acquisition 4 minutes.
The results in Fig. 50 met with the results of fluorescence expression as shown in Fig. 48. It was identified that the signals of MRI appeared gradually from gray to black, as the degree of expressing HER2/neu receptor was increasing.
In case of the cell line with a low expressing degree, it could be identified that the signal turns a little dark color relative to the case employing nanocomposite as a control group, and that it turns gradually blak as the degree of expressing the receptor is increased. That is, herceptin-magnetic nanocomposite was selectively bound to the cell line expressing HER2/neu receptor, whereby the signals of MRI appeared gradually black. It could be consequently identified that herceptin-magnetic nanocomposite of the present invention may be used in diagnosing in vitro breast cancer.
<Experimental Example 12>
Analysis of drug release behavior in the magnetic nanocomposite A. Analysis of drug release behavior in the herceptin-magnetic nanocomposite using the succinimidyl group-magnetic nanocomposite
The drug release experiment of water soluble magnetic nanocomposite enclosing anticancer agent prepared in Example 10, A. above was performed by making a titration curve using UV and extracting samples in a certain time interval
to measure their concentrations, and the result was depicted in Fig. 51. B. Analysis of drug release behavior in the herceptin-magnetic
nanocomposite using the carboxyl group-magnetic nanocomposite
The drug release experiment of water soluble magnetic nanocomposite enclosing anticancer agent prepared in Example 10, B. above was performed by making a titration curve using UV and extracting samples in a certain time interval to measure their concentrations, and the result was depicted in Fig. 52.
C. Analysis of drug release behavior in the suspension type
herceptin-magnetic nanocomposite The drug release experiment of water soluble magnetic nanocomposite enclosing anticancer agent prepared in Example 10, C. above was performed by making a titration curve using UV and extracting samples in certain time interval to measure their concentrations, and the results were depicted in Fig. 53. In case of enclosing a drug only by the physical method (Fig. 53b), the amount of initial release was large. In case of enclosing a drug only by the chemical method (Fig. 53c), the speed of release was slow, but a linear release behavior was shown. In addition, in case of enclosing the anticancer agent by simultaneously using the physical method and the chemical method, the release mode was linear, and the drug release behavior approaching to 100% for relatively short time was shown (Fig. 53a).
<Experimental Example 13>
Identification of target cell selectivity in cell specific emulsion type herceptin-magnetic nanocomposite via a flow cytometry To analyze the binding specificity and efficiency of herceptin-magnetic
nanocomposite prepared in Example 12 above against cancer cell labeled antigen, FACS (Flow cytometer, FACScan, Becton Dickinson, San Diego, CA) was employed. Each cell line (MCF-7 cell line « NIH3T6.7 cell line) was measured in 10,000 events. Fluorescence intensity distribution in a range of mean value to median value was employed as fluorescence indexes. Herceptin-magnetic nanocomposite and a nanocomposite as a control group were treated to cell lines each expressing HER2/new receptor. Then, fluorescence expression was identified using FACS, and the results were depicted in Fig. 54. As shown in Fig. 54, it could be identified that the intensity of fluorescence expression is increased as the degree of expressing
HER2/neu receptor is increased. In addition, it could be identified that IgG-magnetic nanocomposite have no cell selectivity. Experimental Example 14>
To identify possibility of target cell separation using herceptin-magnetic nanocomposite prepared Example 12 above, 1 mg/ml of herceptin-magnetic nanocomposite was incubated in 4*104 NIH3T6.7 for 30 minutes. The unreacted
magnetic nanocomposite was separated and inserted in macro-tube. An external magnetic field (Nd-B-Be magnet, 0.35T) was applied on the outside wall of tube. After applying the magnetic field, it was identified using microscope that the nanocomposite was sensitively moved into the direction of magnet within several seconds. The result was depicted in Fig. 55.
Experimental Example 15> Cytotoxicity test of the emulsion type magnetic nanocomposite using a fatty
acid amphphilic compound as a contrast agent
To identify cytotoxicity of water soluble magnetic nanocomposite prepared in Example 3 above, cytotoxicity analysis was proceeded on NIH3T6.7 cell with concentrations of nanocomposite, and the results were depicted in Fig. 34. The cytotoxicity was identified by examining the concentration of nanocomposite in a range of 104 ~ 10° mg/ml and proceeding incubation time of cells for 0 ~ 72 h. As shown in Fig. 56, the cytotoxicity of the magnetic nanocomposite could not be identified at even higher concentrations. Experimental Example 16>
Cytotoxicity test of the emulsion type magnetic nanocomposite that the
binding part for a hydrophilic active ingredient was substituted with a carboxyl group using a commercially available surfactant
To identify cytotoxicity of the emulsion type magnetic nanocomposite that the binding part for a hydrophilic active ingredient was substituted with a carboxyl group using a commercially available surfactant prepared in Example 6 above, MTT assay was proceeded on MCF7 cell, SKBR3 cell, and NIH3T6.7 cell with concentrations of the nano-contrast agent, and the results were depicted in Fig. 9. As shown in Fig. 57, the cytotoxicity of the magnetic nanocomposite could not be identified at even higher concentrations. Experimental Example 17> Cytotoxicity test of the magnetic nanocomposite Cytotoxicity test of the prepared magnetic nanocomposite was subjected on
NIH3T6.7 cell and MDA-MB-231 cell. The cytotoxicity was identified by representing as a ratio the degree of inhibiting cell growth by DOX alone, herceptin alone, DOX and herceptin, herceptin-magnetic nanop articles, IgG-magnetic nanocomposite, and herceptin-magnetic nanocomposite. 4*103 Cells were injected into 96-well, and the test materials were inserted in the cell containing well, based on the equivalent of herceptin and DOX. After 4 h, the residue was washed and the cells were grown for further 72 h. The cytotoxicity obtained from MTT agent was depicted in Fig. 58. The cytotoxicity of herceptin-magnetic nanocomposite enclosing DOX was higher than that of the case acted by herceptin and DOX together (Fig. 26(i)), and much higher than that of the case that herceptin and DOX were reacted with the cells, using nanop articles. In case of acting herceptin on the cells, NIH3T6.7 cell line showed lower survival rate over MDA-MB-231 cell line. It was also identified that the nanocomposite had cell selectivity. As described in Fig. 2, it can be noted from these results that herceptin-magnetic nanocomposite eclosing DOX is capable to have the synergistic effect of treating cancer cells selectively. <Experimental Example 18>
Identification of possibility in the emulsion type magnetic nanocomposite using a fatty acid amphiphilic compound as a nano-contrast agent via an animal
model
In vivo experiment was subjected, using a nude mouse as an animal model. NIH3T6.7 cells were into the mouse to express cancer cells. After 10 days, the nanocomposite (80 μg Fe + Mn) prepared in Example 3 were injected therein, when the size of cancer cells was 30 mm. MRIs before and after injection were depicted in Fig. 59. That is, there are MRIs before injection (a), just after injection (b), one hour after injection (c), two hours after injection (d), and five hours after injection (e), of the nanocomposite. As represented in Fig. 59, it could be identified that images of liver and cancer cells were apparently changed and the contrasting effect was kept after 1 h, 2 h and 5 h. As a result of making a graph about the change of T2 values over time through the images above, it could be identified that the difference of T2 values after even 5 h is highly kept relative to the value before injection (Fig. 59f).
<Experimental Example 19> Identification of possibility as a nano-contrast agent via an animal model
In vivo experiment was subjected, using a nude mouse as an animal model.
NIH3T6.7 cells positve against antibody were into the mouse to express cancer cells.
After 2 days, the contrast agent prepared in Example 6 was injected therein, when the size of cancer cells was 10 mm. MRIs before and after injection were depicted in Fig. 60. In Fig. 14, there are MRIs before injection (a), just after injection (b), and two hours after injection (c), of the contrast agent. As represented in Fig. 60, it could be identified that images of liver and cancer cells were apparently changed.
In addition, the change from before injection to 2 hours over time was depicted in
Fig. 61. As depicted in Fig. 61, it could be identified that the T2 values after injection were highly changed.
Experimental Example 20>
Identification of possibility in the magnetic nanocomposite as a nano-contrast agent via an aminal model
To know whether the magnetic nanocomposite may trace cancer cells,
NIH3T6.7 cells were implanted into thighs of a group of nude mice. 1.5 T system
(Intera; Philips Medical Systems, Best, The Netherlands) was used for the contrasting effect of MRI, employing micro-47 coil. Coronal images were obtained with Fast Field Echo (FFE) pulse sequence. Specific parameters were as follows: resolution 156 156 μm, slice thickness 0.6 mm, TE = 20 ms, TR =400 ms, number of image excitation 1, time of image acquisition 6 minutes. The contrasting effect was identified over time. Images were obtained, at preliminary (Pre) injection, immediately (Immed) after injection into a tail vein, 4 hours after injection, and 12 hours after injection, of the nanocomposite prepared in Example 10, B., and the results were depicted in Figs. 62 and 63. It could be identified that the very high contrasting effect was represented in the thigh of nude mouse 12 hours after
injection, and that the contrasting effect of IgG-mangetic nanocomposite without herceptin was lowered. As a result, it could be identified that herceptin-magnetic nanocomposite was selectively targeted at cancer cells.
[Industrial Applicability]
The magnetic nanocomposite according to the present invention, covered with the aniphiphilic compound having hydrophobic domains and a hydrophilic domains may be used in a contrast agent for high sensitive MRI, an intelligent contrast agent for diagnosing cancer by binding to the binding parts materials that may specifically be bound to tumor markers, a drug delivery system for diagnosis and treatment of cancer by polymerizing or enclosing a drug in the hydrophobic domains, and a formulation for separating cells and proteins using magnetism by binding an antibody or a protein specific to surface antigens of functional cells, stem
cells or cancer cells thereto.

Claims

[CLAIMS]
[Claim 1]
A magnetic nanocomposite is characterized in that a magnetic nanoparticle is covered with an amphiphilic compound having one or more hydrophobic domains
and one or more hydrophilic domains
[Claim 2]
The magnetic nanocomposite according to claim 1, wherein the magnetic
nanocomposite comprises a core that one or more magnetic nanoparticles are
distributed in the hydrophobic domain, and a shell containing the hydrophilic domain.
[Claim 3]
The magnetic nanocomposite according to claim 1, wherein the magnetic
nanocomposite comprises a core that one magnetic nanoparticle is bound to the
hydrophobic domain, and a shell containing the hydrophilic domain.
[Claim 4] The magnetic nanocomposite according to claim 1, wherein the magnetic
nanoparticle has a diameter of 1 nm to 1000 nm.
[Claim 5]
The magnetic nanocomposite according to claim 2, wherein the magnetic nanocomposite has a diameter of 1 nm to 500 nm.
[Claim 6]
The magnetic nanocomposite according to claim 3, wherein the magnetic nanocomposite has a diameter of 1 nm to 50 nm.
[Claim 7]
The magnetic nanocomposite according to claim 1, wherein the magnetic nanoparticle is a metal, a magnetic material, or a magnetic alloy.
[Claim 8]
The magnetic nanocomposite according to claim 7, wherein the metal is selected from the group consisting of Pt, Pd, Ag, Cu and Au.
[Claim 9]
The magnetic nanocomposite according to claim 7, wherein the magnetic material is selected from the group consisting of Co, Mn, Fe, Ni, Gd, Mo, MM^O4, and MxOy (where each M or M' independently represents Co, Fe, Ni, Mn, Zn, Gd, or Cr, 0 < x =3, 0 < y =5).
[Claim 10]
The magnetic nanocomposite according to claim 7, wherein the magnetic alloy is selected from the group consisting of CoCu, CoPt, FePt, CoSm, NiFe and NiFeCo.
[Claim 11]
The magnetic nanocomposite according to claim 7, wherein the metal, the magnetic material, or the magnetic alloy is bound to an organic surface stabilizer.
[Claim 12]
The magnetic nanocomposite according to claim 11, wherein the organic surface stabilizer is one or more selected from the group consisting of alkyl trimethylammonium halide, a saturated or unsaturated fatty acid, trialkylphosphine, trialkylphosphine oxide, alkyl amine, alkyl thiol, sodium alkyl sulfate, and sodium alkyl phosphate.
[Claim 13]
The magnetic nanocomposite according to claim 12, wherein the organic surface stabilizer is one or more selected from the group consisting of a saturated or
unsaturated fatty acid and alkyl amine.
[Claim 14] The magnetic nanocomposite according to claim 1, wherein the hydrophobic domain is a saturated or unsaturated fatty acid, or a hydrophobic polymer.
[Claim 15]
The magnetic nanocomposite according to claim 14, wherein the saturated
fatty acid is selected from the group consisting of butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, miristic acid, palmitic acid, stearic acid, eicosanoic acid, and docosanoic acid.
[Claim 16]
The magnetic nanocomposite according to claim 14, wherein the unsaturated fatty acid is selected from the group consisting of oleic acid, linoleic acid, arakydonic acid, eicosapentanoic acid, docosahexanoic acid, and erucic acid.
[Claim 17]
The magnetic nanocomposite according to claim 14, wherein the hydrophobic polymer is selected from the group consisting of polyphospazene, polylactide, polylactide-co-glycolide, polycaprolactone, poly anhydride, polymalic acid or derivatives thereof, polyalkylcyanoacrylate, polyhydroxybutylate, polycarbonate, polyorthoester, a hydrophobic polyamino acid and a hydrophobic vinyl based
polymer.
[Claim 18]
The magnetic nanocomposite according to claim 17, wherein the hydrophobic polymer has a weight average molecular weight of 100 to 100,000.
[Claim 19]
The magnetic nanocomposite according to claim 1, wherein the hydrophilic domain is a biodegradable polymer.
[Claim 20]
The magnetic nanocomposite according to claim 19, wherein the
biodegradable polymer is selected from the group consisting of polyalkyleneglycol
(PEG), polyetherimide (PEI), polyvinylpyrrolidone (PVP), a hydrophilic polyamino
acid and a hydrophilic vinyl based polymer.
[Claim 21]
The magnetic nanocomposite according to claim 19, wherein the
biodegradable polymer has a weight average molecular weight of 100 to 100,000.
[Claim 22]
The magnetic nanocomposite according to claim 20, wherein
polyalkyleneglycol is polyethyleneglycol.
[Claim 23]
The magnetic nanocomposite according to claim 22, wherein polyethylene glycol is monomethoxy polyethyleneglycol.
[Claim 24]
The magnetic nanocomposite according to claim 1, wherein the hydrophilic domain has one or more binding parts for a hydrophilic active ingredient within its structure.
[Claim 25]
The magnetic nanocomposite according to claim 24, wherein the hydrophilic active ingredient is selected from the group consisting of a bioactive ingredient, a polymer, and an inorganic support.
[Claim 26]
The magnetic nanocomposite according to claim 28, wherein the binding part for a hydrophilic active ingredient comprises one or more functional groups selected from the group consisting of -COOH, -CHO, -NH2, -SH, -CONH2, -PO3H, -PO4H, -SO3H, -SO4H, -OH, -NR4 +X-, -sulfonate, -nitrate, -phophonate, -succinimidyl,
-maleimide, and -alkyl.
[Claim 27] The magnetic nanocomposite according to claim 1, wherein the magnetic
nanoparticle is covered with an amphiphillic compound having one or more
hydrophobic domains and one or more hydrophillic domains, and one or more
binding parts for a hydrophillic active ingredient present in said hydrophillic domain are bound to a tissue -specific binding substance.
[Claim 28]
The magnetic nanocomposite according to claim 27, wherein said
tissue-specific binding substance is selected from the group consisting of an antigen,
an antibody, RNA, DNA, hapten, avidin, streptavidin, neutravidin, protein A,
protein G, lectin, selectin, a radioisotope labeled component, and a material that may be specifically bound to a tumor marker.
[Claim 29]
The magnetic nanocomposite according to claim 28, wherein said tumor
marker is selected from the group consisting of a ligand, an antigen, a receptor, and
an encoding nucleic acid thereof.
[Claim 30] The magnetic nanocomposite according to claim 29, wherein said tumor marker is selected from the group consisting of C2 of synaptotagmin I, annexin V,
integrin, VEGF, angiopoietin 1, angiopoietin 2, somatostatin, a vasointestinal peptide, a carcinoembryonic antigen, a HER2/neu antigen, a prostate-specific
antigen and a follic acid receptor.
[Claim 31]
The magnetic nanocomposite according to claim 27, wherein the material
that may be specifically bound to said tumor marker, is one or more selected from
the group consisting of phosphatidylserine, VEGFR, an integrin receptor, a Tie2
receptor, a somatostatin receptor, a vasointestinal peptide receptor, Herceptin,
Rituxan, and follic acid.
[Claim 32]
The magnetic nanocomposite according to claim 1, wherein the hydrophobic domain has one or more binding parts for a hydrophobic active ingredient within its
structure.
[Claim 33]
The magnetic nanocomposite according to claim 32, wherein the hydrophobic
active ingredient is selected from the group consisting of a bioactive ingredient, a
polymer, and an inorganic support.
[Claim 34]
The magnetic nanocomposite according to claim 32, wherein the binding part for a hydrophobic active ingredient comprises one or more functional groups selected from the group consisting of -COOH, -CHO, -NH2, -SH, -CONH2, -PO3H, -PO4H, -SO3H, -SO4H, -OH, -succinimidyl, -maleimide, and -alkyl.
[Claim 35]
The magnetic nanocomposite according to claim 1, wherein the magnetic nanoparticle is covered with an amphiphillic compound having one or more hydrophobic domains and one or more hydrophillic domains, and one or more binding parts for a hydrophillic active ingredient present in said hydrophillic
domain are bound to a tissue -specific binding substance.
[Claim 36]
The magnetic nanocomposite according to claim 35, wherein the pharmaceutically active ingredient is one or more selected from the group consisting of an anticancer agent, an antibiotic, a hormone, a hormone antagonist, interleukin, interferon, a growth factor, a tumor necrosis factor, endotoxin,
lymphotoxin, eurokinase, streptokinase, a tissue plasminogen activator, a protease inhibitor, alkylphosphocholine, a radioisotope labeled component, a surfactant, a cardiovascular system drug, a gastrointestinal system drug and a nervous system
drug.
[Claim 37] The magnetic nanocomposite according to claim 36, wherein the anticancer
agent is one or more selected from the group consisting of epirubicin, docetaxel,
gemcitabine, paclitaxel, cisplatin, carboplatin, taxol, procarbazine,
cyclophosphamide, dactinomycin, daunorubicin, etoposide, tamoxifen, doxorubicin,
mitomycin, bleomycin, plicomycin, transplatinum, vinblastin and methotrexate.
[Claim 38]
The magnetic nanocomposite according to claim 1, wherein the amphiphilic
compound comprises a binding part for a hydrophobic active ingredient- a
hydrophobic domain- a hydrophilic domain- a binding part for a hydrophilic active
ingredient.
[Claim 39]
The magnetic nanocomposite according to claim 38, wherein the amphiphilic
compound comprises a binding part for a hydrophobic active ingredient- a
hydrophobic domain-NH2- a hydrophilic domain - a binding part for a hydrophilic
active ingredient.
[Claim 40]
The magnetic nanocomposite according to claim 1, wherein the amphiphilic
compound is monomethoxypolyethyleneglycol-polylactide-co-glycolide copolymer, or
monomethoxypolyethyleneglycol-lauric acid copolymer.
[Claim 41]
The method for preparing a magnetic nanocomposite which comprises the steps of:
A) synthersizing nanop articles in a solvent; and
B) adding an amphiphilic compound having a hydrophobic domain and a
hydrophilic domain to the surfaces of nanoparticles to bind the amphiphilic
compound and nanoparticles.
[Claim 42]
The method for preparing the magnetic nanocomposite according to claim 41,
wherein the method further comprises
C) binding the binding part present in said hydrophilic domain and the
material that may be specifically bound to a tumor marker.
[Claim 43]
The method for preparing the magnetic nanocomposite according to claim 41,
wherein the method further comprises
D) binding or enclosing a pharmaceutically active ingredient in the
hydrophobic domain.
[Claim 44] The method for preparing the magnetic nanocomposite according to claim 41, wherein the step A) of synthesizing nanoparticles in a solvent comprises a) reacting an organic surface stabilizer with precursors of nanoparticles in presence of a solvent; and b) thermolyzing the resulting reactant.
[Claim 45]
The method for preparing the magnetic nanocomposite according to claim 44, wherein the solvent is selected from the group consisting of an ether compound, a heterocyclic compound, an aromatic compound, a sulfoxide compound, an amide compound, an alcohol, a hydrocarbon and water.
[Claim 46]
The method for preparing the magnetic nanocomposite according to claim 45, wherein the solvent is octyl ether, butyl ether, hexyl ether, decyl ether, pyridine, tetrahydrofuran (THF), toluene, xylene, mesitylen, benzene, dimethylsulfoxide
(DMSO), dimethylformamide (DMF), octyl alcohol, decanol, pentane, hexane, heptane, octane, decane, dodecane, tetradecane, hexadecane, or water.
[Claim 47]
The method for preparing the magnetic nanocomposite according to claim 41,
wherein the step B) comprises the steps of: a) dissolving nanoparticles in an organic solvent to prepare an oil phase;
b) dissolving an amphiphilic compound in an aqueous solvent to prepare an aqueous phase;
c) mixing the oil phase with the aqueous phase to form an emulsion; and d) separating the oil phase from the emulsion.
[Claim 48]
The method for preparing the magnetic nanocomposite according to claim 41,
wherein the step B) comprises the steps of:
e) dispersing the nanoparticles in a solution dissolving an amphiphilic
compound to prepare a suspension; and
f) separating the solvent from the suspension.
[Claim 49]
The method for preparing the magnetic nanocomposite according to claim 41,
wherein the step C) comprises the steps of:
g) providing some of the hydrophilic domain with the binding part for a
hydrophilic active ingredient, using a cross linking agent; and h) binding the binding part for a hydrophilic active ingredient and a tissue
specific binding substance.
[Claim 50] The method for preparing the magnetic nanocomposite according to claim 36, wherein the step D) comprises the steps of:
i) providing some of the hydrophobic domain with the binding part for a
hydrophobic active ingredient, using a cross linking agent; and
j) binding the binding part for a hydrophobic active ingredient and the
pharmaceutically active ingredient.
[Claim 51]
The method for preparing the magnetic nanocomposite according to claim 36,
wherein the step D) comprises dissolving the pharmaceutically active ingredient
together with nanoparticles and enclosing the resulting solution.
[Claim 52]
A contrast agent composition which comprises a magnetic nanocomposite
according to any one of claims 1 to 26 and a pharmaceutically acceptable carrier.
[Claim 53]
A composition for diagnosis which comprises a magnetic nanocomposite
according to any one of claims 27 to 31 and a pharmaceutically acceptable carrier.
[Claim 54]
A pharmaceutical composition for simultaneous diagnosis and treatment which comprises a magnetic nanocomposite according to any one of claims 35 to 37 and a pharmaceutically acceptable carrier.
[Claim 55]
A method for using a contrast composition which comprises the steps of: administrating the contrast composition according to claim 52 to an organism or a specimen; and sensing signals emitted by the magnetic nanocomposite from the organism or
the specimen to obtain images.
[Claim 56]
A method for diagnosing disease which comprises the steps of: administrating a composition for diagnosis according to claim 53 to an organism or a specimen; and sensing signals emitted by the magnetic nanocomposite from the organism or
the specimen to obtain images.
[Claim 57]
A method for simultaneously diagnosing and treating disease which
comprises the steps of: administrating the pharmaceutical composition according to claim 54 to an
organism or a specimen; and sensing signals emitted by the magnetic nanocomposite from the organism or the specimen to obtain images.
[Claim 58]
The method for using according to claim 52, characterized by administrating via the intravenous, intraperitoneal, intramuscular, subcutaneous or topical route in the step of administrating the contrast agent composition to an organism or a specimen.
[Claim 59]
The method for using according to claim 52, characterized by using Magnetic
Resonance Imaging (MRI) apparatus in the step of sensing the signals.
[Claim 60] The method for using according to claim 59, wherein the MRI apparatus is
T2 spin-spin relaxation MRI apparatus.
PCT/KR2007/000961 2006-02-24 2007-02-23 Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance WO2007097593A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008556255A JP2009531296A (en) 2006-02-24 2007-02-23 Contrast agent, intelligent contrast agent, drug transmitter for simultaneous diagnosis and treatment and / or magnetic nanocomposite for protein separation
US12/280,474 US20090324494A1 (en) 2006-02-24 2007-02-23 Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance
EP07709086A EP1988928A4 (en) 2006-02-24 2007-02-23 Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance
US13/590,958 US20130045160A1 (en) 2006-02-24 2012-08-21 Magnetic Nano-Composite for Contrast Agent, Intelligent Contrast Agent, Drug Delivery Agent for Simultaneous Diagnosis and Treatment, and Separation Agent for Target Substance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060018469 2006-02-24
KR10-2006-0018469 2006-02-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/590,958 Continuation US20130045160A1 (en) 2006-02-24 2012-08-21 Magnetic Nano-Composite for Contrast Agent, Intelligent Contrast Agent, Drug Delivery Agent for Simultaneous Diagnosis and Treatment, and Separation Agent for Target Substance

Publications (1)

Publication Number Publication Date
WO2007097593A1 true WO2007097593A1 (en) 2007-08-30

Family

ID=38437591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/000961 WO2007097593A1 (en) 2006-02-24 2007-02-23 Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance

Country Status (5)

Country Link
US (2) US20090324494A1 (en)
EP (1) EP1988928A4 (en)
JP (1) JP2009531296A (en)
KR (5) KR100819378B1 (en)
WO (1) WO2007097593A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029599A1 (en) * 2006-08-31 2008-03-13 Canon Kabushiki Kaisha Magnetic particles and process for their production
WO2008073851A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Remotely triggered release from heatable surfaces
WO2009088777A1 (en) * 2007-12-31 2009-07-16 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
WO2009137888A1 (en) * 2008-05-16 2009-11-19 The University Of Sydney Polymer microgel beads and preparative method thereof
EP2200932A1 (en) * 2007-09-21 2010-06-30 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
JP2010142776A (en) * 2008-12-22 2010-07-01 Toshiba Corp Functional particle and method for treating water
CN101966344A (en) * 2010-10-29 2011-02-09 中国科学院上海硅酸盐研究所 Hollow core-shell nanometer mesoporous medicament carrying system with magnetism and luminescent performance, preparation method and application thereof
EP2285422A2 (en) * 2008-05-09 2011-02-23 Industry-Academic Cooperation Foundation, Yonsei University Dual-modality pet/mri contrast agents
WO2012105801A3 (en) * 2011-02-01 2012-12-20 서울대학교 산학협력단 Nanoparticle coated with ligand introduced with long hydrophobic chain and method for preparing same
EP2600903A2 (en) * 2010-08-05 2013-06-12 Hanwha Chemical Corporation Preparation of extremely small and uniform sized, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles and mri t1 contrast agents using the same
US8541029B2 (en) 2006-10-17 2013-09-24 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
ITRM20120350A1 (en) * 2012-07-19 2014-01-20 Univ Degli Studi Milano NANOCOSTRUTTI WITH PHARMACOLOGICAL ACTIVITY.
US8709486B2 (en) 2008-05-16 2014-04-29 The University Of Sydney Administrable compositions
US8765183B2 (en) 2008-05-16 2014-07-01 The University Of Sydney Polymer microgel beads
GB2516882A (en) * 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US9457104B2 (en) 2011-08-03 2016-10-04 Hanwha Chemical Corporation Hydrophilic nanoparticles surface-modified with monosaccharide phosphate or monosaccharide phosphate derivatives, its colloidal solution and use thereof
EP2621541A4 (en) * 2010-09-29 2016-11-23 Univ Alabama Shape-controlled magnetic nanoparticles as t1 contrast agents for magnetic resonance imaging
KR101729554B1 (en) * 2010-08-05 2017-04-24 한화케미칼 주식회사 Preparation of Very Small and Uniform Sized Iron Oxide Nanoparticles and the MRI T1 Contrast Agents Using Thereof
US9649388B2 (en) 2012-01-18 2017-05-16 Bioneer Corporation Magnetic nanoparticle-samirna complex and method for preparing same
ES2758400A1 (en) * 2018-11-02 2020-05-05 Univ Granada MAMC-MEDIATED BIOMIMETIC NANOPARTICLES (Machine-translation by Google Translate, not legally binding)
US10744208B2 (en) 2015-08-20 2020-08-18 Robert E. Sandstrom Method of attacking target cells

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100924786B1 (en) * 2007-06-28 2009-11-03 연세대학교 산학협력단 A magnetic metal nano composite for the diagnosis and treatment
KR100862973B1 (en) * 2007-06-28 2008-10-13 연세대학교 산학협력단 Cationic magnetic nanocomposite for magnetic targeted drug delivery and contrast agent
JP2011509312A (en) * 2007-09-25 2011-03-24 ザ テキサス エー アンド エム ユニバーシティ システム Water-soluble nanoparticles with controlled aggregate size
KR100957560B1 (en) * 2007-10-18 2010-05-11 한국생명공학연구원 Perfluorocarbon Nano Emulsion Containing Quantum Dot Nanoparticles and Method for Preparing Thereof
US9943490B2 (en) * 2007-11-05 2018-04-17 The Trustees Of Princeton University Composite flash-precipitated nanoparticles
WO2009069959A2 (en) * 2007-11-30 2009-06-04 Korea University Industrial & Academic Collaboration Foundation A nanoparticle for separating peptide, method for preparing the same, and method for separating peptide using the same
US20100140548A1 (en) * 2008-02-11 2010-06-10 Julia Xiaojun Zhao Nanoaggregate composition and method for making
KR101043223B1 (en) * 2008-05-20 2011-06-21 연세대학교 산학협력단 Methods for Controlling Heat Generation of Magnetic Nanoparticles and Heat Generating Nanomaterials
US8916134B2 (en) 2008-07-11 2014-12-23 Industry-Academic Cooperation Foundation, Yonsei University Metal nanocomposite, preparation method and use thereof
US20100055803A1 (en) * 2008-08-29 2010-03-04 Kwangyeol Lee Method and apparatus for detecting molecules
CN102264631B (en) * 2008-10-27 2015-09-02 有益系统有限责任公司 Magnetic nano-particle is utilized to carry out the method for liquid purifying
KR100891456B1 (en) * 2008-11-06 2009-04-01 씨지케이 주식회사 Method and apparatus for detecing cellular target materials to bioactive molecules
KR101072773B1 (en) 2008-12-30 2011-10-11 경북대학교 산학협력단 Coated manganese oxide nanoparticles by biocompatible ligand and synthesizing thereof
WO2010076946A1 (en) * 2008-12-30 2010-07-08 경북대학교 산학협력단 Nanoparticulates, complex nanoparticulates, and manufacturing method thereof
US8671769B2 (en) 2009-02-27 2014-03-18 Industry Academic Cooperation Foundation Device for measuring deformation of a structure and a method for measuring deformation of a structure using the same
KR101179471B1 (en) * 2009-05-12 2012-09-07 한국과학기술연구원 SELF-ASSEMBLED POLYMERIC NANOPARTICLES WHICH CAN BE USED FOR siRNA DELIVERY SYSTEM
KR101178512B1 (en) 2009-06-25 2012-08-30 연세대학교 산학협력단 Zinc-Containing Magnetic Nanoparticle-Based Magnetic Sensors
KR101142905B1 (en) * 2009-11-27 2012-05-10 연세대학교 산학협력단 Synthesis of cationic magnetic nano-complexs using cationic amphiphilic polymers
KR101072389B1 (en) 2009-11-30 2011-10-11 재단법인대구경북과학기술원 Sensitivity drug delivery system to thiol comprising amphiphilic polymer
KR101057484B1 (en) * 2010-03-19 2011-08-17 강원대학교산학협력단 Oral imaging agent for imaging in small intestine
KR101196667B1 (en) * 2010-04-15 2012-11-02 포항공과대학교 산학협력단 A DELEVERY SYSTEM OF ANTI-CANCER AGENT USING pH SENSITIVE METAL NANOPARTICLE
JP2013526616A (en) 2010-05-26 2013-06-24 ザ ジェネラル ホスピタル コーポレイション Magnetic nanoparticles
US9555136B2 (en) 2010-06-21 2017-01-31 University Of Washington Through Its Center For Commercialization Coated magnetic nanoparticles
US9259492B2 (en) * 2010-06-21 2016-02-16 University Of Washington Through Its Center For Commercialization Tuned multifunctional magnetic nanoparticles for biomedicine
US9918656B2 (en) * 2010-06-25 2018-03-20 Massachusetts Institute Of Technology Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker
KR101233439B1 (en) * 2010-07-29 2013-02-14 연세대학교 산학협력단 Stimuli sensitive magnetic nanocomposites using pyrene conjugated polymer and contrast compositions
AU2013216619B2 (en) * 2010-08-05 2015-08-27 Hanwha Chemical Corporation Preparation of extremely small and uniform sized, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles and mri t1 contrast agents using the same
WO2012030134A2 (en) 2010-08-30 2012-03-08 Hanwha Chemical Corporation Iron oxide nanocapsules, method of manufacturing the same, and mri contrast agent using the same
KR101642939B1 (en) * 2010-08-31 2016-07-26 한화케미칼 주식회사 Iron Oxide Nano Particle Capsulated Polymer Nano Capsule, Fabrication Method of Polymer Nano Capsule and the MRI Contrast Agents Using Thereof
KR101379971B1 (en) * 2011-01-31 2014-04-10 고려대학교 산학협력단 Nano particles having a curie temperature within biocompatible temperature and method for preparing the same
KR101642903B1 (en) 2011-02-09 2016-07-27 한화케미칼 주식회사 Preparation of hydrophilic material coated iron oxide nanoparticles and magnetic resonance contrast agent using thereof
TWI410253B (en) * 2011-05-04 2013-10-01 Univ Nat Chunghsing Method for preparation of water-soluble and superparamagnetic cluster nanoparticles
WO2012151577A2 (en) * 2011-05-05 2012-11-08 Azte Arizona Technology Enterprises Techniques to increase r1 in nanoparticle contrast agents for mri
GB2491387A (en) * 2011-06-02 2012-12-05 Magnequench Ltd Rare earth material capsule used in making a magnet
KR101351331B1 (en) * 2012-01-09 2014-01-24 한국세라믹기술원 Synthesis method of magnetic nanoparticles for targetable drug delivery system and drug delivery vector using the same
US9545456B2 (en) * 2012-02-22 2017-01-17 Tomowave Laboratories, Inc. Optoacoustic-ultrasonic contrast agents with enhanced efficiency
WO2013130881A1 (en) * 2012-02-28 2013-09-06 Loma Linda University Methods for the production, modification and use of metallic nanoparticles
KR101355176B1 (en) * 2012-03-22 2014-01-27 한국과학기술원 Composition for Diagnosing Circulating Tumor Cells and Method for Detecting Circulating Tumor Cells Using the Same
KR101409296B1 (en) 2012-09-07 2014-06-24 서울대학교산학협력단 Method of selective activation for magnetic nanoparticle and selectively activated magnetic nanoparticle
KR101495652B1 (en) * 2012-10-25 2015-02-25 재단법인대구경북과학기술원 Core cross-linked polymeric micelle and method of manufacturing the same
WO2014074475A1 (en) * 2012-11-07 2014-05-15 Emmetrope Ophthalmics Llc Magnetic eye shields and methods of treatment and diagnosis using the same
TWI482782B (en) 2013-05-31 2015-05-01 Univ Nat Chiao Tung Antibody-conjugated double emulsion core-shell nano structure
JP6145612B2 (en) * 2013-08-23 2017-06-14 国立大学法人 東京大学 Polymer nanoparticle composite and composition for MRI contrast comprising the same
KR101725582B1 (en) * 2013-08-30 2017-04-11 성균관대학교산학협력단 Composition having stable nanoparticle complex in seawater and producing method thereof
CA2949609A1 (en) * 2014-05-20 2015-11-26 Politecnico Di Milano Amphiphilic magnetic nanoparticles and aggregates to remove hydrocarbons and metal ions and synthesis thereof
KR102270242B1 (en) * 2014-09-02 2021-06-25 엘에스아이 메디엔스 코포레이션 Polymer microparticle for carrying physiologically active substance and method for preparing same
US20180051272A1 (en) * 2015-03-09 2018-02-22 Shimadzu Corporation Immobilized protease with improved resistance to change in external environment
KR101580251B1 (en) * 2015-04-14 2015-12-29 가톨릭대학교 산학협력단 TPP-PCL-TPP polymer and nano-drug delivery composition for targeting mitochondria using the same
KR101686341B1 (en) * 2015-08-26 2016-12-13 건양대학교산학협력단 Synthesis method of magnetic nanoparticle for targetable drug delivery system
KR101710702B1 (en) * 2015-09-02 2017-02-28 재단법인대구경북과학기술원 Amphiphilic copolymer, manufacturing method thereof, and functional composites including the same
US20170151347A1 (en) * 2015-11-29 2017-06-01 Berney PENG Functionalized nanoparticles with encapsulated cargo and method of their self-assembly
US10765744B2 (en) 2016-04-27 2020-09-08 University Of Florida Research Foundation, Inc. Magnetic particle conjugates, micelles, and methods of delivering agents
US11311630B2 (en) 2016-04-27 2022-04-26 University Of Florida Research Foundation, Inc. Magnetic particle conjugates, micelles, and methods of delivering agents
CN106290326B (en) * 2016-07-21 2019-02-01 上海大学 Detect colorimetric sensor, preparation method and the application of lipopolysaccharides
KR101963147B1 (en) * 2016-09-29 2019-03-28 연세대학교 산학협력단 MRI contrast for the precise diagnosis of tumor with target specificity of less than 1 nM and method for preparing thereof
KR101882589B1 (en) * 2016-12-28 2018-07-26 영남대학교 산학협력단 Nanocomposite, composition for contrast agent comprising the same, apparatus for manufacturing nanocomposite, and method for manufacturing the same
JP6998004B2 (en) * 2017-05-12 2022-01-18 株式会社Ｌｓｉメディエンス Magnetic particles for supporting physiologically active substances and their manufacturing methods
CN111511484A (en) * 2017-11-04 2020-08-07 索纳纳米技术公司 Metal nanoparticles and method for preparing the same
CN110501208B (en) * 2018-05-17 2023-06-27 国家纳米科学中心 Folic acid functionalized streptavidin modified magnetic nanoparticle, preparation method and application thereof
US10950427B2 (en) * 2018-06-14 2021-03-16 Samsung Electronics Co., Ltd. Quantum dots and production method thereof
KR102154264B1 (en) * 2018-12-19 2020-09-09 한국세라믹기술원 Method of modifying the surface of hydrophobic bead with amphiphilic polymer
KR102249424B1 (en) * 2019-09-19 2021-05-07 훠리스트 주식회사 UV Protection Composition Containing An Active Ingredient Extracted From genus Symbiodinium spp. And Its Manufacturing Method
KR102507204B1 (en) * 2019-10-16 2023-03-09 주식회사 퓨전바이오텍 Micelles that are drug resistant and comprise surface-modified metal nanoparticles therein, uses and preparation methods thereof
KR102379994B1 (en) * 2019-10-22 2022-03-29 훠리스트 주식회사 Antioxidative and antiaging composition containing the skin affinitive ingredients extracted from the flower stem of orchid callus
KR102298773B1 (en) * 2020-02-07 2021-09-07 주식회사 녹십자엠에스 Method for manufacturing nanoparticles having hydrophilic ligands and antibodies conjugated to each surface of them, nanoparticles manufactured using same method, complex containing same nanoparticles, and diagnostic kit containing same nanoparticles
US11826955B2 (en) 2020-07-24 2023-11-28 City University Of Hong Kong Magnetically-drivable microrobot
CN111983221B (en) * 2020-08-19 2024-04-09 深圳市卓润生物科技有限公司 Surface-modified magnetic bead and preparation method and application thereof
WO2022177041A1 (en) * 2021-02-19 2022-08-25 주식회사 녹십자엠에스 Method for preparing nanoparticle with hydrophilic ligand and antibody conjugated to surface thereof, nanoparticle prepared thereby, composite including same nanoparticle, and diagnostic kit including same nanoparticle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065724A1 (en) * 2003-12-30 2005-07-21 Alnis Biosciences, Inc. Formulations of paramagnetic ion complexes
US20050260137A1 (en) * 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3709851A1 (en) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te NMR DIAGNOSTIC LIQUID COMPOSITIONS
ATE156706T1 (en) * 1993-03-17 1997-08-15 Silica Gel Gmbh SUPERPARAMAGNETIC PARTICLES, METHOD FOR THE PRODUCTION AND USE OF THE SAME
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
ATE191086T1 (en) * 1994-07-27 2000-04-15 Pilgrimm Herbert SUPERPARAMAGNETIC PARTICLES, METHOD FOR THE PRODUCTION AND USE THEREOF
US7459145B2 (en) * 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
JP2005000822A (en) * 2003-06-12 2005-01-06 Fuji Clean Kogyo Kk Securing device for cover part of manhole, and septic tank
KR100541282B1 (en) * 2004-06-29 2006-01-10 경북대학교 산학협력단 Liver contrast agent using iron oxide nanoparticles and manufacture method therefor
KR100702671B1 (en) * 2005-01-20 2007-04-03 한국과학기술원 Smart magnetic nano sphere preparation and manufacturing method thereof
DK1945271T3 (en) * 2005-10-24 2020-01-13 Magsense Life Sciences Inc Process for the preparation of polymer-coated microparticles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065724A1 (en) * 2003-12-30 2005-07-21 Alnis Biosciences, Inc. Formulations of paramagnetic ion complexes
US20050260137A1 (en) * 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KIM E.H. ET AL.: "Synthesis of ferrofluid with magnetic nanoparticles by sonochemical method for MRI contrast agent", JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, vol. 289, 2005, pages 328 - 330, XP025364453 *
LEE S.-J. ET AL.: "Nanoparticles of magnetic ferric oxides encapsulated with poly(D,L latide-co-glycoside) and their applications to magnetic resonance imaging contrast agent", JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, vol. 272/276, no. PART 3, pages 2432 - 2433, XP004514432 *
See also references of EP1988928A4 *
SHIEH D.-B. ET AL.: "Aqueous dispersions of magnetic nanoparticles with NH3+ surfaces for magnetic manipulations of biomolecules and MRI contrast agents", BIOMATERIALS, vol. 26, no. 34, 2005, pages 7183 - 7191, XP025280286 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029599A1 (en) * 2006-08-31 2008-03-13 Canon Kabushiki Kaisha Magnetic particles and process for their production
US8541029B2 (en) 2006-10-17 2013-09-24 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
WO2008073851A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Remotely triggered release from heatable surfaces
WO2008073851A3 (en) * 2006-12-08 2009-05-22 Massachusetts Inst Technology Remotely triggered release from heatable surfaces
EP2200932A1 (en) * 2007-09-21 2010-06-30 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
EP2200932A4 (en) * 2007-09-21 2014-09-10 Cytimmune Sciences Inc Nanotherapeutic colloidal metal compositions and methods
WO2009088777A1 (en) * 2007-12-31 2009-07-16 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
EP2285422A2 (en) * 2008-05-09 2011-02-23 Industry-Academic Cooperation Foundation, Yonsei University Dual-modality pet/mri contrast agents
EP2285422A4 (en) * 2008-05-09 2014-11-19 Univ Yonsei Iacf Dual-modality pet/mri contrast agents
AU2009246064B2 (en) * 2008-05-16 2014-05-15 The University Of Sydney Polymer microgel beads and preparative method thereof
US8765183B2 (en) 2008-05-16 2014-07-01 The University Of Sydney Polymer microgel beads
JP2011523961A (en) * 2008-05-16 2011-08-25 ザ・ユニバーシティ・オブ・シドニー Polymer microgel beads and method for producing the same
WO2009137888A1 (en) * 2008-05-16 2009-11-19 The University Of Sydney Polymer microgel beads and preparative method thereof
US8852641B2 (en) 2008-05-16 2014-10-07 The University Of Sydney Polymer microgel beads and preparative method thereof
EP2285881A1 (en) * 2008-05-16 2011-02-23 The University Of Sydney Polymer microgel beads and preparative method thereof
KR101625243B1 (en) 2008-05-16 2016-05-27 유니버시티 오브 시드니 Polymer microgel beads and preparative method thereof
EP2285881A4 (en) * 2008-05-16 2011-06-22 Univ Sydney Polymer microgel beads and preparative method thereof
US8709486B2 (en) 2008-05-16 2014-04-29 The University Of Sydney Administrable compositions
JP2010142776A (en) * 2008-12-22 2010-07-01 Toshiba Corp Functional particle and method for treating water
KR101729554B1 (en) * 2010-08-05 2017-04-24 한화케미칼 주식회사 Preparation of Very Small and Uniform Sized Iron Oxide Nanoparticles and the MRI T1 Contrast Agents Using Thereof
EP2600903A4 (en) * 2010-08-05 2015-04-15 Hanwha Chemical Corp Preparation of extremely small and uniform sized, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles and mri t1 contrast agents using the same
EP2600903A2 (en) * 2010-08-05 2013-06-12 Hanwha Chemical Corporation Preparation of extremely small and uniform sized, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles and mri t1 contrast agents using the same
US9861712B2 (en) 2010-08-05 2018-01-09 Hanwha Chemical Corporation Preparation of extremely small and uniform sized, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles and MRI T1 contrast agents using the same
EP2621541A4 (en) * 2010-09-29 2016-11-23 Univ Alabama Shape-controlled magnetic nanoparticles as t1 contrast agents for magnetic resonance imaging
US9867889B2 (en) 2010-09-29 2018-01-16 The Board Of Trustees Of The University Of Alabama Shape-controlled magnetic nanoparticles as T1 contrast agents for magnetic resonance imaging
CN101966344A (en) * 2010-10-29 2011-02-09 中国科学院上海硅酸盐研究所 Hollow core-shell nanometer mesoporous medicament carrying system with magnetism and luminescent performance, preparation method and application thereof
WO2012105801A3 (en) * 2011-02-01 2012-12-20 서울대학교 산학협력단 Nanoparticle coated with ligand introduced with long hydrophobic chain and method for preparing same
US9925284B2 (en) 2011-02-01 2018-03-27 Cellbion Co., Ltd. Nanoparticle coated with ligand introduced with long hydrophobic chain and method for preparing same
US9457104B2 (en) 2011-08-03 2016-10-04 Hanwha Chemical Corporation Hydrophilic nanoparticles surface-modified with monosaccharide phosphate or monosaccharide phosphate derivatives, its colloidal solution and use thereof
US9649388B2 (en) 2012-01-18 2017-05-16 Bioneer Corporation Magnetic nanoparticle-samirna complex and method for preparing same
ITRM20120350A1 (en) * 2012-07-19 2014-01-20 Univ Degli Studi Milano NANOCOSTRUTTI WITH PHARMACOLOGICAL ACTIVITY.
WO2014013473A1 (en) * 2012-07-19 2014-01-23 Universita' Degli Studi Di Milano - Bicocca Nanoconstructs with pharmacological activity
CN104519914A (en) * 2012-07-19 2015-04-15 米兰比可卡大学 Nanoconstructs with pharmacological activity
GB2516882A (en) * 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US10744208B2 (en) 2015-08-20 2020-08-18 Robert E. Sandstrom Method of attacking target cells
ES2758400A1 (en) * 2018-11-02 2020-05-05 Univ Granada MAMC-MEDIATED BIOMIMETIC NANOPARTICLES (Machine-translation by Google Translate, not legally binding)
WO2020089505A1 (en) * 2018-11-02 2020-05-07 Universidad De Granada Mamc-mediated biomimetic nanoparticles

Also Published As

Publication number Publication date
KR20070088393A (en) 2007-08-29
KR20070088391A (en) 2007-08-29
US20090324494A1 (en) 2009-12-31
KR100848932B1 (en) 2008-07-29
KR100819377B1 (en) 2008-04-04
KR20070088388A (en) 2007-08-29
KR100848930B1 (en) 2008-07-29
KR20070088390A (en) 2007-08-29
KR100819378B1 (en) 2008-04-04
US20130045160A1 (en) 2013-02-21
EP1988928A4 (en) 2011-11-16
KR20070088392A (en) 2007-08-29
JP2009531296A (en) 2009-09-03
EP1988928A1 (en) 2008-11-12
KR100848931B1 (en) 2008-07-29

Similar Documents

Publication Publication Date Title
EP1988928A1 (en) Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance
EP1996508B1 (en) Preparation method for water-soluble magnetic or metal oxide nanoparticles coated with ligands, and usage thereof
KR100862973B1 (en) Cationic magnetic nanocomposite for magnetic targeted drug delivery and contrast agent
Dave et al. Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: a versatile and evolving technology
US20090220431A1 (en) Magnetic resonance imaging contrast agents containing water-soluble nanoparticles of manganese oxide or manganese metal oxide
KR101047422B1 (en) Fluorescent magnetic silica nanoparticles, preparation method thereof, and biomedical composition comprising the same
KR20100030264A (en) Fluorescent magnetic nanohybrids and method for preparing the same
US20100008854A1 (en) Metal nanocomposite, preparation method and use thereof
KR20090119867A (en) Mri t1 contrasting agent comprising manganese oxide nanoparticle
KR101079235B1 (en) Magnetic nanocomposites, contrast compositions and pharmaceutical compositions comprising the same
KR101233439B1 (en) Stimuli sensitive magnetic nanocomposites using pyrene conjugated polymer and contrast compositions
KR101178512B1 (en) Zinc-Containing Magnetic Nanoparticle-Based Magnetic Sensors
KR101142905B1 (en) Synthesis of cationic magnetic nano-complexs using cationic amphiphilic polymers
KR101000480B1 (en) Magnetic nanocomposite, preparation method thereof and biomedical composition comprising the same
KR101615734B1 (en) Multicore-Shell Nanoparticle
KR101178511B1 (en) Zinc-Containing Magnetic Nanoparticle-Based Compositions for Magnetic Separation
KR101711738B1 (en) Complex Of Conductive Polymer And Inorganic Nanoparticle Using Material With Aromatic Compound
WO2011136500A2 (en) Multi-core-shell nanoparticles
Majewski et al. Superparamagnetic magnetite (Fe3O4) nanoparticles for bio-applications
Geinguenaud et al. Magnetic nanoparticle surface functionalization for biomedical applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008556255

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007709086

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12280474

Country of ref document: US